

Utah 1115 Medicaid Reform Demonstration Preliminary Interim Evaluation Report

Report prepared by the Public Consulting Group

Preliminary Interim Report Delivered to UT DHHS: 3/30/26

Draft Interim Report Submittal Date to CMS: 6/30/26

Project Nos. 11-W-00145/8 and 21-W-00054/8

TABLE OF CONTENTS

A. Executive Summary	4
1. Demonstration	4
2. Findings	4
3. Recommendations.....	5
B. General Background Information.....	7
1. Demonstration Name and Timing.....	7
2. Demonstration Goals	7
3. Description.....	8
4. Populations.....	11
4.1 Scope of Interim Evaluation Report.....	11
5. Context	20
C. Evaluation Questions and Hypotheses	21
1. Logic Model	21
2. Hypotheses and Research Questions	22
D. Methodology	28
1. Evaluation Design.....	28
2. Target Populations	28
3. Evaluation Period	29
4. Evaluation Measures	31
5. Data Sources.....	32
5.1 Medicaid Claims Data	32
5.2 Custom Member Survey Data	32
6. Analytic Methods	32
6.1 Quantitative Methods.....	32
E. Methodological Limitations	34
F. Results	35
1. Overview of Claims-based Measures Results.....	35
2. Enrollment	38
3. Access and Engagement.....	39
3.1 Member Satisfaction Survey; Hypothesis 1	39
3.2 Adult Expansion Population; Hypothesis 2.....	43
3.3 Targeted Adult Medicaid Population; Hypothesis 3.....	51
4. SMI and SUD Demonstrations	59
4.1 SMI and SUD Demonstrations; Hypothesis 5.....	59
G. Conclusions	62

1. Member Experience of Care: Strengths and Opportunities for Improvement	62
2. Variation in Acute Care Utilization, Ambulatory Care, and Behavioral Health Care Results Across Demonstration Populations	62
3. Progress and Challenges for the Serious Mental Illness (SMI)/Substance Use Disorder (SUD) Demonstration Populations	62
H. Interpretations, Policy Implications, and Interactions with Other State Initiatives	63
1. Utah's Medicaid Strategy.....	63
2. Impact of COVID-19 Pandemic	63
3. Potential Implications of the One Big Beautiful Bill Act (H.R. 1).....	64
I. Lessons Learned and Recommendations	65
J. Attachments	67
1. Evaluation Design Document	67
2. Evaluation Design Tables.....	121
3. HRSS Participant Interview Methodology	144
4. Member Satisfaction Survey Report.....	146
5. Adult Expansion: Trend Over Time Results by Measure	174
6. Targeted Adult Medicaid: Trend Over Time Results by Measure	178
7. Adult Expansion: Regression Results by Measure	183
8. Targeted Adult Medicaid: Regression Results by Measure	187
9. SMI/SUD Demonstrations: Regression Results by Measure	191

A. EXECUTIVE SUMMARY

1. DEMONSTRATION

On June 30, 2022, the Centers for Medicare & Medicaid Services (CMS) approved a five-year extension of Utah's section 1115 waiver, formerly known as the "Primary Care Network (PCN) Demonstration" (hereafter, "the Demonstration" or "the 1115 Demonstration"). The current extension is entitled "Medicaid Reform 1115 Demonstration" and is approved for the five-year period from July 1, 2022, through June 30, 2027. Through the Demonstration, CMS has granted the state expenditure authorities to expand service offerings for vulnerable populations, move some members into integrated managed care plans, and to provide coverage to populations not otherwise eligible for Medicaid. The Utah Department of Health and Human Services (DHHS), Division of Integrated Healthcare (DIH) administers the Utah Medicaid program and is responsible for the implementation of the Demonstration.

2. FINDINGS

Member Experience of Care: Strengths and Opportunities for Improvement

The state hypothesized that the Demonstration would expand coverage for low-income Utah residents, thereby increasing engagement in health care and improving member satisfaction (Hypothesis 1). Findings from the member satisfaction survey show high rates of access to primary care providers and substance use treatment, as well as generally positive perceptions of provider communication and shared decision-making. However, the results also highlight several persistent challenges. Survey respondents reported barriers to accessing timely urgent, routine, and mental health care; difficulties obtaining needed medical care, tests or treatment; and concerns related to care coordination and providers' screening for health-related social needs. Together, these findings indicate that, while member satisfaction persists across several measures, additional targeted efforts are necessary to strengthen access, coordination, and responsiveness within the health care system.

Variation in Acute Care Utilization, Ambulatory Care, and Behavioral Health Care Results Across Demonstration Populations

The state anticipated that the Demonstration would enhance access to and engagement in health care for the Adult Expansion (AE) and Targeted Adult Medicaid (TAM) populations, thereby reducing reliance on inpatient and emergency department services (Hypotheses 2 and 3). Findings from the first three years of the Demonstration present a mixed picture. While emergency department utilization (EDU) decreased significantly for both populations, the expected reductions in acute hospital utilization (AHU) and emergency department utilization for behavioral health conditions (EDU-BH) were not observed. Several ambulatory and behavioral health measures demonstrated positive movement: adult access to ambulatory/preventive care (AAP) and initiation and engagement in substance use disorder treatment (IET) increased relative to baseline for both populations, and 7-day follow-up after hospitalization for mental illness (FUH) improved for the TAM population. However, anticipated improvements in 7-day FUH for the AE population, 30-day FUH for both groups, and reductions in 30-day all-cause unplanned readmission following hospitalization in an inpatient psychiatric facility (IPF) were not observed. Overall, these results indicate meaningful progress in certain areas of access and engagement, while highlighting ongoing challenges that warrant continued attention and targeted intervention.

Progress and Challenges for the Serious Mental Illness (SMI)/Substance Use Disorder (SUD) Demonstration Populations

The state posited that the SMI and SUD Demonstrations would expand access to appropriate treatment (Hypothesis 5), reflected in expected increases in IET and decreases in IPF. Findings indicate that while the SUD population experienced a significant increase in IET relative to baseline, the anticipated reduction in IPF among individuals with SMI diagnoses was not observed. These results suggest progress in some aspects of treatment access, while highlighting continued challenges in reducing psychiatric readmissions for the SMI population.

3. RECOMMENDATIONS

Based on these preliminary analyses, the IE offers these recommendations to the state:

(1) Anticipate gradual improvement in measurement outcomes

Evidence from prior studies demonstrates that while insurance coverage is a necessary foundation, meaningful increases in engagement and improvements in health outcomes are often not immediately realized.^{1,2} Although the findings indicate progress across several measures, these gains should be interpreted within the broader context of adjustment periods associated with gaining coverage, establishing care relationships, and navigating the health care system.

The results underscore the importance of robust, targeted outreach efforts and comprehensive population health strategies to accelerate engagement and sustain progress over time. Medicaid members who were recently uninsured or underinsured may face persistent barriers—including limited health system familiarity, unmet social needs, and delayed care-seeking behaviors—that are not fully addressed through coverage alone. As such, proactive strategies that support care navigation, connection to primary and preventive services, and culturally responsive engagement are critical. Accordingly, the state should continue to invest in and refine outreach and population health initiatives that complement coverage expansion. Sustained monitoring of trends across program years will be essential to assess the effectiveness of these strategies and to distinguish short-term enrollment effects from longer-term improvements in engagement and health status.

(2) Engage with members to streamline health care access

The state should deepen collaboration with Medicaid members to more comprehensively assess and address areas in need of improvement. Feedback from survey respondents highlighted a broad range of concerns, emphasizing the need for targeted action to improve member experience and access to care. To mitigate these concerns, the state should prioritize strategies to streamline administrative processes, enhance support for identifying in-network providers, expand access to telehealth services, and increase awareness of existing essential supports that facilitate access to care such as non-emergency medical transportation.

The state's existing Beneficiary Advisory Council (BAC), composed of current and former Medicaid members and individuals who support Medicaid populations, provides an important forum for capturing member perspectives and informing program improvements. Continued engagement through the BAC alongside the development of additional feedback and outreach mechanisms such as community-based partnerships, public forums, and targeted communication campaigns would further strengthen the state's ability to incorporate member input into program design and implementation. Collectively, these efforts can support more responsive, member-centered strategies and help ensure that improvements are aligned with the needs and experiences of the populations served.

(3) Strengthen care coordination and address members' health-related social needs (HRSN)

The member satisfaction survey highlights persistent gaps in provider coordination of care and attention to health-related social needs. Fragmentation within the health care system—particularly limited access to comprehensive medical histories, such as prior tests, results, prescribed medications, and specialist care—impedes providers' ability to deliver timely, informed care. These inefficiencies disproportionately affect individuals with chronic or complex health needs, leading to reduced care quality, poorer health outcomes, and increased patient dissatisfaction. Furthermore, screening for health-related social needs is essential to advancing a more holistic approach to care, ensuring the providers can meet the full range of members'

¹ Miller, S., Wherry, L., 2017. *Health and Access to Care during the First 2 Years of the ACA Medicaid Expansion*. The New England Journal of Medicine. [Health and Access to Care during the First 2 Years of the ACA Medicaid Expansion](#)

² Courtemanche, C., Marton, J., Ukert, B., et al., 2017. *Early Effects of the Affordable Care Act on Health Care Access, Risky Health Behaviors, and Self-Assessed Health*. National Bureau of Economic Research. [Early Effects of the Affordable Care Act on Health Care Access, Risky Health Behaviors, and Self-Assessed Health](#)

physical, behavioral, and social needs. Improved information sharing, integrated care approaches, and provider engagement in assessing and addressing health-related social needs are therefore critical to improving member experience and overall health outcomes.

Enhancing care coordination and more effectively addressing members' health-related social needs may also help achieve the anticipated improvements in the evaluated acute, ambulatory, and behavioral health care measures that were not observed during the evaluation period. The state has taken meaningful steps to address health-related social needs through the Housing Related Services and Supports (HRSS) amendment implemented in 2022, which enabled the provision of housing support services, and the HRSS amendment in 2025, which expanded HRSS and additional services for eligible individuals. These initiatives represent an important component of the state's broader strategy to support member health and well-being and should be acknowledged as part of ongoing program development.

(4) *Promote continued integration of behavioral health care*

Evaluation findings indicate substantial unmet behavioral health needs, as the anticipated reductions in EDU-BH and 30-day all-cause unplanned readmission following hospitalization in an inpatient psychiatric facility were not realized. Similarly, expected improvements in FUH were not observed. These patterns underscore the need for comprehensive behavioral health care to more effectively meet members' needs.

The state's planned initiatives to expand access to behavioral health services and strengthen integration across the care continuum (e.g., increasing provider capacity, enhancing the availability of treatment options, and improving access to crisis stabilization services) represent important opportunities to advance more coordinated, effective care for Medicaid members.

B. GENERAL BACKGROUND INFORMATION

1. DEMONSTRATION NAME AND TIMING

On June 30, 2022, the Centers for Medicare & Medicaid Services (CMS) approved a five-year extension of Utah's section 1115 waiver, formerly known as the "Primary Care Network (PCN) Demonstration" (hereafter, "the Demonstration" or "the 1115 Demonstration"). The current extension is entitled "Medicaid Reform 1115 Demonstration" and is approved for the five-year period from July 1, 2022, through June 30, 2027. Through the Demonstration, CMS has granted the state expenditure authorities to expand service offerings for vulnerable populations, move some members into integrated managed care plans, and to provide coverage to populations not otherwise eligible for Medicaid. The Utah Department of Health and Human Services (DHHS), Division of Integrated Healthcare (DIH) administers the Utah Medicaid program and is responsible for the implementation of the Demonstration.

2. DEMONSTRATION GOALS

The Utah DHHS, Division of Integrated Healthcare administers the Utah Medicaid program and is responsible for the implementation of adult Medicaid expansion.

The Demonstration goals, as outlined in the Special Terms and Conditions³, are:

1. Provide health care coverage for low-income Utahns eligible under the Demonstration who would not otherwise have access to, or be able to afford, health care coverage
2. Improve beneficiary health outcomes and quality of life
3. Lower the uninsured rate of low income Utahns
4. Provide continuity of coverage for individuals eligible under the Demonstration
5. Increase access to primary care
6. Reduce uncompensated care provided by Utah hospitals
7. Reduce barriers to health care and housing, an important social determinant of health
8. Increase the utilization of preventive dental services, while reducing emergency dental procedure costs
9. Improve access to services across the continuum of care
10. Provide for better care coordination for individuals transitioning to community-based care
11. Reduce the utilization of emergency departments and inpatient hospital settings for treatment where utilization is preventable or medically inappropriate
12. Reduce the overdose death rate
13. Improve access to fertility preservation services for Medicaid eligible individuals diagnosed with cancer, as well as access to in vitro fertilization (IVF) services for individuals diagnosed with certain genetic disorders

With the addition of the SUD and SMI Institution for Mental Diseases (IMD) amendment approvals, the state has expanded its objectives to include the following for individuals with SUD and/or SMI:

1. Improve access to services across the continuum of care
2. Provide for better care coordination for individuals transitioning to community-based care
3. Reduce the utilization of emergency departments and inpatient hospital settings for treatment, where utilization is preventable or medically inappropriate
4. Reduce the overdose death rate
5. Improve access to care for physical health conditions for these individuals

With the addition of the Pre-Release Services under Reentry Demonstration Initiative amendment approval, the state has further expanded its objectives to include the following for eligible individuals:

³ Centers for Medicare & Medicaid Services, 2025. *Demonstration Approval*. <https://www.medicare.gov/medicaid/section-1115-demonstrations/downloads/ut-medicare-reform-appvl-11132025.pdf>

1. Increase coverage, continuity of care, and appropriate service uptake through assessment of eligibility and availability of coverage for benefits in correctional facility settings prior to release
2. Improve access to services prior to release and improve transitions and continuity of care into the community upon release and during reentry
3. Improve coordination and communication between correctional systems, Medicaid systems, managed care plans (as applicable) and community-based providers
4. Increase additional investments in health care and related services, aimed at improving the quality of care for individuals in correctional facility settings, and in the community to maximize successful reentry post-release
5. Improve connections between correctional facility settings and community services upon release to address physical and behavioral health needs
6. Reduce all-cause deaths in the near-term post-release
7. Reduce the number of emergency department visits and inpatient hospitalizations among recently incarcerated Medicaid individuals through increased receipt of preventive and routine physical and behavioral health care
8. Provide interventions for certain behavioral health conditions, including use of stabilizing medications like long-acting injectable antipsychotics and medications for addiction treatment for SUDs where appropriate, with the goal of reducing overdose and overdose-related death in the near-term post-release

The Demonstration goals and/or objectives may be updated upon integration of the November 2025 amendment in the evaluation design for the summative evaluation report.

3. DESCRIPTION

Utah's 1115 Demonstration was first approved in 2002 and has transformed over the last twenty-four years through extensions and amendments that have added new authorities and Demonstration populations.

The original PCN Demonstration provided a limited package of preventive and primary care benefits (the PCN benefit) to adults ages 19-64 with household incomes up to 150 percent of the Federal Poverty Level (FPL) and a slightly reduced benefit package to Parent/Caretaker Relatives (PCR) who comprised the Current Eligibles population. With Medicaid expansion in April 2019, PCN program participants became eligible for full state plan benefits, and the PCN benefit was phased out. The Current Eligible population was phased out by December 31, 2023, eliminating disparities in benefit packages by parental status. An assessment of the phase-out process is included in the evaluation design.

The 1115 Demonstration has historically served as a vehicle to provide premium assistance to adults with household incomes above Medicaid eligibility requirements. In 2006, the Utah DHHS amended the 1115 Demonstration to establish the Health Insurance Flexibility and Accountability Employer Sponsored Insurance (ESI) program, which provides premium assistance to adults with household incomes up to and including 150 percent of the FPL and CHIP-eligible children with family incomes up to 200 percent of the FPL. This was later amended to include adults with incomes up to 200 percent of the FPL and programmatically eligible adults and children obtaining coverage through COBRA⁴. Under the current 1115 Demonstration, premium assistance helps pay the individual's or family's share of monthly premium costs of ESI or COBRA and is aggregated under Utah's Premium Partnership for Health Insurance Program (UPP). Individuals in the AE population with access to employer-sponsored insurance are required to enroll, with few exceptions. The state also increased the maximum assistance reimbursement amount in July 2021 making this program more substantial and potentially increasing the number of individuals covered by UPP. In February 2024, CMS approved an increase in the premium subsidy for children that would otherwise receive CHIP services under the state plan from \$120 to \$180. If a plan offers dental coverage, the premium subsidy amount will increase from \$140 to \$200.

⁴ Consolidated Omnibus Reconciliation Act of 1986

For nearly a decade, Utah's Demonstration has emphasized improving the behavioral health (BH) continuum of care. In November 2017 the state received approval to establish the TAM eligibility group. The TAM population consists of vulnerable adults ages 19-64, whose incomes are at 5 percent of the FPL, and who meet detailed eligibility criteria in one of three targeted categories: chronically homeless, involved in the justice system and in need of substance use or mental health treatment, or are in need of substance use or mental health treatment.

In December 2019, Utah received authority to enroll Demonstration populations in managed care plans and to create an integrated managed care model, known as the Utah Medicaid Integrated Care (UMIC) plan. The four UMIC plans manage both physical and behavioral health benefits for the AE population in Utah's five most populous counties: Davis, Salt Lake, Utah, Washington, and Weber. The AE population in the rest of the state are enrolled in Accountable Care Organizations (ACOs) for their physical health service delivery system and in Prepaid Mental Health Plans (PMHPs) for their behavioral health service delivery system. The integrated care model is intended to provide more holistic and coordinated care than previously.

In March 2022, CMS approved the HRSS amendment, allowing Utah to provide housing support services, such as tenancy supports, community transition services, and supportive living services to TAM individuals who meet additional eligibility criteria and exhibit one of seven risk factors. In an amendment approved in February 2024, an additional four risk factors were added to the HRSS program eligibility criteria to align eligibility with the sub-groups of the Targeted Adult group. The HRSS are paid on a fee-for-service basis. Providers are required to enroll and are evaluated to ensure they meet HRSS qualifications which includes being a certified case management provider. Once care plans have been approved, providers can submit claims for HRSS and receive reimbursement. As the program ramps up in the current waiver period, the state anticipates that HRSS will serve approximately 5,000 TAM individuals each year. By addressing crucial health-related social needs in a high-needs population, the state anticipates that the HRSS program will improve participant health outcomes or quality of life and reduce non-housing related Medicaid costs.

In January 2025, CMS approved coverage of HRSN services. The amendment:

- Expands the HRSS benefit to the AE population and to recently incarcerated individuals
- Adds short-term rental assistance and short-term recuperative care for AE and TAM populations
- Authorizes HRSN infrastructure investments
- Authorizes the state to provide non-medical transportation (NMT) to and from HRSN services for eligible individuals

Eligibility for HRSN services includes social and clinical risk factors and medical necessity criteria.

The 1115 Demonstration also includes components that focus on individuals with SUD and/or SMI, and youth with significant emotional disorder (SED) and/or behavioral challenges. Utah received approval of the SUD Implementation plan in November 2017. The Opioid Use Disorder (OUD) and SUD Program provides state plan behavioral health benefits to Demonstration participants. The state also received authority to provide residential and inpatient OUD/SUD treatment services to all Medicaid beneficiaries while they are short-term residents in treatment settings that qualify as IMDs.

The SMI/SED implementation plan was approved in December 2020 and is similar in expenditure authority to the OUD/SUD program. The state is taking action to meet key milestones of the SMI/SED program including, ensuring quality of care in psychiatric hospitals and residential settings, improving care coordination and transitions to community-based care, increasing access to the continuum of care including crisis stabilization services, and earlier identification and engagement in treatment and increased integration. Together, the SUD and SMI components expand access to mental health services, opioid use disorder (OUD) and other substance use disorder (SUD) services. The 1115 Demonstration supports state efforts to enhance provider capacity, improve the availability of Medication Assisted Treatment (MAT) and

improve access to a continuum of SMI evidence-based services at varied levels of intensity, including crisis stabilization services.

In February 2019, Utah received CMS approval to provide state plan Medicaid coverage to Former Foster Care Youth from another state (FFCYAS) who were ever enrolled in Medicaid in another state and are not otherwise Medicaid eligible in Utah. State plan coverage is provided to this population until 26 years of age.

In November 2019, Utah received CMS approval for the provision of intensive stabilization services (ISS) to Medicaid eligible children and youth under age 21 in state custody or at risk of being placed in state custody who are experiencing significant emotional and/or behavioral challenges. The ISS program provides both state plan BH services and home and community-based services (HCBS) that are not currently authorized through the state plan.

The Demonstration also authorized the Clinically Managed Residential Withdrawal Pilot from May 1, 2019, to April 1, 2021; this benefit became available statewide as of April 1, 2021 to all eligible Medicaid members. As a result, the state received approval on July 23, 2021, to remove this pilot project from the 1115 Demonstration and CMS is not requiring the state to evaluate this population.

The current 1115 Demonstration includes dental coverage for vulnerable populations. The PCN Demonstration first provided an adult dental benefit to the Current Eligibles population in November 2006. CMS approved dental benefits for adults with disabilities or blindness in 2017. In 2019, the state chose to provide comprehensive dental benefits to TAM adults receiving SUD treatment because research showed that dental coverage could increase initiation and engagement in treatment for individuals living with SUD. In 2020, dental benefits were extended to Medicaid eligible individuals aged 65 and older and to TAM adults in need of porcelain or porcelain-to-metal crowns. In January 2025, CMS approved an expansion of dental benefits to all Medicaid-eligible adults.

In February 2024, CMS approved an amendment to the current 1115 Demonstration enabling the state to receive expenditure authority for fertility preservation services provided to certain individuals diagnosed with cancer, as well as for IVF and genetic testing services for certain individuals. Under the IVF and genetic testing amendment, the state may provide genetic testing services to eligible individuals, preimplantation genetic testing of embryos, and IVF services to eligible individuals, ages 18 through 35, diagnosed by a physician with a genetic trait associated with cystic fibrosis, morquio syndrome, sickle cell anemia, spinal muscular atrophy, or myotonic dystrophy. Under the fertility treatment for individuals diagnosed with cancer amendment, the state is now enabled to provide fertility preservation for eligible individuals diagnosed with cancer and requiring treatment that may cause a substantial risk of sterility or iatrogenic infertility (i.e., infertility caused by treatment for cancer). Services covered under this once per lifetime benefit include the collection and storage of eggs or sperm and coverage for cryopreservation storage. Coverage for cryopreservation storage is covered as a single payment in five-year increments. In January 2025, CMS authorized an increase in the upper age limit for fertility preservation services for individuals diagnosed with cancer from 40 to 50 years of age.

In July 2024, CMS approved an additional amendment to the 1115 Demonstration called the “Pre-Release Services under Reentry Demonstration Initiative” that allows the state to provide limited coverage for a targeted set of services to certain eligible incarcerated individuals for 90 days prior to the individuals’ expected release. This amendment closely aligns with CMS’s “Reentry Demonstration Opportunity”, described in the State Medicaid Director Letter released in April 2023.

Individuals residing in a county jail, state prison, or youth correctional facility who have been determined eligible for Medicaid based on an application filed before or during incarceration are eligible to receive a limited set of pre-release benefits for up to 90 days before their expected release date. These benefits include, but are not limited to, case management, medication-assisted treatment for SUD, and physical and

behavioral health clinical consultation services. A full description of the pre-release services can be found in Exhibit 2.

In November 2025, CMS approved an amendment to the 1115 Demonstration that authorized the following changes:

- Authority for the state to provide extended postpartum coverage to individuals enrolled in Medicaid for up to 12 months from the last day of an individual's pregnancy (effective January 1, 2026).
- Coverage for dental services for children and pregnant or postpartum women enrolled in Medicaid (services to be received through FFS in partnership with the University of Utah School of Dentistry and associated statewide provider network effective July 1, 2026)
- Removal of ISS from the 1115 waiver (CMS and the state do not anticipate a disruption in care as the same service is authorized through a 1915(b) waiver authority)
- Removal of the HRSS program from the 1115 waiver where coverage for those services has fully transitioned to the HRSN program
- Coverage for family planning and family planning related services for adults (effective in 2027).

4. POPULATIONS

Exhibit 1 provides a summary of the Demonstration populations during the Demonstration period. AE is the largest population, consisting of approximately 116,000 adults ages 19-64 with incomes up to 133 percent of the FPL. Additional Demonstration benefits, programs, and services are summarized in Exhibit 2.

4.1 Scope of Interim Evaluation Report

The interim evaluation report will address health care access and engagement among the AE and TAM populations, as well as BH services among the SMI and SUD Demonstration populations. This report does not evaluate the goals of the HRSN amendment, small populations, and certain programs or services (e.g., FFYCAS, UPP/ESI, ISS, and Fertility and Genetic Testing Services) due to data feasibility. ISS has been removed from this 1115 waiver as of the November 2025 amendment, but the population receiving these services will be assessed in the Summative Evaluation Report for the duration of their participation in the demonstration. Additionally, the implementation of the Justice-Involved Reentry Benefit did not begin until February 2026, limiting sufficient data collection to adequately address the benefit within this report. Lastly, the November 2025 CMS approved amendment is undergoing evaluation design and will not be included in this report. Aspects of the Demonstration not discussed within this report will be assessed and shared upon in the summative evaluation report.

EXHIBIT 1: DEMONSTRATION ELIGIBLE POPULATIONS

Demonstration Eligible Populations	Eligibility ⁵	Benefits ²	Estimated Number of Annual Enrollees ⁶
Current Eligibles (CE)	Adults aged 19-64 who are medically needy and not aged, blind, or disabled. Individuals who are pregnant are excluded, through the 60th day postpartum.	Individuals enrolled in this eligibility category receive most of the benefits covered under Utah's state plan according to limitations specified in the state plan. Current Eligibles also receive benefits that are the equivalent of (b)(3) services under the state's 1915(b) PMHP waiver, which include psychoeducational services, personal services, respite care and supportive living services (mental health services in residential treatment settings)	The CE population was phased out entirely on December 31, 2023
Adult Expansion (AE)	Adults, age 19 through 64, who are not Current Eligibles, who are U.S. citizens/qualified non-citizens, are residents of Utah, and have household income at or below 133 percent of the FPL.	Expansion adults will receive state plan benefits and benefits that are the equivalent of (b)(3) services under the state's 1915(b) PMHP waiver, which include psychoeducational services, personal services, respite care and supportive living services.	115,584
Utah Medicaid Integrated Care (UMIC) – a subgroup of the AE population	Adult Expansion members enrolled in the Utah Medicaid Integrated Care program, which operates in Utah's most populous counties: Davis, Salt Lake, Utah, Washington, and Weber.	Expansion adults will receive state plan benefits and benefits that are the equivalent of (b)(3) services under the state's 1915(b) PMHP waiver, which include psychoeducational services, personal services, respite care and supportive living services.	49,963
Demonstration Populations III, V, VI, and Current	Demonstration Population III - working adults, aged 19-64, their spouses, and their children ages 19-26, with gross family incomes above 133 percent of the FPL and up to and including 200 percent of the FPL, are not	Individuals in these eligibility categories are eligible to receive premium assistance (through ESI or COBRA) in paying the employee's, individual's, or family's share of the monthly premium cost of qualifying insurance plans. Together, the ESI and COBRA benefits are the	1,288

⁵ Centers for Medicare & Medicaid Services, 2024. *Demonstration Approval*. <https://www.medicaid.gov/medicaid/section-1115-demonstrations/downloads/ut-cms-amndmnt-aprvl.pdf>

⁶ The annual estimates reflect the enrollment numbers reported in the Annual Monitoring Report for the period July 2021 – June 2022 for populations that are continuing from the prior waiver period. Estimates for TAM HRSS, a new population, are taken from the approved Waiver renewal. Estimates for IVF and genetic testing and fertility preservation treatments, and estimates for HRSN Services, are taken from the state's amendment applications to CMS. Estimates for the Justice-Involved populations are taken from state-generated updates to the state's amendment application to CMS.

Demonstration Eligible Populations	Eligibility ⁵	Benefits ²	Estimated Number of Annual Enrollees ⁶
Eligible CHIP Children	<p>otherwise eligible for Medicaid and participate in an approved ESI plan.</p> <p>Demonstration Population V - same as Demonstration population III, except that the eligible individual or custodial parent/caretaker is able to enroll in COBRA continuation coverage.</p> <p>Current Eligible CHIP Children - these children are eligible for the CHIP, but the children's parents have elected to receive premium assistance for the employee's share of the cost of ESI instead of receiving CHIP direct coverage.</p> <p>Demonstration Population VI - children up to age 19 with family income up to 200 percent of the FPL who would meet the definition of a low-income child. The population is divided into 2 groups: COBRA-Eligible Children and COBRA-Continuation Children.</p>	<p>"Utah Premium Partnership Program" (UPP). Premium assistance is the sole Medicaid benefit provided to these members.</p>	
Targeted Adult Medicaid (TAM)	<p>Includes adults, ages 19 through 64, with incomes below five percent of the FPL and no dependent children, who meet detailed criteria in one of three major categories:</p> <ul style="list-style-type: none"> ● Chronic homelessness ● Involved in the criminal justice system and in need of substance use or mental health treatment. ● In need of substance use or mental health treatment 	<p>Individuals enrolled in this eligibility category receive full Medicaid state plan benefits.</p>	9,384

Demonstration Eligible Populations	Eligibility ⁵	Benefits ²	Estimated Number of Annual Enrollees ⁶
Intensive Stabilization Services (ISS)	Medicaid eligible children and youth under age 21, who are in state custody, or at risk of state custody, and experiencing significant emotional and/or behavioral challenges.	Individuals eligible for this category will receive state plan and home community-based crisis stabilization services during the first eight-weeks of the intensive program on a FFS basis using a daily bundled rate.	Anticipate 20
Former Foster Care Youth from Another State (FFCYAS)	Individuals under age 26, who were in foster care under the responsibility of a state other than Utah, or a tribe in such other state when they turned 18 (or such higher age as the state has elected for termination of federal foster care assistance under title IV-E of the Act), were ever enrolled in Medicaid, are now applying for Medicaid in Utah, and are not otherwise eligible for Medicaid.	Individuals enrolled in this eligibility category receive full Medicaid state plan benefits.	17

EXHIBIT 2: ADDITIONAL DEMONSTRATION BENEFITS, PROGRAMS, AND SERVICES

Additional Demonstration Benefits, Programs, and Services	Eligibility ⁷	Benefits ²	Estimated Number of Annual Enrollees ⁸
Dental Benefit	<p>As of the amendment approved in January 2025, all individuals enrolled in Medicaid and are the age of 21 or older. Previously, dental benefits were available only to the aged, blind, or disabled groups, and to TAM members receiving SUD treatment.</p> <p>As of the amendment approved in November 2025, children and pregnant or postpartum women enrolled in Medicaid will have coverage for dental services.</p>	<p>Individuals that are enrolled in this eligibility category will receive state plan dental benefits that are defined in the Utah Medicaid Provider Manual, Dental Services and porcelain or porcelain-to-metal crowns, if needed.</p> <p>Following the November 2025 amendment, dental services for children and pregnant or postpartum women will be offered through a FFS delivery system in partnership with the University of Utah School of Dentistry and their associated statewide provider network rather than through managed care plans.</p>	<p>Entire Adult Expansion population 115,584</p> <p>Number of children to receive November 2025 dental benefit TBD</p>
Health-Related Social Needs (HRSN) Services	<p>As of the amendment approved in January 2025: the following covered populations will be eligible to receive HRSN services if they also satisfy the applicable clinical and social risk criteria and the HRSN services are determined to be medically appropriate:</p> <p>Recently Incarcerated Individuals are eligible for HRSS.</p> <p>Adult Expansion and TAM Demonstration populations are eligible for HRSS, Short-Term Rental Assistance, Short-Term Recuperative Care, and Short-Term Post Transition Housing</p>	<p>Housing-Related Services and Supports (HRSS): includes pre-tenancy navigation services, tenancy sustaining services, one-time transition and moving costs other than rent, home accessibility modifications and remediations that are medically necessary.</p> <p>Short-Term Rental Assistance: payment for rent and/or short-term temporary stays for up to six months in a 5-year period.</p> <p>Short-Term Recuperative Care (a/k/a Medical Respite): clinically oriented recuperative or rehabilitative services and supports for individuals</p>	5,000

⁷ Centers for Medicare & Medicaid Services, 2024. *Demonstration Approval*. <https://www.medicaid.gov/medicaid/section-1115-demonstrations/downloads/ut-cms-amndmnt-aprvl.pdf>

⁸ The annual estimates reflect the enrollment numbers reported in the Annual Monitoring Report for the period July 2021 – June 2022 for populations that are continuing from the prior waiver period. Estimates for TAM HRSS, a new population, are taken from the approved Waiver renewal. Estimates for IVF and genetic testing and fertility preservation treatments, and estimates for HRSN Services are taken from the state's amendment applications to CMS. Estimates for the Justice-Involved populations are taken from state-generated updates to the state's amendment application to CMS.

Additional Demonstration Benefits, Programs, and Services	Eligibility ⁷	Benefits ²	Estimated Number of Annual Enrollees ⁸
		<p>who require ongoing monitoring and continuous access to medical care.</p> <p>Short-Term Post Transition Housing: clinically oriented rehabilitative services and supports for individuals who do not require ongoing monitoring and continuous access to medical care.</p>	
Serious Mental Illness (SMI) IMD Benefit	Medicaid recipients, age 21 through 64 receiving SMI services in IMD treatment settings.	The Demonstration grants Utah expenditure authority for services provided to beneficiaries during short term stays in an IMD to receive acute care for a primary diagnosis of SMI or SED for stays of up to 60 days, as long as the state shows at its midpoint assessment that it is meeting the requirement of a 30 day or less average length of stay (ALOS) for beneficiaries residing in an IMD who are receiving covered services in an IMD.	8
Opioid Use Disorder/ Substance Use Disorder Program	SUD benefits are available to all Medicaid members through state plan authority.	The Demonstration grants Utah expenditure authority to provide the following services in IMDs: residential treatment, withdrawal management, medication-assisted treatment (MAT), peer support, residential crisis stabilization.	767
In Vitro Fertilization and Genetic Testing Services	In Vitro Fertilization (IVF): Medicaid recipients ages 18-35 diagnosed by a physician or qualified health professional as having a genetic trait associated with cystic fibrosis, morquio syndrome, sickle cell anemia, or spinal muscular atrophy, and has a reproductive partner who has been diagnosed with the same condition. Has been diagnosed by a physician or qualified health professional as having a genetic trait associated with myotonic dystrophy.	In vitro fertilization services, genetic testing services, and preimplantation genetic testing to test embryos for genetic disorders prior to transfer to the uterus. These services require prior authorization, and qualifying beneficiaries may receive up to three cycles of IVF per lifetime.	50

Additional Demonstration Benefits, Programs, and Services	Eligibility ⁷	Benefits ²	Estimated Number of Annual Enrollees ⁸
	Genetic testing: Medicaid recipients who have a familial medical history or are in an ethnic group that has a high risk of one or more of the following medical conditions: cystic fibrosis, morquio syndrome, myotonic dystrophy, sickle cell anemia, or spinal muscular atrophy.		
Fertility Preservation Benefit for Individuals Diagnosed with Cancer	Medicaid recipients diagnosed by a physician or qualified health professional as having an active cancer diagnosis requiring treatment that may cause a substantial risk of sterility or iatrogenic infertility. Individuals must be post pubertal and younger than age 50.	Individuals can receive egg and sperm collection and storage, preimplantation genetic testing prior to cryopreservation storage, and cryopreservation storage. These benefits require prior authorization and are available once per lifetime.	226
Justice-Involved Reentry Benefit	Individuals who are inmates residing in county jails, state prisons, or youth correctional facilities and have been determined eligible for Medicaid pursuant to an application filed before or during incarceration.	<p>Eligible individuals can receive the following pre-release services starting 90 days before their release from incarceration:</p> <ul style="list-style-type: none"> • Case management to assess and address physical and behavioral health needs • Medication-assisted treatment services for all types of SUD as clinically appropriate, with accompanying counseling • A 30-day supply of all prescription medications that have been prescribed for the individuals at the time of release provided to the individual immediately upon release from the correctional facility • Physical and behavioral health clinical consultation services, as clinically appropriate, to diagnose health conditions, provide treatment, and support pre-release case managers' development of a post- 	<p>Adults: 3,600</p> <p>Youth:15</p>

Additional Demonstration Benefits, Programs, and Services	Eligibility ⁷	Benefits ²	Estimated Number of Annual Enrollees ⁸
		<p>release treatment plan and discharge planning</p> <ul style="list-style-type: none"> ● Diagnostic services, including laboratory and radiology services, and treatment services in addition to coverage for MAT described above ● Prescribed drugs, in addition to MAT and the 30-day supply of prescription medication, and medication administration ● Family planning services and supplies ● Services provided by community health workers ● Peer support services ● Treatment for Hepatitis C ● Medical equipment and supplies and/or medical equipment provided upon release <p>Youth eligible for CHIP will receive pre-release screening, diagnostic, and case management services starting 30 days before their release.⁹</p>	
<p>Family Planning Services and Family Planning Related Services</p>	<p>Individuals ages 18 and older with family income at or below 185 percent of the FPL (5% income disregard) who are not in a public institution and are not otherwise eligible for Medicaid or the Children’s Health Insurance Program (CHIP)</p>	<p>The demonstration provides a set of family planning services and family planning related services delivered through a FFS delivery system:</p> <ul style="list-style-type: none"> ● Comprehensive family planning visits, which include counseling, education or management of contraceptive methods ● FDA approved methods of contraception ● FDA-approved vaccination for Human Papillomavirus (HPV) 	<p>TBD</p>

⁹ Authority for pre-release services for CHIP eligible youth is covered under the SPA, and not held under the Utah Medicaid Reform 1115 Demonstration waiver; this evaluation will not include this population.

Additional Demonstration Benefits, Programs, and Services	Eligibility ⁷	Benefits ²	Estimated Number of Annual Enrollees ⁸
		<ul style="list-style-type: none"> • Screening for sexually transmitted infection (STI) or sexually transmitted disease (STD) during a family planning visit, pap smears, and pelvic exams • Drug, supplies, or devices related to family planning services as prescribed by a health care provider • Treatment for STIs/STDs, except for HIV/AIDS and hepatitis, when the STI/STD is identified/diagnosed during a screen pursuant to a routine or periodic family planning visit • STI/STD diagnosis and treatment pursuant to a family planning visit • Sterilization procedures and devices, the office visits or physical exams related to and necessary for sterilization or long-acting reversible contraception, and insertion of contraception and/or approved prescription of anxiety and pain medication in relation to the sterilization procedure (covered procedures include vasectomies, salpingectomy, tubal occlusions, and tubal ligations) 	
Extended Postpartum Coverage	Individuals enrolled in any Medicaid eligibility group while pregnant (including during a period of retroactive eligibility)	Eligible individuals will remain enrolled continuously within their eligibility group regardless of changes in circumstances (except for changes in state residency, if the individual requests voluntary termination, or the individual is deceased) from pregnancy through the duration of the extended 12-month postpartum period	13,805 – 13,992

5. CONTEXT

The Utah Medicaid 1115 Demonstration also coincided with the unwinding of the Medicaid Continuous Enrollment requirement associated with the Covid-19 pandemic beginning in 2020. Enrollment in Medicaid remained high during the continuous enrollment period as states were required to keep current Medicaid beneficiaries enrolled. The unwinding of continuous eligibility for Medicaid began on March 1, 2023.¹⁰ Under Utah's unwinding plan¹¹, every member's case was slated for a full review, with cases spread over a 12-month period. Cases most likely to change programs or coverage were prioritized for review, and those most likely to remain Medicaid eligible were deferred to later in the year. DHHS communicated with providers and beneficiaries about the redetermination process. Members were urged to update their contact information and check the unwinding website¹² to learn their anticipated review date. During the redetermination process, between April 2023 to March 2024, there was a 36% decrease in Medicaid enrollment.¹³

¹⁰ Tolbert, J. and Ammula, M., 2023. *10 Things to Know About the Unwinding of the Medicaid Continuous Enrollment Provision*. KFF. [10 Things to Know About the Unwinding of the Medicaid Continuous Enrollment Provision | KFF](#)

¹¹ Utah Department of Health & Human Services. *Unwinding Continuous Medicaid Eligibility*. <https://medicaid.utah.gov/unwinding/>


¹² Utah Department of Workforce Services. *MyCase*. <https://jobs.utah.gov/mycase/>

¹³ Strohecker, J. and Burt, K., 2024. *Utah Medicaid Unwinding Closeout*. Utah Department of Health & Human Services. <https://le.utah.gov/interim/2024/pdf/00002275.pdf>

C. EVALUATION QUESTIONS AND HYPOTHESES

1. LOGIC MODEL

EXHIBIT 3: LOGIC MODEL¹⁴



¹⁴ The logic model will include the November 2025 amendment once measures are determined.

2. HYPOTHESES AND RESEARCH QUESTIONS

The logic model above illustrates how the Demonstration objectives are expected to be achieved by program activities, following a natural progression from proximate to distal outcomes as the Demonstration goes on. Each outcome is represented by a testable hypothesis, listed below, about the impact of the Demonstration activities, and a corresponding research question. Tables 15-25 specify the measures that will be used to assess each hypothesis.

The hypotheses are organized by population or program/benefit and are focused on the broad themes of increasing health care coverage, increasing access to primary care and appropriate utilization, reducing high-cost acute care utilization, including potentially preventable utilization, and reducing the cost of uncompensated care.

The first objective of the 1115 Demonstration, providing health care coverage for low-income Utahns eligible who would not otherwise have access to or be able to afford health care coverage, is achieved through enrollment in a number of the Demonstration populations, including the AE, TAM, UPP, and ISS. Individuals in these populations would not otherwise be eligible for Medicaid without the presence of the Demonstration in Utah.¹⁵ The first hypothesis is thus focused on the impact of the 1115 Demonstration overall on the population of low-income UT residents. A large fraction of low-income UT residents is expected to report having access to coverage and engaging in health care relative to reported access and engagement in other states. Engagement in care is expected to improve member satisfaction and lead to reductions in inappropriate care utilizations, also known as “Low Value Care”.

The second hypothesis is similar to the first hypothesis and focuses specifically on the AE population’s improved health care access and engagement. The state hypothesizes that by providing coverage through Medicaid expansion, members will engage in primary and preventive care, which will lead to reductions in acute care utilization. The UMIC population, a subpopulation of the AE population, consists of members in Utah’s five-most populous counties who are enrolled in plans that integrate care for physical and behavioral health needs. Thus, the UMIC research questions are specific to the outcomes produced when members gain access to behavioral health care that is managed by the same managed care organization that manages their physical health care. It is anticipated that the UMIC population will experience improved engagement in BH services and reduced ED utilization.

The third hypothesis examines access and engagement in health care, for the TAM population. The state hypothesizes that the Demonstration will continue to improve health care access and engagement for this population.

The fourth hypothesis addresses the HRSN Demonstration, which expands the HRSS benefit previously available only to TAM members, to the entire AE population who meet the needs-based eligibility criteria. The state is authorized to provide HRSS, short-term rental assistance, short-term recuperative care, short-term post-transition housing, and NMT. The evaluation design focuses on HRSS and NMT. The other authorized services had not been implemented at the time of writing this report. The other services may, or may not, be implemented later in the Demonstration period. If they are implemented, they should contribute to the same outcomes theorized for HRSS. It is anticipated that the HRSN Demonstration will reduce the prevalence and severity of housing and transportation needs, increase continuity of BH treatment, and improve health outcomes for eligible members. Research questions include whether HRSN services were provided and utilized as planned, care manager perspectives on incorporating this new benefit, whether there is unmet need, and whether HRSS improves perceived health status. Other research questions about the HRSN Demonstration focus on how HRSN affects high-cost acute care utilization.

¹⁵ Individuals in the Current Eligibles population received expanded benefits through the waiver, although they would have received coverage regardless of the presence of the waiver.

The fifth and sixth hypotheses speak to BH services provided to Demonstration participants and Medicaid beneficiaries with SMI and SUD treated in IMD. The state anticipates that BH coverage for residential and inpatient services provided to members in IMDs will lead to a reduction in inpatient stays, ED utilization, and rate of unplanned readmission among recipients, resulting in cost decrease or stabilization. The state also anticipates this will lessen unmet needs and increase engagement in treatment to reduce overdose deaths in the long-term. The IE will monitor the impact of the state's efforts to increase access to crisis stabilization services. Greater utilization of non-hospital, non-residential services is anticipated to lead to greater reductions in inpatient stays, ED utilization, and overdose deaths in the long-term.

The seventh hypothesis addresses smaller Demonstration populations, which include UPP/ESI, ISS, TAM Dental, and FFCYAS. The state anticipates that utilization of the services provided to these populations will increase and total cost of care will decrease, as these members engage in acute and preventive care. Although the number of AE members enrolled in Employer Sponsored Insurance will grow due to the new provision present in this waiver requiring enrollment in ESI for all AE members who have access to insurance through their employers, the number of members enrolled in ESI is not projected to exceed 1,385 members during this Demonstration period. As a result, the ESI policy by itself is unlikely to lead to population-level reductions in uncompensated care and inappropriate care utilization. In addition, the number of individuals in the FFCYAS population, and the number receiving ISS, were both very small in the prior Demonstration period. Therefore, the evaluation will include counts and a qualitative summary of program implementation.

Hypotheses eight through eleven focus on the justice-involved (JI) population and the newly covered pre-release and reentry services. The state anticipates that the Demonstration will enhance cross-system collaboration between the correctional and community-based services systems, that enrollment and redetermination support will improve continuity of coverage, and that coverage of pre-release and reentry services will improve engagement in high quality care, reduce unnecessary acute care utilization, and ultimately improve health outcomes for the JI population.

In addition, the state will conduct a Demonstration cost assessment including administrative costs of Demonstration implementation and operation, Medicaid health services expenditures, and provider uncompensated care costs. The evaluation design is being revised to reflect the November 2025 waiver amendment, including family planning services, at the time of the drafting of this report. New hypotheses and research questions will be included in the summative evaluation report, following CMS approval of the revised evaluation design document.

Hypothesis 1: The Demonstration overall will improve access to coverage and engagement in health care for low-income UT residents.

- Primary research question 1.1: Did the fraction of low-income residents with no coverage decrease, relative to comparison states?
- Primary research question 1.2: Did the fraction of low-income residents who avoided care due to cost decrease, relative to comparison states?
- Primary research question 1.3: Did the fraction of low-income residents who have a personal doctor or usual source of care increase, relative to comparison states?
- Primary research question 1.4: Did the fraction of low-income residents who had a primary or specialty care appointment in the last year increase, relative to comparison states?
- Primary research question 1.5: Did the fraction of low-income residents who had a preventive screening in the last year increase, relative to comparison states?
- Primary research question 1.6: What is the member experience of care in terms of access, timeliness, and patient-centeredness?
- Primary research question 1.7: Did Low Value Care decrease among Demonstration participants, relative to baseline?

Hypothesis 2: The Demonstration will improve health care access and engagement for the AE population.

- Primary research question 2.1: Did inpatient hospital utilization decrease, relative to baseline, for the AE population?
- Primary research question 2.2: Did ED visits decrease, relative to baseline, for the AE population?
 - Subsidiary research question 2.2.a: Did ED visits for BH conditions decrease, relative to baseline, for the AE population?
 - Subsidiary research question 2.2.b: Did UMIC plans reduce ED visits for BH conditions for AE population, relative to FFS or physical health-only ACO plans?
- Primary research question 2.3: Did engagement in primary and ambulatory care increase, relative to baseline, for the AE population?
- Primary research question 2.4: Did engagement in behavioral health care increase, relative to baseline, for the AE population?
 - Subsidiary research question 2.4.a: Did UMIC plans improve engagement in behavioral health care for the AE population, relative to FFS or physical health-only ACO plans?
- Primary research question 2.5: Did engagement in treatment for chronic conditions increase, relative to baseline, for the AE population?
- Primary research question 2.6: Did preventive cancer screening increase, relative to baseline, for the AE population?
- Primary research question 2.7: Did dental service provision increase relative to baseline for the AE population?
- Primary research question 2.8: Did ED visits for non-traumatic dental conditions decrease relative to baseline for the AE population?
- Primary research question 2.9: Did follow-up after ED visits for non-traumatic dental conditions increase relative to baseline for the AE population?
- Primary research question 2.10: To what extent are beneficiaries aware of the dental care benefit?

Hypothesis 3: The Demonstration will improve health care access and engagement for the TAM population.

- Primary research question 3.1: Did inpatient hospital utilization decrease, relative to baseline, for the TAM population?
- Primary research question 3.2: Did ED visits decrease, relative to baseline, for the TAM population?
 - Subsidiary research question 3.2.a: Did ED visits for BH conditions decrease, relative to baseline, for the TAM population?
- Primary research question 3.3: Did engagement in primary and ambulatory care increase, relative to baseline, for the TAM population?
- Primary research question 3.4: Did engagement in behavioral health care increase, relative to baseline, for the TAM population?
- Primary research question 3.5: Did dental service provision increase relative to baseline for the TAM population?
- Primary research question 3.6: Did ED visits for non-traumatic dental conditions decrease relative to baseline for the TAM population?
- Primary research question 3.7: Did follow-up after ED visits for non-traumatic dental conditions increase relative to baseline for the TAM population?

Hypothesis 4: The HRSN Services Demonstration will effectively mitigate members' housing and transportation needs, lead to more appropriate service utilization and improved physical and mental health outcomes.

- Primary research question 4.1: What is the prevalence and severity of beneficiaries' social needs?
- Primary research question 4.2: Were HRSN services provided and utilized as planned?
- Primary research question 4.3: Did the HRSN Demonstration effectively mitigate beneficiaries' housing and transportation needs?

- Primary research question 4.4: Did high-cost acute utilization decrease, relative to baseline, for HRSN recipients?
- Primary research question 4.5: Did engagement in primary and ambulatory care increase, relative to baseline, for HRSN recipients?
- Primary research question 4.6: Did engagement in behavioral health care increase, relative to baseline, for HRSN recipients?
- Primary research question 4.7: From the beneficiaries' perspective, did the HRSN services meet their housing-related needs, support their engagement in behavioral health care, and overall positively impact their physical and mental health?
- Primary research question 4.8: Did state and local investments in housing supports change over time during the HRSN Demonstration?
- Primary research question 4.9: Were there any improvements in the quality and effectiveness of downstream housing-related services and supports?

Hypothesis 5: The SMI and SUD Demonstrations increased access to appropriate treatment.

- Primary research question 5.1: Did the number of individuals receiving services for SMI and/or SUD increase, relative to baseline?
- Primary research question 5.2: Did ED visits for BH conditions decrease among individuals with SMI and/or SUD diagnoses, relative to baseline?
- Primary research question 5.3: Did inpatient days (outside of IMDs) decrease, relative to baseline, for individuals with SMI and/or SUD?
- Primary research question 5.4: Did engagement in SUD treatment increase among individuals with SUD diagnoses relative to baseline?
- Primary research question 5.5: Did unplanned readmission following hospitalization for psychiatric treatment decrease among individuals with SMI relative to baseline?
- Primary research question 5.6: Did utilization of any mental health service increase among low-income residents, relative to comparison states?
- Primary research question 5.7: Did the number of individuals needing but not receiving SUD treatment decrease among low-income residents, relative to comparison states?
- Primary research question 5.8: Did the rate of overdose deaths decrease, relative to baseline?
- Primary research question 5.9: Did the number of individuals receiving crisis stabilization services increase (with an emphasis on non-hospital, non-residential services)¹⁶?

Hypothesis 6: The SMI and SUD Demonstrations stabilized or reduced cost of care for these populations.

- Primary research question 6.1: Did the total cost of care for individuals with SMI diagnoses change, relative to baseline?
 - Subsidiary research question 6.1.a: Did costs related to the diagnosis and treatment of SMI change, relative to baseline? (SMI-IMD costs + other SMI costs + non-SMI costs)?
 - Subsidiary research question 6.1.b: What types of care (inpatient + non-ED outpatient, + ED outpatient + pharmacy, + long-term care) are the primary drivers of the cost of care for the SMI population?
- Primary research question 6.2: Did the total cost of care for individuals with SUD diagnoses change, relative to baseline?
 - Subsidiary research question 6.2.a: Did costs related to the diagnosis and treatment of SUD change, relative to baseline? (SUD-IMD costs + other SUD costs + non-SUD costs)?
 - Subsidiary research question 6.2.b: What types of care (inpatient + non-ED outpatient, + ED outpatient + pharmacy, + long-term care) are the primary drivers of the cost of care for the SUD population?

¹⁶ This includes services made available through crisis call centers, mobile crisis units, and coordinated community response services as defined in STC 12.4 SMI/SED Financing Plan.

Hypothesis 7: The Demonstration delivered coverage/ services appropriately to individuals in the smaller Demonstration populations and programs.

UPP/ESI

- Primary research question 7.1: Did the number of individuals receiving coverage increase relative to baseline?
- Primary research question 7.2: What was the average total Medicaid cost of care for enrollees?
- Primary research question 7.3: Did the pmpm cost for enrollees change over time?

ISS

- Primary research question 7.4: Did the number of individuals receiving ISS increase relative to baseline?

FFCYAS

- Primary research question 7.5: How many FFCYAS received coverage?

Fertility and Genetic Testing Services

- Primary research question 7.6: Did the number of individuals receiving fertility preservation services increase relative to baseline?
- Primary research question 7.7 Did the number of individuals receiving genetic testing services increase relative to baseline?

Hypothesis 8: The JI Reentry Benefit will enhance cross-system communication and coordination between correctional and community services.

- Primary research question 8.1: Did the Demonstration's services facilitate beneficiaries' post-release transitions to care?
- Primary research question 8.2: Was communication and coordination between the correctional system and community-based health services enhanced?

Hypothesis 9: The JI Reentry Benefit will improve pre-release service provision during the covered period and continuity of coverage for the justice-involved population.

- Primary research question 9.1: What Demonstration services did JI individuals receive in the pre-release period?
- Primary research question 9.2: What was beneficiaries' experience of pre-release service provision?
- Primary research question 9.3: Were beneficiaries potentially in need of behavioral health services identified in the pre-release period?
- Primary research question 9.4: What fraction of JI individuals received navigation support for accessing Medicaid coverage pre-release?
- Primary research question: 9.5: Did reentry continuity of coverage improve for incarcerated individuals compared to the pre-Demonstration comparison population?

Hypothesis 10: The JI Reentry Benefit's 90-day pre-release coverage period ("the coverage timeline") will support effective program implementation.

- Primary research question 10.1: Did the coverage timeline facilitate providing more coordinated, efficient, and effective reentry planning?
 - Subsidiary research question 10.1.a: Were assessments and care plans completed in a timely manner?
 - Subsidiary research question 10.1.b: Did beneficiaries receive a 30-day supply of all prescribed medications immediately upon release from the carceral setting?
- Primary research question 10.2: Did the coverage timeline enable pre-release management and stabilization of clinical, physical, and behavioral health conditions?

- Primary research question 10.3: Did the coverage timeline help mitigate potential operational challenges the state might have encountered in a more compressed timeline?

Hypothesis 11: The JI Reentry Benefit will improve engagement in health care and social services, reduce acute care utilization, and improve health outcomes for the justice-involved population post-release.

- Primary research question 11.1: Did engagement in appropriate health care services post-release increase relative to a pre-Demonstration comparison population?
- Primary research question 11.2: Did inpatient hospital utilization post-release decrease relative to the pre-Demonstration comparison population?
- Primary research question 11.3: Did ED visits post-release decrease, relative to the pre-Demonstration comparison population?
- Primary research question 11.4: Did the rate of deaths post-release decrease relative to the pre-Demonstration population?
- Primary research question 11.5: Was the timing or provision of specific pre-release services associated with better post-release outcomes?

D. METHODOLOGY

1. EVALUATION DESIGN

The Independent Evaluator (IE) used a mixed-methods evaluation approach for the interim evaluation report that combined survey and Medicaid claims data to address the goals and hypotheses presented in the Demonstration. The evaluation design for the entirety of the Demonstration, including the HRSS participant interview methodology undergoing qualitative data collection for the summative evaluation report, can be found in the Attachments (Sections J.1 and J.3, respectively). For a brief summary of what is included in the interim evaluation report and planned for the summative evaluation report, see Exhibit 4 below.

EXHIBIT 4: INTERIM AND SUMMATIVE REPORT ANALYSIS DETAILS

	Interim Evaluation Report	Summative Evaluation Report
Time period	July 1, 2017 – June 30, 2022 (Baseline) July 1, 2022 – June 30, 2025 (Intervention Period)	July 1, 2017 – June 30, 2022 (Baseline) July 1, 2022 – June 30, 2027 (Intervention Period)
Data sources	<ul style="list-style-type: none"> ✓ Medicaid Claims (MMIS) ✓ Custom Member Survey Data 	<ul style="list-style-type: none"> ✓ National Survey Data ✓ Medicaid Claims (MMIS) ✓ Administrative Data ✓ Beneficiary Interviews
Approach	Quasi-experimental	Quasi-experimental Qualitative Interviews
Findings	Trends within the first three years of the Demonstration	Impact of full five years of Demonstration

2. TARGET POPULATIONS

As described in Exhibit 1, the Demonstration provided coverage and services for multiple populations. The Demonstration populations (the target groups) for the interim evaluation report are shown below in Exhibit 5. For each population, the comparison was to pre-Demonstration baseline trends.

EXHIBIT 5: DEMONSTRATION POPULATIONS AND COMPARISONS

Demonstration Population	Program Implementation Start	Baseline Years	Comparison ¹	Analytic Approach
Adult Expansion Population (AE)	April 1, 2019 (partial expansion, up to 100% of the FPL) January 1, 2020 (full expansion)	July 1, 2018- June 30, 2022	Pre-Demonstration baseline	Trend Over Time Regression Modeling
Targeted Adult Medicaid (TAM)	November 1, 2017	November 1, 2017 - June 30, 2022	Pre-Demonstration baseline	Trend Over Time Regression Modeling

Serious Mental Illness (SMI) IMD	December 1, 2020	December 1, 2020 - June 30, 2022	Pre-Demonstration baseline	Trend Over Time Regression Modeling
Substance Use Disorder (SUD) IMD	November 9, 2017	November 1, 2017 - June 30, 2022	Pre-Demonstration baseline	Trend Over Time Regression Modeling

¹The term “pre-Demonstration baseline” refers to the period before the start of the current Demonstration period; before July 1, 2022.

3. EVALUATION PERIOD

This summative evaluation report will cover the five-year Demonstration period from July 1, 2022, through June 30, 2027. The interim evaluation report covers the first three years of the Demonstration: July 1, 2022, through June 30, 2025. The summative evaluation report will extend these findings and incorporate additional analyses through the end of the Demonstration period, June 30, 2027. See Exhibit 6 for the breakdown of eligibility groups and services across the Demonstration timeline.

EXHIBIT 6: ELIGIBILITY GROUPS AND SERVICES TIMELINE¹⁷

	Prior Demonstration Period					Early Demonstration		Late Demonstration		
	DY1 (7/1/17- 6/30/18)	DY2 (7/1/18- 6/30/19)	DY3 (7/1/19- 6/30/20)	DY4 (7/1/20- 6/30/21)	DY5 (7/1/21- 6/30/22)	DY1 (7/1/22- 6/30/23)	DY2 (7/1/23- 6/30/24)	DY3 (7/1/24- 6/30/25)	DY4 (7/1/25- 6/30/26)	DY5 (7/1/26- 6/30/27)
Eligibility Groups	Public Health Emergency									
Utah Premium Partnership	11/1/06									
Targeted Adult Medicaid (TAM)	11/1/17									
	TAM Dental: 3/1/19					TAM HRSS: 12/1/22				
Intensive Stabilization Services	7/1/20									
Former Foster Care Youth from Another State	4/1/19									
Adult Expansion	4/1/19									
Benefits, Programs, and Services										
Substance Use Disorder IMD	11/9/17									
Serious Mental Illness IMD	1/1/21									
Fertility and Genetic Testing Services	5/1/24									
Dental Benefit	1/1/25									
Justice-Involved Reentry, Youth	1/1/25									
Justice-Involved Reentry, Adults	2/1/26									
Health-Related Social Needs	7/1/25									

¹⁷ New eligibility groups and services authorized under the November 2025 amendment will be included once implementation start dates are determined.

4. EVALUATION MEASURES

The Medicaid claims data were used to calculate Healthcare Effectiveness Data and Information Set (HEDIS) measures explored in the interim evaluation report. The standardized HEDIS measures are described below in Exhibit 7.

EXHIBIT 7: CLAIMS-BASED HEDIS MEASURES

Measure	Description
Acute Care Measures	
Acute Hospital Utilization (AHU)	The rate per member per year of inpatient admissions among members 19–64 years of age.
Emergency Department Utilization (EDU)	The rate per 1,000 of members 19–64 years of age who had emergency department visits during the measurement year.
Emergency Department Utilization for Behavioral Health Conditions (EDU-BH)	The rate per 1,000 of members 19–64 years of age who had emergency department visits for behavioral health conditions during the measurement year.
Ambulatory and Behavioral Health Care Measures	
Adults' Access to Ambulatory/Preventive Care (AAP)	The percentage of members 19–64 years of age and older who had an ambulatory or preventive care visit during the measurement year.
Initiation and Engagement of Substance Use Disorder Treatment (IET)	The percentage of members 19–64 years of age with a substance use disorder (SUD) episode that results in treatment initiation and engagement. Two rates are reported: <ol style="list-style-type: none"> <i>Initiation of SUD Treatment</i> – The percentage of new SUD episodes that result in treatment initiation through an inpatient SUD admission, outpatient visit, intensive outpatient encounter, partial hospitalization, telehealth visit or medication treatment within 14 days. <i>Engagement of SUD Treatment</i> – The percentage of new SUD episodes that have evidence of treatment engagement within 34 days of initiation.
Follow-Up After Hospitalization for Mental Illness (FUH)	The percentage of discharges for members 19–64 years of age who were hospitalized for a principal diagnosis of mental illness, or any diagnosis of intentional self-harm, and had a mental health follow-up service. Two rates are reported: <ol style="list-style-type: none"> <i>7-Day Follow-Up</i> – The percentage of discharges for which the member received follow-up within 7 days after discharge. <i>30-Day Follow-Up</i> – The percentage of discharges for which the member received follow-up within 30 days after discharge.
30-Day All-Cause Unplanned Readmission Following Psychiatric Hospitalization in an Inpatient Psychiatric Facility (IPF)	The rate of unplanned, 30-day readmission for members 19–64 years of age discharged from an inpatient psychiatric facility (IPF) with a principal discharge diagnosis of a psychiatric disorder or dementia/Alzheimer's disease. A readmission is any admission, for any reason, to an IPF or short-stay acute care hospital (including Critical Access Hospitals) that occurs within 30 days after the discharge date from an eligible index admission to an IPF, except those considered planned.

5. DATA SOURCES

The evaluation utilized the following quantitative data sources for the interim evaluation report:

- Medicaid Claims (MMIS)
- Custom Member Survey

5.1 Medicaid Claims Data

The IE received claims data from the state on an annual basis. Administrative data was of high quality, in terms of completeness and accuracy, with the exception of race/ethnicity data. The demographic summary provided in Results (Section F.2) indicates that race/ethnicity was “other” or missing for a large portion of each population (35.7% for AE and 31.1% for TAM).

5.2 Custom Member Survey Data

The IE developed a custom member survey with subcontracted commissioned ForHealth Consulting at UMass Chan Medical School to design and conduct a custom member survey evaluating the impact of the Demonstration on Utah Medicaid members’ access to an engagement in health care. The full report is provided in the Attachments (Section J.4). The member satisfaction survey consisted of custom survey questions and select questions from the Consumer Assessment of Healthcare Providers and Systems (CAHPS) surveys. The survey was administered from July 2, 2025, to September 17, 2025, in English and Spanish. Members had the opportunity to complete the survey via mail, online, or by phone. Among the 23,011 Utah AE Medicaid members in the sampling frame, 6,000 members were selected for the survey, and 1,865 completed the survey, yielding a response rate of 32%.

6. ANALYTIC METHODS

6.1 Quantitative Methods

The evaluation design includes multiple analytic strategies to answer the research questions and provide robust conclusions. The approach includes quasi-experimental analyses, employing descriptive statistics and mixed effects regression. Quasi-experimental analyses were conducted where data was available. Multivariate regression was used to model outcomes over time, following individuals longitudinally. This approach allows for the trend over time to be adjusted for changes in the Demonstration populations as members enter and leave the Populations. The specific analytic method for each research question and measure is provided in Attachments (Section J.2).

Descriptive Statistics

The IE used descriptive statistical methods to generate summary tables of population size and characteristics for the AE and TAM Demonstration participants. Data were presented as counts and percentages. These tables were used to develop a quantitative picture of the population, to describe raw trends, and to identify characteristics that will be included as covariates in regression modeling.

Trend Over Time

The outcomes of interest were plotted over time, illustrating changes between the baseline and Demonstration years. The trend over time figures can be found in Attachments (Sections J.5 and J.6).

Regression Modeling

All measures underwent an event study analysis to determine whether there was a significant trend in the outcome of interest prior to the Demonstration. If the pre-Demonstration trend was significant, an interrupted time series analysis was conducted. If the pre-Demonstration trend was insignificant, a logistic (binary outcome) or negative binomial (count outcome) regression model was conducted.

Logistic regression models accommodate both fixed and random effects. In this case, it allows for the fact that members can appear multiple times in the datasets and that they can appear different numbers of times resulting in unbalanced data. The models included the ‘client id’ variable as a random effect. The

outcome variable is the binary or count outcome. To assess changes over time for each population, a fixed effect for measurement year and population was included in addition to an interaction term between them. Measurement year was included as a continuous variable after plotting raw trends to assess linearity. Adjusted models included the covariates age (continuous), gender, ethnicity, and race. Models are described in the following formulas.

Interrupted Time Series Model

$$Y = \beta_0 + \beta_1 T + \beta_2 X + \beta_3 XT + \varepsilon$$

Where Y represents the outcome of interest, β_0 the y-intercept, β_1 the baseline trend, β_2 the post-level change, and β_3 the post-Demonstration trend change.

Logistic Regression Model

$$\text{logit}(Y = 1_{ij}) = \beta_0 + \beta_1 \text{Pop}_i + \beta_2 \text{MY}_{ij} + \beta_3 \text{MY}_{ij} * \text{Pop}_i + \beta_x X_i + \gamma_{0i}$$

Negative Binomial Regression Model

$$\log \log (Y)_{ij} = \beta_0 + \beta_1 \text{Pop}_i + \beta_2 \text{MY}_{ij} + \beta_3 \text{MY}_{ij} * \text{Pop}_i + \beta_x X_i + \gamma_{0i} + \ln(\text{offset})$$

Where Y corresponds to outcome of interest with a different expression depending on its distribution, β_0 to the overall intercept of the model, $\beta_1 \text{Pop}_i$ to the effect of belonging to the post-Demonstration, $\beta_2 \text{MY}_{ij}$ to the effect of measurement year as a continuous variable, $\beta_3 \text{MY}_{ij} * \text{Pop}_i$ is the interaction effect between population and measurement year which allows us to estimate change over time between populations, $\beta_x X_i$ corresponds to individual level adjustment covariates, and γ_{0i} corresponds to the random intercept of each client to account for the clustering effect of appearing in more than one measurement year. In the case of negative binomial models, the model includes an offset, for EDU corresponding the total number of clients and for IPU to the total member-months.

Tables were produced that contain the respective adjusted coefficients, standard errors, 95% confidence intervals, and p-value distinctions at $p < 0.05$, $p < 0.01$ and $p < 0.001$.

E. METHODOLOGICAL LIMITATIONS

1. **Lack of a true comparison group.** The Demonstration is implemented statewide, making a perfect comparison group impossible. For the analysis, the IE compared the Demonstration to the pre-Demonstration baseline.
2. **Historic effects.** The impacts of the Covid-19 PHE were profound in 2020 and 2021, and lingering effects continued into 2022. Medicaid unwinding took place during the Demonstration period under evaluation, with eligibility redeterminations beginning in April 2023. Ongoing direct and indirect impacts of the PHE such as staffing shortages should be considered in interpreting findings. The continuous enrollment policy and concomitant increase in Medicaid enrollment created a limitation in interpreting evaluation findings. PHE policy prevented states from removing individuals from the rolls when their income rose above eligibility thresholds, which in effect expanded Medicaid eligibility nationally. Sensitivity analyses excluding the years of the Covid-19 PHE will be included in the summative evaluation report.
3. **Missing race/ethnicity data.** In the claims data set used for measures of engagement in care, the race/ethnicity field was missing for a substantial number of individuals. Given this, the IE was unable to draw meaningful conclusions about racial disparities in Demonstration outcomes. For regression analysis, the field was included as a covariate using three categories: White, Non-white (Black, Hispanic, Pacific Islander, AIAN) and Missing/Other.

F. RESULTS

Results are organized by hypothesis. Exhibit 8 summarizes the hypotheses and corresponding research questions addressed in this interim evaluation report due to data availability and analytic feasibility; the remaining hypotheses and research questions for the Demonstration will be examined in the summative evaluation report.

EXHIBIT 8. INTERIM EVALUATION REPORT HYPOTHESES AND RESEARCH QUESTIONS OVERVIEW

Research Question (RQ)	Description
Hypothesis 1: The Demonstration overall will improve access to coverage and engagement in health care for low-income UT residents.	
Primary RQ 1.6	What is the member experience of care in terms of access, timeliness, and patient-centeredness?
Hypothesis 2: The Demonstration will improve health care access and engagement for the Adult Expansion population.	
Primary RQ 2.1	Did inpatient hospital utilization decrease over time, for the AE population?
Primary RQ 2.2	Did ED visits decrease, relative to baseline, for the AE population?
Subsidiary RQ 2.2a	Did ED visits for BH conditions decrease over time, for the AE population?
Primary RQ 2.3	Did engagement in primary and ambulatory care increase over time for the AE population?
Primary RQ 2.4	Did engagement in behavioral health care increase over time for the AE population?
Hypothesis 3: The Demonstration will improve health care access and engagement for the TAM population.	
Primary RQ 3.1	Did inpatient hospital utilization decrease, relative to baseline, for the TAM population?
Primary RQ 3.2	Did ED visits decrease, relative to baseline, for the TAM population?
Subsidiary RQ 3.2a	Did ED visits for BH conditions decrease, relative to baseline, for the TAM population?
Primary RQ 3.3	Did engagement in primary and ambulatory care increase, relative to baseline, for the TAM population?
Primary RQ 3.4	Did engagement in behavioral health care increase, relative to baseline, for the TAM population?
Hypothesis 5: The SMI and SUD Demonstrations increased access to appropriate treatment.	
Primary RQ 5.4	Did engagement in SUD treatment increase among individuals with SUD diagnoses relative to baseline?
Primary RQ 5.5	Did unplanned readmission following hospitalization for psychiatric treatment decrease among individuals with SMI relative to baseline?

1. OVERVIEW OF CLAIMS-BASED MEASURES RESULTS

The analytic approach for the claims-based measures include trend over time and regression models. Trend over time figures and full regression result tables are provided in the Attachments (Sections J.5 - J.9). Abbreviated regression result tables and corresponding figures are found within the report. Regression models adjusted for age, gender, ethnicity, and race.

Baseline and Demonstration Years

The baseline and Demonstration years begin on July 1 and end on June 30 of the following year. The claims-based measures were calculated annually and included in the appropriate regression models. Select measures required two years of continuous enrollment data for inclusion; therefore, the first baseline year was excluded from analysis for these measures. To avoid excessively lengthy labels in charts and graphs, throughout this report, the baseline and Demonstration years are referenced as shown below in Exhibit 9.

EXHIBIT 9: SUMMARY OF BASELINE AND DEMONSTRATION POPULATIONS UNDER EVALUATION

Baseline/Demonstration Year	Time Period	References in Text or Tables*
Baseline Year 1 (BY1)	July 1, 2017 to June 30, 2018	BY1 (2017-2018)
Baseline Year 2 (BY2)	July 1, 2018 to June 30, 2019	BY2 (2018-2019)
Baseline Year 3 (BY3)	July 1, 2019 to June 30, 2020	BY3 (2019-2020)
Baseline Year 4 (BY4)	July 1, 2020 to June 30, 2021	BY4 (2020-2021)
Baseline Year 5 (BY5)	July 1, 2021 to June 30, 2022	BY5 (2021-2022)
Demonstration Year 1 (DY1)	July 1, 2022 to June 30, 2023	DY1 (2022-2023)
Demonstration Year 2 (DY2)	July 1, 2023 to June 30, 2024	DY2 (2023-2024)
Demonstration Year 3 (DY3)	July 1, 2024 to June 30, 2025	DY3 (2024-2025)

*In instances where an axis is labeled with the year only (2018), it represents the end of the BY or DY. "2018" indicates BY1, which ended June 2018.

Regression Table Interpretation

Below is an example illustrating how the coefficients are interpreted (Exhibit 10). In this example, EDU is modeled for the TAM population over time using logistic regression.

- The coefficient for Measure Year (a time indicator illustrating year irrespective of the baseline or Demonstration period) represents the change in the odds of EDU for a one-year increase during the baseline period, adjusting for covariates.
- The coefficient for Post-Demonstration*Measure Year represents the change in the odds of EDU for a one-year increase during the Demonstration, adjusting for covariates.

EXHIBIT 10: REGRESSION TABLE INTERPRETATION EXAMPLE: EMERGENCY DEPARTMENT UTILIZATION, TAM

	Adjusted	SE	CI
Measure Year	0.982	0.013	[0.957,1.007]
Post-Demonstration*Measure Year	0.913***	0.023	[0.869,0.960]
Age	1.004***	0.001	[1.003,1.005]
Gender			
Male	1	-	[1,1]
Female	1.102***	0.027	[1.050,1.157]
Ethnicity			
Non-Hispanic	1	-	[1,1]
Hispanic	1.011	0.042	[0.932,1.098]
Race			
White	1	-	[1,1]
Non-White	1.056*	0.027	[1.004,1.111]
Other or Missing	0.864**	0.043	[0.783,0.953]
N	36,719		

95% confidence intervals in brackets
 *p < 0.05, **p < 0.01, ***p < 0.001

Following the Demonstration, the odds of EDU significantly decreased by 8.7% annually (p< 0.001) among the TAM population.


Higher odds of ED visits were associated with older age, female gender, and non-White race. Lower odds of ED visits were associated with other or missing race.

Regression Figure Interpretation

Below is an example indicating how to interpret the figures in conjunction with the result tables. In this example, EDU is modeled for the TAM population over time using logistic regression. (Exhibit 11)

- The red vertical dashed line indicates the beginning of the DY1.
- The black line represents predicted values without the Demonstration.
- The blue line represents predicted values with the Demonstration.
- The width of the black and blue lines is indicative of the corresponding 95% CI.

EXHIBIT 11: REGRESSION FIGURE INTERPRETATION EXAMPLE: EMERGENCY DEPARTMENT UTILIZATION, TAM



There was no significant trend in the odds of EDU during the baseline period (black line).

The odds of EDU significantly decreased following the Demonstration (blue line).


The beginning of the Demonstration (DY1; red vertical dashed line).

2. ENROLLMENT

EXHIBIT 12: ENROLLMENT OVER DEMONSTRATION YEARS

		DY1 (2022-2023)	DY2 (2023-2024)	DY3 (2024-2025)
Adult Expansion	UMIC	106,042	102,599	77,568
	FFS	33,047	32,223	22,982
	ACO	17,691	17,071	12,745
	Total	156,780	151,893	113,295
Targeted Adult Medicaid		11,696	11,678	9,448

EXHIBIT 13: ENROLLMENT TRENDS OVER TIME – COMPARISON AMONG AE POPULATION



Enrollment in AE plans and TAM trended downward across the Demonstration (Exhibit 13). There was a small decline between DY1 and DY2 across all plans (UMIC: -3.25%, FFS: -2.49%, ACO: -3.50%, TAM: -0.15%) with a greater rate of decline between DY2 and DY3 (UMIC: -24.40%, FFS: -28.68%, ACO: -25.34%, TAM: -19.10%).

EXHIBIT 14: AE AND TAM DEMOGRAPHIC INFORMATION

Demographic Characteristics		Adult Expansion N (%)	Targeted Adult Medicaid N (%)
Gender	Male	118,837 (46.0%)	13,064 (77.3%)
	Female	139,722 (54.0%)	3,847 (22.7%)
Age	19-44	194,871 (70.0%)	13,351 (70.5%)
	45-54	47,233 (17.0%)	3,994 (21.1%)
	55-64	36,120 (13.0%)	1,589 (8.4%)
Ethnicity	Hispanic	24,704 (9.3%)	1,683 (9.4%)
	Non-Hispanic	241,423 (90.7%)	16,188 (90.6%)
Race	White	94,272 (28.0%)	7,076 (28.7%)

	Non-White	121,781 (36.2%)	9,926 (40.2%)
	Other/Missing	120,046 (35.7%)	7,672 (31.1%)
SMI/SUD Diagnosis	None	216,619 (76.2%)	8,524 (36.3%)
	SMI Only	17,637 (6.2%)	944 (4.0%)
	SUD Only	33,816 (11.9%)	9,830 (41.9%)
	Both SMI/SUD	16,171 (5.7%)	4,175 (17.8%)

Note: The characteristics shown above represent every person enrolled across baseline and Demonstration years (7/1/2017-6/30/2025). Individuals may be represented in more than one year.

The AE population was relatively evenly split between males and females (46.0% vs. 54.0%), but the TAM population had a substantially larger male population than female (77.3% vs 22.7%). The majority of the AE and TAM populations were between the ages of 19 and 44 years old (70.0% and 70.5%), non-Hispanic (90.7% and 90.6%), and non-White (36.2% and 40.2%). Demographic factors were adjusted in the measure analyses. (Exhibit 14)

Most individuals in the AE population did not have SMI/SUD diagnoses (76.2%). In the TAM population, however, more individuals had SUD only diagnoses than any other category (41.9%).

3. ACCESS AND ENGAGEMENT

3.1 Member Satisfaction Survey; Hypothesis 1

Hypothesis 1: The Demonstration overall will improve access to coverage and engagement in health care for low-income UT residents.

Member Satisfaction Survey Results

Research question 1.6 assesses access to care, experiences with health care, and health status among low-income residents in Utah.

- Primary research question 1.6: What is the member experience of care in terms of access, timeliness, and patient-centeredness?

Participant Demographic Characteristics

The demographic characteristics of members who completed the survey are depicted in Exhibit 15. Survey respondents averaged 41 years of age, and identified as mostly female (60%), non-Hispanic White (39%), and as having English as their primary language (93%).

EXHIBIT 15: DEMOGRAPHIC CHARACTERISTICS OF MEMBER SATISFACTION SURVEY RESPONDENTS

Demographic Characteristics		Percent (%)
Age	19-25	14%
	26-35	25%
	36-45	24%
	46-55	19%
	56-64	19%
Gender	Male	40%

	Female	60%
Race/Ethnicity	White (non-Hispanic)	39%
	Hispanic or Latino	9%
	Black (non-Hispanic)	1%
	Asian (non-Hispanic)*	1%
	Another race or multi-race	4%
	Missing	46%
Primary Language	English	93%
	Spanish	4%
	Another Language	3%
Completed Surveys: 1,865		

*In the Utah Medicaid member database, Asian includes "Asian or Pacific Islander"

Survey respondents had the highest enrollment in UMIC (74%), followed by FFS (14%), then ACO (13%). Furthermore, the average length of enrollment in a Medicaid plan was 14 months, with 37% reporting enrollment for less than 6 months, 37% reporting enrollment for 6 to 12 months, 22% reporting enrollment for 13 to 24 months, and 14% reporting enrollment for 25 months or more.

Respondents were asked to rate their overall health and overall mental or emotional health. Less than one third of respondents rated their overall health (27%) or mental or emotional health (30%) as very good or excellent.

Access to Care

The majority of respondents (86%) reported having a personal doctor (e.g., primary care provider). Of them, 83% reported having had a visit with their personal doctor in the last six months.

Similarly, respondents were asked about their experience of accessing mental health care. 42% of respondents reported needing mental health counseling in the last 6 months. Among them, 78% received mental health counseling.

Respondents that received mental health counseling were asked how difficult it was to find a mental health counselor, and nearly half (49%) reported experiencing no difficulty at all, while 27% reported it was somewhat or very difficult to find a mental health counselor. The 27% of respondents who found it somewhat or very difficult to find a mental health counselor were asked to select all the applicable reasons why it was difficult. Respondents were also allowed to write in "other reasons" as applicable. The top three reasons include not finding a counselor in the network (60%), not finding a counselor they felt comfortable with (57%), and not finding a counselor who was taking new patients (52%).

Despite these initial barriers to accessing mental health care, 85% of those that were able to receive mental health counseling did not report experiencing much difficulty in making appointments with their counselor.

A majority of respondents who need substance use treatment reported being able to access it. Six percent of respondents reported needing any health care services in the last 6 months to help with alcohol or drug use. Among them, 82% reported receiving substance use treatment.

Timeliness of Care

Respondents were asked about their experience obtaining timely care. Nearly half (49%) reported having an illness, injury, or condition that needed care right away. Among them, 56% reported always getting care

as soon as it was needed, indicating a gap in respondent access to urgent care. Respondents who reported sometimes or never getting urgent care as soon as it was needed (15%) were asked to select all the reasons they could not get timely care. Respondents were also allowed to write in “other reasons” as applicable. The top three reasons include long wait times to get an appointment (61%), not getting an appointment at a time that was good for them (35%), and other reasons (e.g., complex steps to care, delayed care due to work commitment, the doctor/ER not treating the health problem as urgent, and Medicaid coverage having been cancelled; 33%)

Roughly three-quarters of respondents (76%) reported making appointments for routine care in the past six months. Among them, 48% reported always getting an appointment as soon as it was needed, highlighting a gap in access to routine care.

The survey findings illustrated gaps in respondents’ ease of accessing needed medical care, tests, or treatment. Overall, 53% of respondents reported it was always easy to get the care, tests, or treatment they needed in the past six months, indicating a gap of 47%.

Patient-Centered Care

Respondents that reported visiting their personal doctor in the last 6 months were asked about their perceptions of communication with their personal doctor. Respondent perceptions were relatively positive, as 85% reported their personal doctor always shows respect for what they have to say, 79% reported their personal doctor always explains things in a way that is easy to understand, and 77% reported their personal doctor always listens carefully to them. Respondent perceptions of their personal doctor’s time spent with them, however, showed a wider gap for improvement with only 70% of respondents reporting that their personal doctor always spends enough time with them.

Respondents’ perceptions of how well their mental health counselor communicates with them were mostly positive, as 84% reported their mental health counselor always shows respect for what they have to say, and 77% reported their mental health counselor always listens carefully to them. Respondent perceptions of their mental health counselor spending enough time with them showed a slightly wider gap for improvement, with only 74% of respondents reporting their mental health counselor always spends enough time with them.

Respondents who had a visit with a personal doctor in the last 6 months were asked about their personal doctors’ use of information to coordinate care, and several gaps were identified. When asked if their personal doctor knew important information about their medical history, 65% of respondents reported their personal doctor always knew. Among respondents who reported taking prescription medicine in the last 6 months (96%), 70% reported their personal doctor always discussed all prescription medications they were taking. Additionally, for those who had a specialist visit in the last 6 months (62%), 56% reported their personal doctor always seemed informed and up to date about their care from the specialists, and 59% reported their personal doctor always knew about any tests or results from specialists.

Nearly 90% of respondents who had a personal doctor visit in the last 6 months reported needing medical treatment. Among them, 73% reported that their personal doctor always involved them when developing their treatment plan.

89% of respondents who received mental health counseling in the last 6 months reported needing a treatment plan. Among them, 72% reported that their mental health counselor always involved them when developing their treatment plan.

Provider follow-up for medication management was limited. 83% of respondents reported they currently need to take prescription medication, mostly for a condition that has lasted for at least three months (96%); however, only 36% reported that their provider’s office contacted them to ensure they were taking the medication as directed.

Respondents were asked about their experience with HRSN screenings at their personal doctor's office. Among respondents who had a personal doctor visit in the last 6 months, 49% reported that someone from their personal doctor's office asked if there were things that made it hard for them to take care of their health, and only 44% reported being asked if they are facing any difficulties with food, housing, transportation, or childcare. Screening for HRSN remains an area for improvement.

Key Findings

Access to care

- Many respondents report having primary care providers, but experience difficulty accessing mental health counseling.
- Majority of respondents who need substance use treatment can access it.

Timeliness of Care

- There are gaps in respondent experience obtaining timely urgent and routine care.
- There is a gap in respondents' ease of accessing medical care, tests, or treatment.

Patient Centered Care

- Perception of how well primary care providers and mental health counselors communicate are largely positive.
- There is room for improvement on care coordination.
- Perceptions of shared decision-making are relatively positive.
- Providers' screening for HRSN appears to be limited.

3.2 Adult Expansion Population; Hypothesis 2

Hypothesis 2: The Demonstration will improve health care access and engagement for the AE population.

Changes in access and engagement measures for the AE population were modeled over time. Regression models adjusted for gender, age, race, and ethnicity.

Acute Care Utilization Summary

Research questions 2.1 and 2.2 assess health outcomes among the AE population by measuring acute care utilization. Decreases are hypothesized.

- Primary research question 2.1: Did inpatient hospital utilization decrease over time, for the AE population?
- Primary research question 2.2: Did ED visits decrease, relative to baseline, for the AE population?
 - Subsidiary research question 2.2a: Did ED visits for BH conditions decrease over time, for the AE population?

EXHIBIT 16: REGRESSION MODELS: ACUTE CARE MEASURES, AE

	Adjusted	SE	CI
Acute Hospital Utilization (AHU)			
Negative Binomial Regression (N=314,247)			
Measure Year	0.028	0.023	[-0.018, 0.074]
Post-Demonstration*Measure Year	0.159***	0.033	[0.094, 0.224]
Emergency Department Utilization (EDU)			
Interrupted Time Series (N=8,170)			
Measure Year	43.555***	3.104	[37.471, 49.639]
Post-Demonstration*Measure Year	-67.164***	7.094	[-81.071, -53.257]
Emergency Department Utilization, Behavioral Health Condition (EDU-BH)			
Interrupted Time Series (N=2,983)			
Measure Year	19.437***	4.890	[9.850, 29.025]
Post-Demonstration*Measure Year	2.603	13.132	[23.146, 28.352]

95% confidence intervals in brackets


*p < 0.05, **p < 0.01, ***p < 0.001

Among the acute care utilization measures for the AE population, EDU decreased over time as hypothesized. AHU significantly increased over time, and emergency department utilization for EDU-BH had no significant difference over time. (Exhibit 16)

Acute Care Utilization Details

Acute Hospital Utilization


EXHIBIT 17: NEGATIVE BINOMIAL REGRESSION MODEL: ACUTE HOSPITAL UTILIZATION , AE



A negative binomial regression model was used to estimate the change in AHU among the AE population. There was no significant trend in the rate ratio of AHU during the baseline period; however, the rate ratio of AHU significantly increased by a factor of 1.17 for each additional year in the Demonstration ($p < 0.001$). Higher rates of AHU were associated with older age. Lower rates of AHU were associated with female gender. (Exhibit 17)

Emergency Department Utilization


EXHIBIT 18: INTERRUPTED TIME SERIES MODEL: EMERGENCY DEPARTMENT UTILIZATION, AE



An interrupted time series model was used to estimate the change in EDU per 1,000 members among the AE population. Prior to the Demonstration, EDU significantly increased by an average of 43.56 visits per 1,000 members annually ($p < 0.001$). However, following the Demonstration, EDU significantly decreased by an average of 67.16 visits per 1,000 members annually ($p < 0.001$). Higher rates of EDU were associated with Hispanic ethnicity and non-White race. Lower rates of EDU were associated with older age, female gender, and other or missing race. (Exhibit 18)

Emergency Department Utilization, Behavioral Health Condition

EXHIBIT 19: INTERRUPTED TIME SERIES MODEL: EMERGENCY DEPARTMENT UTILIZATION, BEHAVIORAL HEALTH CONDITION, AE



An interrupted time series model was used to estimate the change in EDU-BH per 1,000 members among the AE population. EDU-BH significantly increased by an average of 19.44 visits per 1,000 members annually during the baseline period ($p < 0.01$). There was no significant trend in EDU-BH following the Demonstration. Lower rates of EDU-BH were associated with female gender and other or missing races. (Exhibit 19)

Ambulatory and Behavioral Health Care Summary

Research questions 2.3 and 2.4 assess engagement in primary and ambulatory care, and in behavioral health treatment through utilization measures for the AE population. Increases are hypothesized for all measures except IPF.

- Primary research question 2.3: Did engagement in primary and ambulatory care increase over time for the AE population?
- Primary research question 2.4: Did engagement in behavioral health care increase over time for the AE population?

EXHIBIT 20: REGRESSION MODELS: AMBULATORY AND BEHAVIORAL HEALTH CARE MEASURES, AE

	Adjusted	SE	CI
Adult Access to Ambulatory/Preventive Care (AAP)			
Interrupted Time Series (N=2,875)			
Measure Year	-0.843***	0.204	[-1.243, -0.444]
Post-Demonstration*Measure Year	2.790***	0.485	[1.840, 3.741]

Initiation and Engagement in SUD Treatment (IET), Initiation			
Logistic Regression (N=45,241)			
Measure Year	0.982	0.026	[0.932, 1.035]
Post-Demonstration*Measure Year	1.387***	0.119	[1.171, 1.642]
Initiation and Engagement in SUD Treatment (IET), Engagement			
Interrupted Time Series (N=2,785)			
Measure Year	0.820	0.444	[-0.050, 1.690]
Post-Demonstration*Measure Year	3.546**	1.350	[0.900, 6.192]
Follow-Up After Hospitalization for Mental Illness (FUH), 7 Day			
Logistic Regression (N=16,003)			
Measure Year	1.100***	0.029	[1.045, 1.158]
Post-Demonstration*Measure Year	1.021	0.041	[0.944, 1.105]
Follow-Up After Hospitalization for Mental Illness (FUH), 30 Day			
Logistic Regression (N=16,003)			
Measure Year	1.099***	0.017	[1.066, 1.132]
Post-Demonstration*Measure Year	0.977	0.031	[0.918, 1.040]
30-Day All-Cause Unplanned Readmission Following Hospitalization in an Inpatient Psychiatric Facility (IPF)			
Logistic Regression (N=21,197)			
Measure Year	1.037	0.051	[0.942, 1.142]
Post-Demonstration*Measure Year	1.287***	0.068	[1.160, 1.427]

95% confidence intervals in brackets


*p < 0.05, **p < 0.01, ***p < 0.001

AAP and IET significantly increased following the Demonstration for the AE population, as hypothesized. There was no significant change during the Demonstration for either 7-day or 30-day FUH. It was hypothesized that 30-day all-cause IPF would decrease; however, it significantly increased following the Demonstration. (Exhibit 20)

Ambulatory and Behavioral Health Care Details

Adult Access to Ambulatory/Preventive Care


EXHIBIT 21: INTERRUPTED TIME SERIES MODEL: ADULT ACCESS TO AMBULATORY/PREVENTIVE CARE, AE



An interrupted time series model was used to estimate the change in the percentage of members with an AAP among the AE population. During the baseline period, the rate of AAP significantly decreased by an average of 0.84% annually. Following the Demonstration, the rate of AAP significantly increased by an average of 2.79% annually. Higher rates of AAP were associated with older age and female gender. Lower rates of AAP were associated with Hispanic ethnicity and non-White race. (Exhibit 21)

Initiation and Engagement in SUD Treatment, Initiation


EXHIBIT 22: LOGISTIC REGRESSION MODEL: INITIATION AND ENGAGEMENT IN SUD TREATMENT, INITIATION, AE



A logistic regression model was used to estimate the change in initiation of SUD treatment (IET initiation) among the AE population. There was no significant trend in IET initiation during the baseline period. Following the Demonstration, the odds of IET initiation significantly increased by 38.7% annually ($p < 0.001$). Higher odds of IET initiation were associated with older age and female gender. Lower odds of IET initiation were associated with Hispanic ethnicity. (Exhibit 22)

Initiation and Engagement in SUD Treatment, Engagement


EXHIBIT 23: INTERRUPTED TIME SERIES MODEL: INITIATION AND ENGAGEMENT IN SUD TREATMENT, ENGAGEMENT, AE



An interrupted time series model was used to estimate the change in engagement in SUD treatment (IET engagement) among the AE population. There was no significant trend in IET engagement during the baseline period. However, IET engagement significantly increased by an average of 3.55% annually following the Demonstration ($p < 0.01$). Higher rates of IET engagement were associated with female gender. Lower rates of IET engagement were associated with Hispanic ethnicity and non-White race. (Exhibit 23)

Follow-Up After Hospitalization for Mental Illness, 7 Day


EXHIBIT 24: LOGISTIC REGRESSION MODEL: FOLLOW-UP AFTER HOSPITALIZATION FOR MENTAL ILLNESS, 7 DAY, AE



A logistic regression model was used to estimate the change in follow-up after hospitalization for mental illness within 7 days of discharge (7-day FUH) among the AE population. The odds of 7-day FUH increased by 10% annually during the baseline period ($p < 0.001$). There was no significant trend in the odds of 7-day FUH during the Demonstration period. Higher odds of 7-day FUH were associated with female gender. Lower odds of 7-day FUH were associated with older age, Hispanic ethnicity, non-White race, and other or missing race. (Exhibit 24)

Follow-Up After Hospitalization for Mental Illness, 30 Day


EXHIBIT 25: LOGISTIC REGRESSION MODEL: FOLLOW-UP AFTER HOSPITALIZATION FOR MENTAL ILLNESS, 30 DAY, AE



A logistic regression model was used to estimate the change in follow-up after hospitalization for mental illness within 30 days of discharge (30-day FUH) among the AE population. The odds of 30-day FUH increased by 9.9% annually during the baseline period ($p < 0.001$). There was no significant trend in the odds of 30-day FUH during the Demonstration period. Higher odds of 30-day FUH were associated with female gender. Lower odds of 30-day FUH were associated with Hispanic ethnicity, non-White race, and other or missing race. (Exhibit 25)

30-Day All-Cause Unplanned Readmission Following Hospitalization in an Inpatient Psychiatric Facility

EXHIBIT 26: LOGISTIC REGRESSION MODEL: 30-DAY ALL-CAUSE UNPLANNED READMISSION FOLLOWING HOSPITALIZATION IN AN INPATIENT PSYCHIATRIC FACILITY, AE



A logistic regression model was used to estimate the change in IPF among the AE population. There was no significant trend in IPF during the baseline period. The odds of IPF significantly increased by 28.7% annually following the Demonstration ($p < 0.001$). Higher odds of IPF were associated with older age. Lower odds of IPF were associated with female gender. (Exhibit 26)

Key Findings

Trends in acute care utilization were mixed among the AE population.

- EDU decreased over time and relative to baseline, as hypothesized.
- AHU increased over time and relative to baseline.
- EDU-BH had no significant change over time.

Trends in ambulatory and behavioral health care were mixed among the AE population.

- AAP and IET increased over time and relative to baseline, as hypothesized.
- FUH had no significant change over time.
- IPF increased over time and relative to baseline.

3.3 Targeted Adult Medicaid Population; Hypothesis 3

Hypothesis 3: The Demonstration will improve health care access and engagement for the TAM population.

Changes in access and engagement measures for the TAM population were modeled over time. Regression models were adjusted for gender, age, race, and ethnicity.

Acute Care Utilization Summary

Research questions 3.1 and 3.2 assess health outcomes among the TAM population by measuring acute care utilization. Decreases are hypothesized.

- Primary research question 3.1: Did inpatient hospital utilization decrease, relative to baseline, for the TAM population?
- Primary research question 3.2: Did ED visits decrease, relative to baseline, for the TAM population?
 - Subsidiary research question 3.2a: Did ED visits for BH conditions decrease, relative to baseline, for the TAM population?

EXHIBIT 27: REGRESSION MODELS: ACUTE CARE MEASURES, TAM

	Adjusted	SE	CI
Acute Hospital Utilization (AHU)			
Negative Binomial Regression (N=28,147)			
Measure Year	0.010	0.037	[-0.062, 0.082]
Post-Demonstration*Measure Year	-0.087	0.054	[-0.193, 0.019]
Emergency Department Utilization (EDU)			
Logistic Regression (N=36,719)			
Measure Year	0.982	0.013	[0.957, 1.007]
Post-Demonstration*Measure Year	0.913***	0.023	[0.869, 0.960]
Emergency Department Utilization, Behavioral Health Condition (EDU-BH)			
Interrupted Time Series (N=2,172)			
Measure Year	46.577**	17.366	[15.521, 83.633]
Post-Demonstration*Measure Year	-45.816	38.642	[-121.594, 29.963]

95% confidence intervals in brackets


*p < 0.05, **p < 0.01, ***p < 0.001

Across the acute care utilization measures for the TAM population, EDU decreased over time as hypothesized. There was no significant difference in AHU or EDU-BH over time. (Exhibit 27)

Acute Care Utilization Details

Acute Hospital Utilization


EXHIBIT 28: NEGATIVE BINOMIAL REGRESSION MODEL: ACUTE HOSPITAL UTILIZATION, TAM



A negative binomial regression model was used to estimate the change in AHU among the TAM population. There was no significant trend in the rate ratio of AHU during the baseline or Demonstration periods. Higher rates of AHU were associated with older age. Lower rates of AHU were associated with non-White race. (Exhibit 28)

Emergency Department Utilization

EXHIBIT 29: LOGISTIC REGRESSION MODEL: EMERGENCY DEPARTMENT UTILIZATION, TAM




A logistic regression model was used to estimate the change in EDU among the TAM population. There was no significant trend in the odds of EDU during the baseline period. Following the Demonstration, the

odds of EDU significantly decreased by 8.7% annually ($p < 0.001$). Higher odds of EDU were associated with older age, female gender, and non-White race. Lower odds of EDU were associated with other or missing race. (Exhibit 29)

Emergency Department Utilization, Behavioral Health Condition

EXHIBIT 30: INTERRUPTED TIME SERIES MODEL: EMERGENCY DEPARTMENT UTILIZATION, BEHAVIORAL HEALTH CONDITION, TAM



An interrupted time series model was used to estimate the change in EDU-BH among the TAM population. EDU-BH significantly increased by an average of 46.58 visits per 1,000 members annually during the baseline period ($p < 0.01$). There was no significant trend in EDU-BH following the Demonstration. Lower rates of EDU-BH were associated with older age and other or missing race. (Exhibit 30)

Ambulatory and Behavioral Health Care Summary

Research questions 3.3 and 3.4 assess engagement in primary and ambulatory care, and in behavioral health treatment through utilization measures for the TAM population. Increases are hypothesized for all measures except IPF.

- Primary research question 3.3: Did engagement in primary and ambulatory care increase, relative to baseline, for the TAM population?
- Primary research question 3.4: Did engagement in behavioral health care increase, relative to baseline, for the TAM population?

EXHIBIT 31: REGRESSION MODELS: AMBULATORY AND BEHAVIORAL HEALTH CARE MEASURES, TAM

	Adjusted	SE	CI
Adult Access to Ambulatory/Preventive Care (AAP)			
Logistic Regression (N=89,355)			
Measure Year	1.041**	0.014	[1.013, 1.069]
Post-Demonstration*Measure Year	1.314***	0.026	[1.265, 1.366]
Initiation and Engagement in SUD Treatment (IET), Initiation			
Interrupted Time Series (N=1,993)			
Measure Year	1.571**	0.526	[0.539, 2.603]
Post-Demonstration*Measure Year	3.611*	1.434	[0.799, 6.422]
Initiation and Engagement in SUD Treatment (IET), Engagement			
Logistic Regression (N=14,378)			
Measure Year	0.993	0.019	[0.956, 1.031]
Post-Demonstration*Measure Year	1.483***	0.032	[1.421, 1.548]
Follow-Up After Hospitalization for Mental Illness (FUH), 7 Day			
Logistic Regression (N=2,879)			
Measure Year	1.030	0.019	[0.993, 1.069]
Post-Demonstration*Measure Year	1.141*	0.064	[1.022, 1.273]
Follow-Up After Hospitalization for Mental Illness (FUH), 30 Day			
Logistic Regression (N=2,879)			
Measure Year	1.026	0.023	[0.981, 1.073]
Post-Demonstration*Measure Year	1.044	0.062	[0.929, 1.173]
30-Day All-Cause Unplanned Readmission Following Hospitalization in an Inpatient Psychiatric Facility (IPF)			
Logistic Regression (N=4,383)			
Measure Year	0.995	0.080	[0.849, 1.165]
Post-Demonstration*Measure Year	0.978	0.065	[0.859, 1.113]


95% confidence intervals in brackets

*p < 0.05, **p < 0.01, ***p < 0.001

AAP, IET, and 7-day FUH significantly increased following the Demonstration for the TAM population, as hypothesized. There was no significant change during the Demonstration for either 30-day FUH or IPF. (Exhibit 31)

Ambulatory and Behavioral Health Care Details
Adult Access to Ambulatory/Preventive Care


EXHIBIT 32: LOGISTIC REGRESSION MODEL: ADULT ACCESS TO AMBULATORY/PREVENTIVE CARE, TAM



A logistic regression model was used to estimate the change in adult access to AAP among the TAM population. The odds of AAP significantly increased by 4.1% annually ($p < 0.01$) during the baseline period. Following the Demonstration, the odds of AAP significantly increased by 31.4% annually ($p < 0.001$). Higher odds of AAP were associated with older age and female gender. Lower odds of AAP were associated with Hispanic ethnicity, non-White race, and other or missing race. (Exhibit 32)

Initiation and Engagement in SUD Treatment, Initiation


EXHIBIT 33: INTERRUPTED TIME SERIES MODEL: INITIATION AND ENGAGEMENT IN SUD TREATMENT, INITIATION, TAM



An interrupted time series model was used to estimate the change in initiation of SUD treatment (IET initiation) among the TAM population. IET initiation significantly increased by an average of 1.57% annually during the baseline period ($p < 0.01$). Following the Demonstration, IET initiation increased by an average of 3.61% annually ($p < 0.05$). Lower rates of IET initiation were associated with non-White race. (Exhibit 33)

Initiation and Engagement in SUD Treatment, Engagement


EXHIBIT 34: LOGISTIC REGRESSION MODEL: INITIATION AND ENGAGEMENT IN SUD TREATMENT, ENGAGEMENT, TAM



A logistic regression model was used to estimate the change in engagement in SUD treatment (IET engagement) among the TAM population. There was no significant trend in IET engagement during the baseline period. However, the odds of IET engagement significantly increased by 48.3% annually ($p < 0.001$) following the Demonstration. Higher odds of IET engagement were associated with older age. Lower odds of IET engagement were associated with non-White race. (Exhibit 34)

Follow-Up After Hospitalization for Mental Illness, 7 Day


EXHIBIT 35: LOGISTIC REGRESSION MODEL: FOLLOW-UP AFTER HOSPITALIZATION FOR MENTAL ILLNESS, 7 DAY, TAM



A logistic regression model was used to estimate the change in 7-day FUH among the TAM population. There was no significant trend in the odds of 7-day FUH during the baseline period. Following the Demonstration, the odds of 7-day FUH significantly increased by 14.1% annually ($p < 0.05$). (Exhibit 35)

Follow-Up After Hospitalization for Mental Illness, 30 Day


EXHIBIT 36: LOGISTIC REGRESSION MODEL: FOLLOW-UP AFTER HOSPITALIZATION FOR MENTAL ILLNESS, 30 DAY, TAM



A logistic regression model was used to estimate the change in 30-day FUH among the TAM population. There was no significant trend in the odds of 30-day FUH during the baseline or Demonstration periods. Higher odds of 30-day FUH were associated with female gender. (Exhibit 36)

30-Day All-Cause Unplanned Readmission Following Hospitalization in an Inpatient Psychiatric Facility

EXHIBIT 37: LOGISTIC REGRESSION MODEL: 30-DAY ALL-CAUSE UNPLANNED READMISSION FOLLOWING HOSPITALIZATION IN AN INPATIENT PSYCHIATRIC FACILITY, TAM



A logistic regression model was used to estimate the change in IPF among the TAM population. There was no significant trend in IPF during the baseline or Demonstration periods. Higher odds of IPF were associated with older age. Lower odds of IPF were associated with female gender. (Exhibit 37)

Key Findings

Trends in acute care utilization improved or experienced no change among the TAM population.

- EDU decreased over time and relative to baseline, as hypothesized.
- AHU and EDU-BH had no significant change over time.

Trends in ambulatory and behavioral health care improved or experienced no change among the TAM population.

- AAP, IET, and FUH (7-day) increased over time and relative to baseline, as hypothesized.
- FUH (30-day) and IPF had no significant change over time.

4. SMI AND SUD DEMONSTRATIONS

4.1 SMI and SUD Demonstrations; Hypothesis 5

Hypothesis 5: The SMI and SUD Demonstrations increased access to appropriate treatment.

Changes in access and engagement measures for individuals diagnosed with SMI or SUD were modeled over time. Regression models adjusted for gender, age, race, and ethnicity.

Behavioral Health Care Summary

Research questions 5.4 and 5.5 assess engagement in behavioral health treatment through utilization measures for individuals diagnosed with SMI or SUD. Increases are hypothesized for IET, and decreases are hypothesized for 30 Day All Cause Unplanned Readmission Following Hospitalization in IPF.

- Primary research question 5.4: Did engagement in SUD treatment increase among individuals with SUD diagnoses relative to baseline?
- Primary research question 5.5: Did unplanned readmission following hospitalization for psychiatric treatment decrease among individuals with SMI relative to baseline?

EXHIBIT 38: REGRESSION MODELS: BEHAVIORAL HEALTH CARE MEASURES, SMI/SUD

	Adjusted	SE	CI
Initiation and Engagement in SUD Treatment (IET), Initiation			
Logistic Regression (N=75,605)			
Measure Year	0.990	0.019	[0.954, 1.028]
Post-Demonstration*Measure Year	1.406***	0.060	[1.294, 1.528]
Initiation and Engagement in SUD Treatment (IET), Engagement			
Logistic Regression (N=75,605)			
Measure Year	0.987	0.012	[0.964, 1.010]
Post-Demonstration*Measure Year	1.270***	0.040	[1.193, 1.351]
30-Day All-Cause Unplanned Readmission Following Hospitalization in an Inpatient Psychiatric Facility (IPF)			
Interrupted Time Series (N=3,687)			
Measure Year	3.020***	0.383	[2.269, 3.771]
Post-Demonstration*Measure Year	4.815***	1.177	[2.507, 7.122]

95% confidence intervals in brackets


*p < 0.05, **p < 0.01, ***p < 0.001

IET among individuals with SUD diagnoses significantly increased following the Demonstration, as hypothesized. Contrary to the hypothesis, 30-day all-cause unplanned readmission following hospitalization in an IPF also significantly increased among individuals with SMI diagnoses. (Exhibit 38)

Behavioral Health Care Details

Initiation and Engagement in SUD Treatment, Initiation


EXHIBIT 39: LOGISTIC REGRESSION MODEL: INITIATION AND ENGAGEMENT IN SUD TREATMENT, INITIATION, SUD



A logistic regression model was used to estimate the change in initiation of SUD treatment (IET initiation) among individuals with SUD diagnoses. There was no significant trend in IET initiation during the baseline period. The odds of IET initiation significantly increased by 40.6% annually following the Demonstration ($p < 0.001$). Higher odds of IET initiation were associated with older age and female gender. Lower odds of IET initiation were associated with Hispanic ethnicity and non-White race. (Exhibit 39)

Initiation and Engagement in SUD Treatment, Engagement


EXHIBIT 40: LOGISTIC REGRESSION MODEL: INITIATION AND ENGAGEMENT IN SUD TREATMENT, ENGAGEMENT, SUD



A logistic regression model was used to estimate the change in engagement in SUD treatment (IET engagement) among individuals with SUD diagnoses. There was no significant trend in IET engagement during the baseline period. The odds of IET engagement significantly increased by 27.0% annually following the Demonstration ($p < 0.001$). Lower odds of IET engagement were associated with older age, Hispanic ethnicity, and non-White race. (Exhibit 40)

30-Day All-Cause Unplanned Readmission Following Hospitalization in an Inpatient Psychiatric Facility

EXHIBIT 41: INTERRUPTED TIME SERIES MODEL: 30-DAY ALL-CAUSE UNPLANNED READMISSION FOLLOWING HOSPITALIZATION IN AN INPATIENT PSYCHIATRIC FACILITY, SMI



An interrupted time series model was used to estimate the change in IPF among individuals with SMI diagnoses. Prior to the Demonstration, IPF significantly increased by an average of 3.02% annually ($p < 0.001$). Following the Demonstration, IPF increased by an average of 4.82% annually ($p < 0.001$). Higher rates of IPF were associated with older age. Lower rates of IPF were associated with female gender, Hispanic ethnicity, and non-White race. (Exhibit 41)

Key Findings

Trends in behavioral health care were mixed among the SMI/SUD Demonstrations

- IET increased over time and relative to baseline, as hypothesized.
- IPF increased over time and relative to baseline.

G. CONCLUSIONS

1. MEMBER EXPERIENCE OF CARE: STRENGTHS AND OPPORTUNITIES FOR IMPROVEMENT

The state hypothesized that the Demonstration would expand coverage for low-income Utah residents, thereby increasing engagement in health care and improving member satisfaction (Hypothesis 1). Findings from the member satisfaction survey show high rates of access to primary care providers and substance use treatment, as well as generally positive perceptions of provider communication and shared decision-making. However, the results also highlight several persistent challenges. Survey respondents reported barriers to accessing timely urgent, routine, and mental health care; difficulties obtaining needed medical care, tests or treatment; and concerns related to care coordination and providers' screening for health-related social needs. Together, these findings indicate that, while member satisfaction persists across several measures, additional targeted efforts are necessary to strengthen access, coordination, and responsiveness within the health care system.

2. VARIATION IN ACUTE CARE UTILIZATION, AMBULATORY CARE, AND BEHAVIORAL HEALTH CARE RESULTS ACROSS DEMONSTRATION POPULATIONS

The state anticipated that the Demonstration would enhance access to and engagement in health care for the AE and TAM populations, thereby reducing reliance on inpatient and emergency department services (Hypotheses 2 and 3). Findings from the first three years of the Demonstration present a mixed picture. While EDU decreased significantly for both populations, the expected reductions in AHU and EDU-BH were not observed. Several ambulatory and behavioral health measures demonstrated positive movement: AAP and IET increased relative to baseline for both populations, and 7-day FUH improved for the TAM population. However, anticipated improvements in 7-day FUH for the AE population, 30-day FUH for both groups, and reductions in 30-day all-cause unplanned readmission following hospitalization in an inpatient psychiatric facility were not observed. Overall, these results indicate meaningful progress in certain areas of access and engagement, while highlighting ongoing challenges that warrant continued attention and targeted intervention.

3. PROGRESS AND CHALLENGES FOR THE SERIOUS MENTAL ILLNESS (SMI)/SUBSTANCE USE DISORDER (SUD) DEMONSTRATION POPULATIONS

The state posited that the SMI and SUD Demonstrations would expand access to appropriate treatment (Hypothesis 5), reflected in expected increases in IET and decreases in IPF. Findings indicate that while the SUD population experienced a significant increase in IET relative to baseline, the anticipated reduction in IPF among individuals with SMI diagnoses was not observed. These results suggest progress in some aspects of treatment access, while highlighting continued challenges in reducing psychiatric readmissions for the SMI population.

H. INTERPRETATIONS, POLICY IMPLICATIONS, AND INTERACTIONS WITH OTHER STATE INITIATIVES

1. UTAH'S MEDICAID STRATEGY

The Medicaid Reform Demonstration is being implemented in the context of Utah's long-term strategy of using managed care to increase access and quality while containing cost. The transition to managed care plans for beneficiaries began in 1982 under Utah's 1915(b) waiver program. Utah's Primary Care Network section 1115 Demonstration waiver was first approved in 2002 and included a pre-ACA coverage expansion (called the Primary Care Network) to certain non-disabled adults. Since 2013, four full-risk ACOs have managed physical health care for all residents of designated counties and for other beneficiaries who opt in to ACO plans. Utah has also operated a 1915(b)-waiver program called the Prepaid Mental Health Plan (PMHP) since July 1, 1991. The PMHP was designed to maximize the contractors' flexibility to effectively and responsibly use Medicaid funds to ensure Medicaid beneficiaries have access to BH services and to improve BH outcomes for Medicaid beneficiaries. Under the PMHP, Medicaid beneficiaries have access to a spectrum of inpatient and outpatient mental health care and outpatient substance use disorder care.

2. IMPACT OF COVID-19 PANDEMIC

The COVID-19 public health emergency impacted Utah Medicaid profoundly during this Demonstration period through multiple mechanisms. In 2020 at the onset of the pandemic, many facilities cancelled non-emergency services, and many individuals avoided going to health care facilities. Health plans altered or paused their planned care delivery initiatives, including outreach to individuals newly eligible under AE, and rollouts of care coordination programs. As the PHE progressed, telehealth expanded from a small fraction of care delivery into a critical tool in routine use for primary care, behavioral health, chronic disease management, and urgent care. Vaccines became available, and vaccinating the patient population became a priority for all providers, health plans, and state agencies. By the end of the Demonstration period in 2022, approximately two-thirds of adult Utah residents had been fully vaccinated, and health plans were resurrecting their plans for population health programs.

The continuous enrollment policy also impacted the Medicaid system. Nationally, Medicaid enrollment increased by roughly 30%, reflecting both new enrollments and paused redeterminations of enrolled members. Continuous enrollment nearly eliminated the churn typically seen as individuals on the edge of income eligibility cycle in and out of eligibility. At that stage, key goals were using existing data to identify individuals at risk of losing coverage and reaching out to members to obtain accurate contact information. When unwinding officially began in March of 2023, CMS urged states to improve call center assistance for renewing members, and Utah reviewed and streamlined processes in order to reduce call wait times and improve messaging to members. Utah Medicaid worked with DWS to leverage existing data and partnered with health plans to provide more assistance to members. Before the PHE, Utah had discussed automating the process of ex-parte renewal to reduce administrative burden and avoidable loss of coverage; in 2022 this initiative gained urgency. Utah developed a custom tool for renewals, including a smartphone app that went live in January 2023. Among individuals whose coverage was renewed during the unwinding process by October 2023, 54% experienced successful ex-parte renewals, similar to national rates.¹⁸

National trends show that health care utilization remained lower through 2021, and did rebound in 2022, though not fully to pre-PHE levels.¹⁹ ED utilization remained about 4% below historical levels. For BH services, in-person services remain about 20% below pre-PHE levels, but telehealth BH appointments in

¹⁸ Corallo, B. and Tolbert, J., 2023. *Understanding Medicaid Ex Parte Renewals During the Unwinding*. KFF Accessed 02/15/2024. [Understanding Medicaid Ex Parte Renewals During the Unwinding | KFF](#)

¹⁹ McGough, M. et al., 2023. *How has healthcare utilization changed since the pandemic?* KFF Accessed 02/15/2024 [How has healthcare utilization changed since the pandemic? - Peterson-KFF Health System Tracker](#)

the post-acute stage of the PHE were at more than 10 times the pre-PHE rate.²⁰ The observation that overall mental health utilization stayed 10% higher than pre-PHE rates²¹ suggests that replacement of some in-person BH services with telehealth is a permanent change in care delivery. Telehealth utilization is highest among Medicaid members, with 28% of Medicaid members nationally reporting that they received a telehealth service in the 2021-22 survey period.²² This adds urgency to the development of evidence-based policies and guidelines for telehealth use, which in turn depends on ongoing research and collective sharing of emerging practices.

3. POTENTIAL IMPLICATIONS OF THE ONE BIG BEAUTIFUL BILL ACT (H.R. 1)

On July 4, 2025, the One Big Beautiful Bill Act (H.R. 1) was signed into law by President Trump, introducing substantial changes to Medicaid including eligibility and financing. The Congressional Budget Office estimates that the H.R. 1 Medicaid provisions will significantly reduce federal Medicaid spending, decrease enrollment, and increase the number of uninsured individuals nationwide, with far reaching implications for health care access and outcomes.²³⁻²⁴ Although the analyses presented in this interim evaluation report predate the enactment of H.R. 1, it provides important baseline context for interpreting potential impacts that will be examined in the forthcoming summative evaluation report.

²⁰ Cantor, J., McBain, R., Ho, P., 2023. *Telehealth and In-Person Mental Health Service Utilization and Spending, 2019 to 2022*. *Jama Health Forum* Accessed 02/29/2024. [Telehealth and In-Person Mental Health Service Utilization and Spending, 2019 to 2022](#)

²¹ 2023. *COVID-19 Pandemic Impacted Behavioral Health in D.C. and Drove Significant Growth in Telehealth Care*. Georgetown University Medical Center Accessed 02/29/2024. [COVID-19 Pandemic Impacted Behavioral Health in D.C. and Drove Significant Growth in Telehealth Care](#)

²² Lee, E., Grigorescu, V., Enogieru, I., et al., 2023. *Updated National Survey Trends in Telehealth Utilization and Modality (2021-2022)*. HHS ASPE Office of Health Policy Accessed 02/29/2024. [Updated National Survey Trends in Telehealth Utilization and Modality \(2021-2022\)](#)

²³ Ortaliza, J., McGough, M., Cox, C., et al., 2025. *How Will the One Big Beautiful Bill Act Affect the ACA, Medicaid, and the Uninsured Rate?* KFF. [How Will the One Big Beautiful Bill Act Affect the ACA, Medicaid, and the Uninsured Rate?](#)

²⁴ Baumrucker, E., Fernandez, B., Forsberg, V., et al., 2025. *Health Coverage Provisions in One Big Beautiful Bill Act (H.R. 1) as Passed by the House with Comparison of Senate Draft Language*. Congressional Research Service. [Health Coverage Provisions in One Big Beautiful Bill Act \(H.R. 1\) as Passed by the House with Comparison of Senate Draft Language](#)

I. LESSONS LEARNED AND RECOMMENDATIONS

Based on these preliminary analyses, the IE offers these recommendations to the state:

(1) Anticipate gradual improvement in measurement outcomes

Evidence from prior studies demonstrates that while insurance coverage is a necessary foundation, meaningful increases in engagement and improvements in health outcomes are often not immediately realized.²⁵⁻²⁶ Although the findings indicate progress across several measures, these gains should be interpreted within the broader context of adjustment periods associated with gaining coverage, establishing care relationships, and navigating the health care system.

The results underscore the importance of robust, targeted outreach efforts and comprehensive population health strategies to accelerate engagement and sustain progress over time. Medicaid members who were recently uninsured or underinsured may face persistent barriers—including limited health system familiarity, unmet social needs, and delayed care-seeking behaviors—that are not fully addressed through coverage alone. As such, proactive strategies that support care navigation, connection to primary and preventive services, and culturally responsive engagement are critical. Accordingly, the state should continue to invest in and refine outreach and population health initiatives that complement coverage expansion. Sustained monitoring of trends across program years will be essential to assess the effectiveness of these strategies and to distinguish short-term enrollment effects from longer-term improvements in engagement and health status.

(2) Engage with members to streamline health care access

The state should deepen collaboration with Medicaid members to more comprehensively assess and address areas in need of improvement. Feedback from survey respondents highlighted a broad range of concerns, emphasizing the need for targeted action to improve member experience and access to care. To mitigate these concerns, the state should prioritize strategies to streamline administrative processes, enhance support for identifying in-network providers, expand access to telehealth services, and increase awareness of existing essential supports that facilitate access to care such as non-emergency medical transportation.

The state's existing BAC, composed of current and former Medicaid members and individuals who support Medicaid populations, provides an important forum for capturing member perspectives and informing program improvements. Continued engagement through the BAC alongside the development of additional feedback and outreach mechanisms such as community-based partnerships, public forums, and targeted communication campaigns would further strengthen the state's ability to incorporate member input into program design and implementation. Collectively, these efforts can support more responsive, member-centered strategies and help ensure that improvements are aligned with the needs and experiences of the populations served.

(3) Strengthen care coordination and address members' health-related social needs

The member satisfaction survey highlights persistent gaps in provider coordination of care and attention to health-related social needs. Fragmentation within the health care system—particularly limited access to comprehensive medical histories, such as prior tests, results, prescribed medications, and specialist care—impedes providers' ability to deliver timely, informed care. These inefficiencies disproportionately affect individuals with chronic or complex health needs, leading to reduced care quality, poorer health outcomes, and increased patient dissatisfaction. Furthermore, screening for health-related social needs is essential to advancing a more holistic approach to care, ensuring the providers can meet the full range of members' physical, behavioral, and social needs. Improved information sharing, integrated care

²⁵ Miller, S., Wherry, L., 2017. *Health and Access to Care during the First 2 Years of the ACA Medicaid Expansion*. The New England Journal of Medicine. [Health and Access to Care during the First 2 Years of the ACA Medicaid Expansion](#)

²⁶ Courtemanche, C., Marton, J., Ukert, B., et al., 2017. *Early Effects of the Affordable Care Act on Health Care Access, Risky Health Behaviors, and Self-Assessed Health*. National Bureau of Economic Research. [Early Effects of the Affordable Care Act on Health Care Access, Risky Health Behaviors, and Self-Assessed Health](#)

approaches, and provider engagement in assessing and addressing health-related social needs are therefore critical to improving member experience and overall health outcomes.

Enhancing care coordination and more effectively addressing members' health-related social needs may also help achieve the anticipated improvements in the evaluated acute, ambulatory, and behavioral health care measures that were not observed during the evaluation period. The state has taken meaningful steps to address health-related social needs through the HRSS amendment implemented in 2022, which enabled the provision of housing support services, and the HRSN amendment in 2025, which expanded HRSS and additional services for eligible individuals. These initiatives represent an important component of the state's broader strategy to support member health and well-being and should be acknowledged as part of ongoing program development.

(4) Promote continued integration of behavioral health care

Evaluation findings indicate substantial unmet behavioral health needs, as the anticipated reductions in EDU-BH and 30-day all-cause unplanned readmission following hospitalization in an inpatient psychiatric facility were not realized. Similarly, expected improvements in FUH were not observed. These patterns underscore the need for comprehensive behavioral health care to more effectively meet members' needs.

The state's planned initiatives to expand access to behavioral health services and strengthen integration across the care continuum (e.g., increasing provider capacity, enhancing the availability of treatment options, and improving access to crisis stabilization services) represent important opportunities to advance more coordinated, effective care for Medicaid members.

J. ATTACHMENTS

1. EVALUATION DESIGN DOCUMENT

Utah Medicaid Reform 1115 Demonstration: Evaluation Design Document

Report prepared by the Public Consulting Group

Draft EDD Submittal Date: March 15, 2023

Final EDD Submittal Date: July 31, 2023

Revised Final EDD Submittal Date: December 20, 2023

Second Revised Final EDD Submittal Date: February 9, 2024

Third Revised Final EDD Submittal Date: May 30, 2024

Fourth Revised Final EDD Submittal Date: December 30, 2024

Fifth Revised Final EDD Submittal Date: May 30, 2025

Sixth Revised Final EDD Submittal Date: November 19, 2025

TABLE OF CONTENTS

A. General Background Information	3
1. Demonstration Name and Timing	3
2. Demonstration Goals	3
3. Description	4
4. Populations	7
Table 1: Demonstration Eligible Populations	8
Table 2: Additional Demonstration Benefits, Programs, and Services	11
5. Context	15
B. Evaluation Questions and Hypotheses	16
1. Logic Model	16
<i>Figure 1: Medicaid Reform Demonstration Overall Logic Model</i>	16
2. Hypotheses and Research Questions	17
3. Independent Assessments	23
Wind-down of Current Eligibles	23
Cost Assessments	23
Table 3: Description of Cost Assessments	23
Table 4: Cost Assessment Measures & Data Sources	24
C. Methodology	25
1. Evaluation Approach	25
2. Target and Comparison Populations	25
Table 5: Demonstration Populations, Benefits, and Comparisons	26
Table 6: Small Demonstration Populations	28
3. Evaluation Period	28
<i>Figure 2: Eligibility Groups and Services Timeline</i>	29
4. Evaluation Measures	30
5. Data Sources	30
National Surveys and Other Publicly Available Data Sources	30
Table 7: Minimum Detectable Effect Sizes	31
Table 8: National Surveys and Other Publicly Available Data	32

Medicaid Administrative Data	32
Custom member survey	33
Table 9: Member Survey Topics	33
Participant interviews with members receiving HRSS and/or pre-release and reentry services	34
Table 10: Participant Interview Topics	35
Key Informant Interviews	35
Table 11: Topics for Key Informant Interviews	36
6. Analytic Methods	36
Quantitative Analyses	36
Table 12: Summary of Analytic Tactics to be Used for Evaluation	38
Table 13: Previous Waiver Demonstration Period; Population Characteristics	41
Qualitative analysis	42
D. Methodological Limitations	43
F. Attachments	45
1. Independent Evaluator	45
2. Evaluation Budget	47
Table 14: Estimated Evaluation Budget	47
<i>Figure 3: Evaluation Timeline</i>	48
4. Evaluation Tables	49
Table 15: Evaluation Summary, Hypothesis 1, Low-income UT residents	49
Table 16: Evaluation Summary, Hypothesis 2, Adult Expansion / UMIC	50
Table 17: Evaluation Summary, Hypothesis 3, TAM	53
Table 18: Evaluation Summary, Hypothesis 4, HRSN Demonstration	56
Table 19: Evaluation Summary, Hypothesis 5, SMI/SUD	59
Table 20: Evaluation Summary, Hypothesis 6, SMI/SUD Cost of Care	61
Table 21: Evaluation Summary, Hypothesis 7, Small Demonstration Populations: UPP/ESI, ISS, FFCYAS, Fertility and Genetic Testing Services	62
Table 22: Evaluation Summary, Hypothesis 8, Justice-Involved Populations	64
Table 23: Evaluation Summary, Hypothesis 9, Justice-Involved Populations	65
<i>Table 24: Evaluation Summary, Hypothesis 10, Justice-Involved Populations</i>	68
Table 25: Evaluation Summary, Hypothesis 11, Justice-Involved Populations	69

A. General Background Information

1. Demonstration Name and Timing

On June 30, 2022, the Centers for Medicare & Medicaid Services (CMS) approved a five-year extension of Utah's section 1115 waiver, formerly known as the "Primary Care Network (PCN) Demonstration" (hereafter, "the Demonstration" or "the 1115 Demonstration"). The current extension is entitled "Medicaid Reform 1115 Demonstration" and is approved for the five-year period from July 1, 2022, through June 30, 2027. Through the Demonstration, CMS has granted the state expenditure authorities to expand service offerings for vulnerable populations, move some members into integrated managed care plans, and to provide coverage to populations not otherwise eligible for Medicaid. The Utah Department of Health and Human Services (DHHS), Division of Integrated Healthcare (DIH) administers the Utah Medicaid program and is responsible for the implementation of the Demonstration.

2. Demonstration Goals

The Medicaid Reform 1115 Demonstration expands coverage for populations not traditionally eligible for Medicaid through direct coverage or premium subsidies. By providing access to preventive care and enhanced services to vulnerable populations, the Demonstration aims to improve health outcomes and to reduce cost of care.

The Demonstration goals, as outlined in the Special Terms and Conditions²⁷, are:

Provide health care coverage for low-income Utahns eligible under the Demonstration who would not otherwise have access to, or be able to afford, health care coverage;

Improve beneficiary health outcomes and quality of life;

Lower the uninsured rate of low income Utahns;

Provide continuity of coverage for individuals eligible under the Demonstration;

Increase access to primary care;

Reduce uncompensated care provided by Utah hospitals;

Reduce barriers to health care and housing, an important social determinant of health;

Increase the utilization of preventive dental services, while reducing emergency dental procedure costs;

Improve access to services across the continuum of care;

Provide for better care coordination for individuals transitioning to community-based care;

Reduce the utilization of emergency departments and inpatient hospital settings for treatment where utilization is preventable or medically inappropriate;

Reduce the overdose death rate; and

Improve access to fertility preservation services for Medicaid eligible individuals diagnosed with cancer, as well as access to in vitro fertilization (IVF) services for individuals diagnosed with certain genetic disorders

With the addition of the Substance Use Disorder (SUD) and Serious Mental Illness (SMI) Institution for Mental Diseases (IMD) amendment approvals, the state expanded its objectives to

²⁷ Source: [medicaid.gov/medicaid/section-1115-demonstrations/downloads/ut-primary-care-network-protocol-apprvl-ltr-01082025.pdf](https://www.medicaid.gov/medicaid/section-1115-demonstrations/downloads/ut-primary-care-network-protocol-apprvl-ltr-01082025.pdf)

include the following for individuals with SUD and/or SMI:

Improve access to services across the continuum of care;

Provide for better care coordination for individuals transitioning to community-based care;

Reduce the utilization of emergency departments and inpatient hospital settings for treatment, where utilization is preventable or medically inappropriate;

Reduce the overdose death rate; and

Improve access to care for physical health conditions for these individuals.

With the addition of the Pre-Release Services under Reentry Demonstration Initiative amendment approval, the state has further expanded its objectives to include the following for eligible individuals:

Increase coverage, continuity of care, and appropriate service uptake through assessment of eligibility and availability of coverage for benefits in correctional facility settings prior to release;

Improve access to services prior to release and improve transitions and continuity of care into the community upon release and during reentry;

Improve coordination and communication between correctional systems, Medicaid systems, managed care plans (as applicable) and community-based providers

Increase additional investments in health care and related services, aimed at improving the quality of care for individuals in correctional facility settings, and in the community to maximize successful reentry post-release;

Improve connections between correctional facility settings and community services upon release to address physical and behavioral health needs;

Reduce all-cause deaths in the near-term post-release;

Reduce the number of emergency department visits and inpatient hospitalizations among recently incarcerated Medicaid individuals through increased receipt of preventive and routine physical and behavioral health care; and

Provide interventions for certain behavioral health conditions, including use of stabilizing medications like long-acting injectable antipsychotics and medications for addiction treatment for SUDs where appropriate, with the goal of reducing overdose and overdose-related death in the near-term post-release

3. Description

Utah's 1115 Demonstration was first approved in 2002 and has transformed over the last twenty years through extensions and amendments that have added new authorities and Demonstration populations.

The original PCN Demonstration provided a limited package of preventive and primary care benefits (the PCN benefit) to adults ages 19-64 with household incomes up to 150 percent of the Federal Poverty Level (FPL) and a slightly reduced benefit package to Parent/Caretaker Relatives (PCR) who comprised the Current Eligibles population. With Medicaid expansion in April 2019, PCN program participants became eligible for full state plan benefits, and the PCN benefit was phased out. The Current Eligible population was phased out by December 31, 2023, eliminating disparities in benefit packages by parental status. An assessment of the phase-out process is included in the evaluation design.

The 1115 Demonstration has historically served as a vehicle to provide premium assistance to adults with household incomes above Medicaid eligibility requirements. In 2006, the Utah Department of Health and Human Services (DHHS) amended the 1115 Demonstration to establish the Health Insurance Flexibility

and Accountability Employer Sponsored Insurance (ESI) program, which provides premium assistance to adults with household incomes up to and including 150 percent of the FPL and CHIP-eligible children with family incomes up to 200 percent of the FPL. This was later amended to include adults with incomes up to 200 percent of the FPL and programmatically eligible adults and children obtaining coverage through COBRA²⁸. Under the current 1115 Demonstration, premium assistance helps pay the individual's or family's share of monthly premium costs of ESI or COBRA and is aggregated under Utah's Premium Partnership for Health Insurance Program (UPP). Individuals in the AE population with access to employer-sponsored insurance are required to enroll, with few exceptions. The state also increased the maximum assistance reimbursement amount in July 2021 making this program more substantial and potentially increasing the number of individuals covered by UPP. In February 2024, CMS approved an increase in the premium subsidy for children that would otherwise receive CHIP services under the state plan from \$120 to \$180. If a plan offers dental coverage, the premium subsidy amount will increase from \$140 to \$200.

For nearly a decade, Utah's Demonstration has emphasized improving the behavioral health (BH) continuum of care. In November 2017 the state received approval to establish the Targeted Adult Medicaid (TAM) eligibility group. The TAM population consists of vulnerable adults ages 19-64, whose incomes are at or 0 percent of the FPL (effectively 5 percent of the FPL with the 5 percent disregard), and who meet detailed eligibility criteria in one of three targeted categories: chronically homeless, involved in the justice system and in need of substance use or mental health treatment, or are in need of substance use or mental health treatment. As of June 2022, enrollment in TAM was 9,384 individuals.

In December 2019, Utah received authority to enroll demonstration populations in managed care plans and to create an integrated managed care model, known as the Utah Medicaid Integrated Care (UMIC) plan. The four UMIC plans manage both physical and behavioral health benefits for the AE population in Utah's five most populous counties: Davis, Salt Lake, Utah, Washington, and Weber. The AE population in the rest of the state are enrolled in Accountable Care Organizations (ACOs) for their physical health service delivery system and in Prepaid Mental Health Plans (PMHPs) for their behavioral health service delivery system. The integrated care model is intended to provide more holistic and coordinated care than previously.

In March 2022, CMS approved the Housing Related Services and Supports (HRSS) amendment, allowing Utah to provide housing support services, such as tenancy supports, community transition services, and supportive living services to TAM individuals who meet additional eligibility criteria and exhibit one of seven risk factors. In an amendment approved in February 2024, an additional four risk factors were added to the HRSS program eligibility criteria to align eligibility with the sub-groups of the Targeted Adult group. The HRSS are paid on a fee-for-service basis. Providers are required to enroll and are evaluated to ensure they meet HRSS qualifications which includes being a certified case management provider. Once care plans have been approved, providers can submit claims for HRSS and receive reimbursement. As the program ramps up in the current waiver period, the state anticipates that HRSS will serve approximately 5,000 TAM individuals each year. By addressing crucial health-related social needs in a high-needs population, the state anticipates that the HRSS program will improve participant health outcomes or quality of life and reduce non-housing related Medicaid costs.

In January 2025, CMS approved coverage of Health-Related Social Needs (HRSN) services. The amendment:

expands the HRSS benefit to the AE population and to recently incarcerated individuals;

adds short-term rental assistance and short-term recuperative care for Adult Expansion and TAM populations;

authorizes HRSN infrastructure investments; and

²⁸ Consolidated Omnibus Reconciliation Act of 1986

authorizes the state to provide non-medical transportation (NMT) to and from HRSN services for eligible individuals.

Eligibility for HRSN services includes social and clinical risk factors and medical necessity criteria.

The 1115 Demonstration also includes components that focus on individuals with SUD and/or SMI, and youth with significant emotional disorder (SED) and/or behavioral challenges. Utah received approval of the SUD Implementation plan in November 2017. The Opioid Use Disorder (OUD) and SUD Program provides state plan behavioral health benefits to Demonstration participants. The state also received authority to provide residential and inpatient OUD/SUD treatment services to all Medicaid beneficiaries while they are short term residents in treatment settings that qualify as IMDs.

The SMI/SED Implementation plan was approved in December 2020 and is similar in expenditure authority to the OUD/SUD program. The state is taking action to meet key milestones of the SMI/SED program including, ensuring quality of care in psychiatric hospitals and residential settings, improving care coordination and transitions to community-based care, increasing access to the continuum of care including crisis stabilization services, and earlier identification and engagement in treatment and increased integration. Together, the SUD and SMI components expand access to mental health services, opioid use disorder (OUD) and other substance use disorder (SUD) services. The 1115 Demonstration supports state efforts to enhance provider capacity, improve the availability of Medication Assisted Treatment (MAT) and improve access to a continuum of SMI evidence-based services at varied levels of intensity, including crisis stabilization services.

In February 2019, Utah received CMS approval to provide state plan Medicaid coverage to Former Foster Care Youth from another state (FFCYAS) who were ever enrolled in Medicaid in another state and are not otherwise Medicaid eligible in Utah. State plan coverage is provided to this population until 26 years of age.

In November 2019, Utah received CMS approval for the provision of intensive stabilization services (ISS) to Medicaid eligible children and youth under age 21 in state custody or at risk of being placed in state custody who are experiencing significant emotional and/or behavioral challenges. The ISS program provides both state plan BH services and home and community-based services (HCBS) that are not currently authorized through the state plan.

The Demonstration also authorized the Clinically Managed Residential Withdrawal Pilot from May 1, 2019, to April 1, 2021; this benefit became available statewide as of April 1, 2021 to all eligible Medicaid members. As a result, the State received approval on July 23, 2021, to remove this pilot project from the 1115 Demonstration and CMS is not requiring the State to evaluate this population.

The current 1115 Demonstration includes dental coverage for vulnerable populations. The PCN Demonstration first provided an adult dental benefit to the Current Eligibles population in November 2006. CMS approved dental benefits for adults with disabilities or blindness in 2017. In 2019, the state chose to provide comprehensive dental benefits to TAM adults receiving SUD treatment because research showed that dental coverage could increase initiation and engagement in treatment for individuals living with SUD. In 2020 dental benefits were extended to Medicaid eligible individuals aged 65 and older and to TAM adults in need of porcelain or porcelain-to-metal crowns. In January 2025, CMS approved an expansion of dental benefits to all Medicaid-eligible adults.

In February 2024, CMS approved an amendment to the current 1115 Demonstration enabling the state to receive expenditure authority for fertility preservation services provided to certain individuals diagnosed with cancer, as well as for in vitro fertilization (IVF) and genetic testing services for certain individuals. Under the IVF and genetic testing amendment, the state may provide genetic testing services to eligible individuals, preimplantation genetic testing of embryos, and IVF services to eligible individuals, ages 18 through 35, diagnosed by a physician with a genetic trait associated with cystic fibrosis, morquio syndrome, sickle cell anemia, spinal muscular atrophy, or myotonic dystrophy. Under the fertility treatment for individuals diagnosed with cancer amendment, the state is now enabled to provide fertility

preservation for eligible individuals diagnosed with cancer and requiring treatment that may cause a substantial risk of sterility or iatrogenic infertility (i.e., infertility caused by treatment for cancer). Services covered under this once per lifetime benefit include the collection and storage of eggs or sperm and coverage for cryopreservation storage. Coverage for cryopreservation storage is covered as a single payment in five-year increments. In January 2025, CMS authorized an increase in the upper age limit for fertility preservation services for individuals diagnosed with cancer from 40 to 50 years of age.

In July 2024, CMS approved an additional amendment to the 1115 Demonstration called the “Pre-Release Services under Reentry Demonstration Initiative” that allows the state to provide limited coverage for a targeted set of services to certain eligible incarcerated individuals for 90 days prior to the individuals’ expected release. This amendment closely aligns with CMS’s “Reentry Demonstration Opportunity,” described in the State Medicaid Director Letter released in April 2023.

Individuals residing in a county jail, state prison, or youth correctional facility who have been determined eligible for Medicaid based on an application filed before or during incarceration are eligible to receive a limited set of pre-release benefits for up to 90-days before their expected release date. These benefits include, but are not limited to, case management, medication-assisted treatment for SUD, and physical and behavioral health clinical consultation services. A full description of the pre-release services can be found in Table 2: Additional Demonstration Benefits, Programs and Services

4. Populations

Table 1 provides a summary of the demonstration populations during the Demonstration period. Adult Expansion (AE) is the largest population, consisting of approximately 116,000 adults ages 19-64 with incomes up to 133 percent of the FPL. Additional demonstration benefits, programs, and services are summarized in Table 2. The evaluation design includes hypotheses and research questions for all key policies and programs of the demonstration.

Table 1: Demonstration Eligible Populations

Demonstration Eligible Populations	Eligibility ²⁹	Benefits ²	Estimated Number of Annual Enrollees ³⁰
Current Eligibles (CE)	Adults aged 19-64 who are medically needy and not aged, blind, or disabled. Individuals who are pregnant are excluded, through the 60th day postpartum.	Individuals enrolled in this eligibility category receive most of the benefits covered under Utah's state plan according to limitations specified in the state plan. Current Eligibles also receive benefits that are the equivalent of (b)(3) services under the state's 1915(b) PMHP waiver, which include; psychoeducational services, personal services, respite care and supportive living services (mental health services in residential treatment settings)	The CE population will be phased out entirely no later than December 31, 2023
Adult Expansion (AE)	Adults, age 19 through 64, who are not Current Eligibles, who are U.S. citizens/qualified non-citizens, are residents of Utah, and have household income at or below 133 percent of the FPL.	Expansion adults will receive state plan benefits and benefits that are the equivalent of (b)(3) services under the state's 1915(b) PMHP waiver, which include; psychoeducational services, personal services, respite care and supportive living services.	115,584
Utah Medicaid Integrated Care (UMIC) – a subgroup of the AE population	Adult Expansion members enrolled in the Utah Medicaid Integrated Care program, which operates in Utah's most populous counties: Davis, Salt Lake, Utah, Washington, and Weber.	Expansion adults will receive state plan benefits and benefits that are the equivalent of (b)(3) services under the state's 1915(b) PMHP waiver, which include; psychoeducational services, personal services, respite care and supportive living services.	49,963
Demonstration Populations III, V, VI, and Current	Demonstration Population III - working adults, aged 19-64, their spouses, and their children ages 19-26, with gross family incomes above 133 percent of the FPL and up to and including 200 percent of the FPL, are not	Individuals in these eligibility categories are eligible to receive premium assistance (through ESI or COBRA) in paying the employee's, individual's, or family's share of the monthly premium cost of qualifying	1,288

²⁹ [ut-cms-amndmnt-aprvl.pdf \(medicaid.gov\)](#)

³⁰ The annual estimates reflect the enrollment numbers reported in the Annual Monitoring Report for the period July 2021 – June 2022 for populations that are continuing from the prior waiver period. Estimates for TAM HRSS, a new population, are taken from the approved Waiver renewal. Estimates for IVF and genetic testing and fertility preservation treatments, and estimates for HRSN Services, are taken from the state's amendment applications to CMS. Estimates for the Justice-Involved populations are taken from state-generated updates to the state's amendment application to CMS.

Demonstration Eligible Populations	Eligibility ²⁹	Benefits ²	Estimated Number of Annual Enrollees ³⁰
Eligible CHIP Children	<p>otherwise eligible for Medicaid and participate in an approved ESI plan.</p> <p>Demonstration Population V - same as Demonstration population III, except that the eligible individual or custodial parent/caretaker is able to enroll in COBRA continuation coverage.</p> <p>Current Eligible CHIP Children - these children are eligible for the CHIP, but the children's parents have elected to receive premium assistance for the employee's share of the cost of ESI instead of receiving CHIP direct coverage.</p> <p>Demonstration Population VI - children up to age 19 with family income up to 200 percent of the FPL who would meet the definition of a low-income child. Population is divided into 2 groups: COBRA-Eligible Children and COBRA-Continuation Children.</p>	insurance plans. Together, the ESI and COBRA benefits are the "Utah Premium Partnership Program" (UPP). Premium assistance is the sole Medicaid benefit provided to these members.	
Targeted Adult Medicaid (TAM)	<p>Includes adults, ages 19 through 64, with incomes below five percent of the FPL and no dependent children, who meet detailed criteria in one of three major categories:</p> <p>Chronic homelessness</p> <p>Involved in the criminal justice system and in need of substance use or mental health treatment.</p> <p>In need of substance use or mental health treatment</p>	Individuals enrolled in this eligibility category receive full Medicaid state plan benefits.	9,384
Intensive Stabilization Services (ISS)	Medicaid eligible children and youth under age 21, who are in state custody, or at risk of state custody, and	Individuals eligible for this category will receive state plan and home community-based crisis stabilization	Anticipate 20

Demonstration Eligible Populations	Eligibility ²⁹	Benefits ²	Estimated Number of Annual Enrollees ³⁰
	experiencing significant emotional and/or behavioral challenges.	services during the first eight-weeks of the intensive program on a FFS basis using a daily bundled rate.	
Former Foster Care Youth from Another State (FFCYAS)	Individuals under age 26, who were in foster care under the responsibility of a state other than Utah, or a tribe in such other state when they turned 18 (or such higher age as the state has elected for termination of federal foster care assistance under title IV-E of the Act), were ever enrolled in Medicaid, are now applying for Medicaid in Utah, and are not otherwise eligible for Medicaid.	Individuals enrolled in this eligibility category receive full Medicaid state plan benefits.	17

In addition to the benefits associated with each eligibility pathway outlined above, the Demonstration includes several benefits, programs, and services that have expanded over time to broaden access to care and to meet the needs of vulnerable populations (see Table 2).

Table 2: Additional Demonstration Benefits, Programs, and Services

Additional Demonstration Benefits, Programs, and Services	Eligibility ³¹	Benefits ²	Estimated Number of Annual Enrollees ³²
Dental Benefit	<p>As of the amendment approved in January 2025: all individuals enrolled in Medicaid and are the age of 21 or older.</p> <p>Previously, dental benefits were available only to the aged, blind, or disabled groups, and to TAM members receiving SUD treatment.</p>	Individuals that are enrolled in this eligibility category will receive state plan dental benefits that are defined in the Utah Medicaid Provider Manual, Dental Services and porcelain or porcelain-to-metal crowns, if needed.	Entire Adult Expansion population 115,584
Health-Related Social Needs (HRSN) Services	<p>As of the amendment approved in January 2025: the following covered populations will be eligible to receive HRSN services if they also satisfy the applicable clinical and social risk criteria and the HRSN services is determined to be medically appropriate:</p> <p>Recently Incarcerated Individuals are eligible for HRSS.</p> <p>Adult Expansion and TAM demonstration populations are eligible for HRSS, Short-Term Rental Assistance, Short-Term Recuperative Care, and Short-Term Post Transition Housing</p>	<p>Housing-Related Services and Supports (HRSS): includes pre-tenancy navigation services, tenancy sustaining services, one-time transition and moving costs other than rent, home accessibility modifications and remediations that are medical necessary.</p> <p>Short-Term Rental Assistance: payment for rent and/or short-term temporary stays for up to six months in a 5-year period.</p> <p>Short-Term Recuperative Care (a/k/a Medical Respite): clinically oriented recuperative or rehabilitative services and supports for individuals</p>	5,000

³¹ [ut-cms-amndmnt-aprvl.pdf \(medicaid.gov\)](#)

³² The annual estimates reflect the enrollment numbers reported in the Annual Monitoring Report for the period July 2021 – June 2022 for populations that are continuing from the prior waiver period. Estimates for TAM HRSS, a new population, are taken from the approved Waiver renewal. Estimates for IVF and genetic testing and fertility preservation treatments, and estimates for HRSN Services are taken from the state's amendment applications to CMS. Estimates for the Justice-Involved populations are taken from state-generated updates to the state's amendment application to CMS.

Additional Demonstration Benefits, Programs, and Services	Eligibility ³¹	Benefits ²	Estimated Number of Annual Enrollees ³²
		<p>who require ongoing monitoring and continuous access to medical care.</p> <p>Short-Term Post Transition Housing: clinically oriented rehabilitative services and supports for individuals who do not require ongoing monitoring and continuous access to medical care.</p>	
Serious Mental Illness (SMI) IMD Benefit	Medicaid recipients, age 21 through 64 receiving SMI services in IMD treatment settings.	The Demonstration grants Utah expenditure authority for services provided to beneficiaries during short term stays in an IMD to receive acute care for a primary diagnosis of SMI or SED for stays of up to 60 days, as long as the state shows at its midpoint assessment that it is meeting the requirement of a 30 day or less average length of stay (ALOS) for beneficiaries residing in an IMD who are receiving covered services in an IMD.	8
Opioid Use Disorder/ Substance Use Disorder Program	SUD benefits are available to all Medicaid members through state plan authority.	The Demonstration grants Utah expenditure authority to provide the following services in IMDs: residential treatment, withdrawal management, medication-assisted treatment (MAT), peer support, residential crisis stabilization.	767
In Vitro Fertilization and Genetic Testing Services	In Vitro Fertilization (IVF): Medicaid recipients ages 18-35 diagnosed by a physician or qualified health professional as having a genetic trait associated with cystic fibrosis, morquio syndrome, sickle cell anemia, or spinal muscular atrophy, and has a reproductive partner who has been diagnosed with the same condition. Has been diagnosed by a physician or qualified health	In vitro fertilization services, genetic testing services, and preimplantation genetic testing to test embryos for genetic disorders prior to transfer to the uterus. These services require prior authorization, and qualifying beneficiaries may receive up to three cycles of IVF per lifetime.	50

Additional Demonstration Benefits, Programs, and Services	Eligibility ³¹	Benefits ²	Estimated Number of Annual Enrollees ³²
	<p>professional as having a genetic trait associated with myotonic dystrophy.</p> <p>Genetic testing: Medicaid recipients who have a familial medical history or are in an ethnic group that has a high risk of one or more of the following medical conditions: cystic fibrosis, morquio syndrome, myotonic dystrophy, sickle cell anemia, or spinal muscular atrophy.</p>		
Fertility Preservation Benefit for Individuals Diagnosed with Cancer	Medicaid recipients diagnosed by a physician or qualified health professional as having an active cancer diagnosis requiring treatment that may cause a substantial risk of sterility or iatrogenic infertility. Post pubertal and up to age 50.	Individuals can receive egg and sperm collection and storage, preimplantation genetic testing prior to cryopreservation storage, cryopreservation storage. These benefits require prior authorization and are available once per lifetime.	226
Justice-Involved Reentry Benefit	Individuals who are inmates residing in county jails, state prisons, or youth correctional facilities and have been determined eligible for Medicaid pursuant to an application filed before or during incarceration.	<p>Eligible individuals can receive the following pre-release services starting 90 days before their release from incarceration:</p> <p>Case management to assess and address physical and behavioral health needs;</p> <p>Medication-assisted treatment services for all types of SUD as clinically appropriate, with accompanying counseling;</p> <p>A 30-day supply of all prescription medications that have been prescribed for the individuals at the time of release; provided to the individual immediately upon release from the correctional facility;</p>	<p>Adults: 3,600</p> <p>Youth: 15</p>

Additional Demonstration Benefits, Programs, and Services	Eligibility ³¹	Benefits ²	Estimated Number of Annual Enrollees ³²
		<p>Physical and behavioral health clinical consultation services, as clinically appropriate, to diagnose health conditions, provide treatment, and support pre-release case managers' development of a post-release treatment plan and discharge planning;</p> <p>Diagnostic services, including laboratory and radiology services, and treatment services in addition to coverage for MAT described above;</p> <p>Prescribed drugs, in addition to MAT and the 30-day supply of prescription medication, and medication administration;</p> <p>Family planning services and supplies;</p> <p>Services provided by community health workers;</p> <p>Peer support services;</p> <p>Treatment for Hepatitis C; and</p> <p>Medical equipment and supplies and/or medical equipment provided upon release</p> <p>Youth eligible for CHIP will receive pre-release screening, diagnostic, and case management services starting 30 days before their release.³³</p>	

³³ Authority for pre-release services for CHIP eligible youth is covered under the SPA, and not held under the Utah Medicaid Reform 1115 Demonstration waiver; this evaluation will not include this population.

5. Context

The Utah Medicaid 1115 Demonstration also coincided with the unwinding of the Medicaid Continuous Enrollment requirement associated with the Covid-19 pandemic beginning in 2020. Enrollment in Medicaid remained high during the continuous enrollment period as states were required to keep current Medicaid beneficiaries enrolled. The unwinding of continuous eligibility for Medicaid began on March 1, 2023.³⁴ Under Utah's unwinding plan³⁵, every member's case was slated for a full review, with cases spread over a 12-month period. Cases most likely to change programs or coverage were prioritized for review, and those most likely to remain Medicaid eligible were deferred to later in the year. DHHS communicated with providers and beneficiaries about the redetermination process. Members are urged to update their contact information and check the unwinding website³⁶ to learn their anticipated review date. Redetermination will likely affect enrollment numbers in the Demonstration, as some individuals moved from one eligibility category to another, and individuals above income limits transitioned off Medicaid coverage. This evaluation design includes qualitative interviews and process metrics on implementation as it will be a moderating factor that may affect Demonstration outcomes.

³⁴ [10 Things to Know About the Unwinding of the Medicaid Continuous Enrollment Provision | KFF](#)

³⁵ <https://medicaid.utah.gov/unwinding/>

³⁶ <https://jobs.utah.gov/mycase/>

B. Evaluation Questions and Hypotheses

1. Logic Model




FIGURE 1: MEDICAID REFORM DEMONSTRATION OVERALL LOGIC MODEL

2. Hypotheses and Research Questions

The logic model above illustrates how the Demonstration objectives are expected to be achieved by program activities, following a natural progression from proximate to distal outcomes as the Demonstration goes on. Each outcome is represented by a testable hypothesis, listed below, about the impact of the Demonstration activities, and a corresponding research question. Tables 15-25 specify the measures that will be used to assess each hypothesis.

The hypotheses are organized by population or program/benefit, and are focused on the broad themes of increasing health care coverage, increasing access to primary care and appropriate utilization, reducing high-cost acute care utilization, including potentially preventable utilization, and reducing the cost of uncompensated care.

The first objective of the 1115 Demonstration, providing health care coverage for low-income Utahns eligible who would not otherwise have access to or be able to afford health care coverage, is achieved through enrollment in a number of the Demonstration populations, including the Adult Expansion, TAM, UPP, and ISS. Individuals in these populations would not otherwise be eligible for Medicaid without the presence of the Demonstration in Utah.³⁷ The first hypothesis is thus focused on the impact of the 1115 Demonstration overall on the population of low-income UT residents. A larger fraction of low-income UT residents is expected to report having access to coverage and engaging in health care relative to reported access and engagement in other states. Engagement in care is expected to improve member satisfaction and lead to reductions in inappropriate care utilizations, also known as “Low Value Care”.

The second hypothesis is similar to the first hypothesis, and focuses specifically on the Adult Expansion population. The second hypothesis is that the Demonstration will improve health care access and engagement for the Adult Expansion population. The state hypothesizes that by providing coverage through Medicaid expansion, members will engage in primary and preventive care, which will lead to reductions in acute care utilization. The Utah Medicaid Integrated Care (UMIC) population, a subpopulation of the Adult Expansion population, consists of members in Utah’s five-most populous counties who are enrolled in plans that integrate care for physical and behavioral health needs. Thus, the UMIC research questions are specific to the outcomes produced when members gain access to behavioral health care that is managed by the same managed care organization that manages their physical health care. It is anticipated that UMIC will improve engagement in BH services and reduce ED utilization.

The third hypothesis again focuses on access and engagement in health care, this time focusing on the TAM population. The state hypothesizes that the Demonstration will continue to improve health care access and engagement for this population.

The fourth hypothesis addresses the HRSN demonstration, which essentially expands the housing-related services and supports (HRSS) benefit previously available only to TAM members, to the entire Adult Expansion population who meet the needs-based eligibility criteria. The state is authorized to provide HRSS, short-term rental assistance, short-term recuperative care, short-term post-transition housing, and non-medical transportation (NMT). The evaluation design focuses on HRSS and NMT, with a planned implementation date of July 1, 2025. The other authorized services may, or may not, be implemented during the current demonstration period. If they are implemented, they should contribute to the same outcomes theorized for HRSS. It is anticipated that the HRSN demonstration will reduce the prevalence and severity of housing and transportation needs, increase continuity of BH treatment, and improve health outcomes for eligible members. Research questions include whether HRSN services were provided and utilized as planned, care manager perspectives on incorporating this new benefit, whether there is unmet need, and whether HRSS improves perceived health status. Other research questions about the HRSN demonstration focus on how HRSN affects high-cost acute care utilization.

³⁷ Individuals in the Current Eligibles population received expanded benefits through the waiver, although they would have received coverage regardless of the presence of the waiver.

The fifth and sixth hypotheses speak to BH services provided to Demonstration participants and Medicaid beneficiaries with SMI and SUD treated in Institutions of Mental Disease (IMD). The state anticipates that BH coverage for residential and inpatient services provided to members in IMDs will lead to a reduction in inpatient stays, ED utilization, and rate of unplanned readmission among recipients, resulting in cost decrease or stabilization. The state also anticipates this will lessen unmet need and increase engagement in treatment to reduce overdose deaths in the long-term. The IE will monitor the impact of the state's efforts to increase access to crisis stabilization services. Greater utilization of non-hospital, non-residential services should lead to greater reductions in inpatient stays, ED utilization, and overdose deaths in the long-term.

The seventh hypothesis addresses smaller Demonstration populations, which include UPP/ESI, ISS, , TAM Dental, and FFCYAS. The state anticipates that utilization for the services provided to these populations will increase and total cost of care will decrease, as these members engage in acute and preventive care. Although the number of Adult Expansion members enrolled in Employer Sponsored Insurance will grow due to the new provision present in this waiver requiring enrollment in ESI for all Adult Expansion members who have access to insurance through their employers, the number of members enrolled in ESI is not projected to exceed 1,385 members during this Demonstration period. As a result, the ESI population by itself is unlikely to lead to reductions in uncompensated care and inappropriate care utilization. In addition, the number of individuals in the FFCYAS population, and the number receiving ISS, were both very small in the prior Demonstration period. Therefore, the evaluation will include counts and a qualitative summary of program implementation.

Finally, hypotheses eight through eleven focus on the justice-involved (JI) population and the pre-release and reentry services newly covered. The state anticipates that the demonstration will enhance cross-system collaboration between the correctional and community-based services systems, that enrollment and redetermination support will improve continuity of coverage, and that coverage of pre-release and reentry services will improve engagement in high quality care, reduce unnecessary acute care utilization, and ultimately improve health outcomes for the JI population. In addition, the State will conduct a demonstration cost assessment including administrative costs of demonstration implementation and operation, Medicaid health services expenditures, and provider uncompensated care costs. The results of the cost assessment will be included in the Interim and Summative Evaluation Reports.

Hypothesis 1: The Demonstration overall will improve access to coverage and engagement in health care for low-income UT residents.

Primary research question 1.1: Did the fraction of low-income residents with no coverage decrease, relative to comparison states?

Primary research question 1.2: Did the fraction of low-income residents who avoided care due to cost decrease, relative to comparison states?

Primary research question 1.3: Did the fraction of low-income residents who have a personal doctor or usual source of care increase, relative to comparison states?

Primary research question 1.4: Did the fraction of low-income residents who had a primary or specialty care appointment in the last year increase, relative to comparison states?

Primary research question 1.5: Did the fraction of low-income residents who had a preventive screening in the last year increase, relative to comparison states?

Primary research question 1.6: What is the member experience of care in terms of access, timeliness, and patient-centeredness?

Primary research question 1.7: Did Low Value Care decrease among Demonstration participants, relative to baseline?

Hypothesis 2: The Demonstration will improve health care access and engagement for the Adult Expansion population.

Primary research question 2.1: Did inpatient hospital utilization decrease, relative to baseline, for the Adult Expansion population?

Primary research question 2.2: Did ED visits decrease, relative to baseline, for the Adult Expansion population?

Subsidiary research question 2.2.a: Did ED visits for BH conditions decrease, relative to baseline, for the Adult Expansion population?

Subsidiary research question 2.2.b: Did UMIC plans reduce ED visits for BH conditions for Adult Expansion population, relative to FFS or physical health-only ACO plans?

Primary research question 2.3: Did engagement in primary and ambulatory care increase, relative to baseline, for the Adult Expansion population?

Primary research question 2.4: Did engagement in behavioral health care increase, relative to baseline, for the Adult Expansion population?

Subsidiary research question 2.4.a: Did UMIC plans improve engagement in behavioral health care for the Adult Expansion population, relative to FFS or physical health-only ACO plans?

Primary research question 2.5: Did engagement in treatment for chronic conditions increase, relative to baseline, for the Adult Expansion population?

Primary research question 2.6: Did preventive cancer screening increase, relative to baseline, for the Adult Expansion population?

Primary research question 2.7: Did dental service provision increase relative to baseline for the Adult Expansion population?

Primary research question 2.8: Did ED visits for non-traumatic dental conditions decrease relative to baseline for the Adult Expansion population?

Primary research question 2.9: Did follow-up after ED visits for non-traumatic dental conditions increase relative to baseline for the Adult Expansion population?

Primary research question 2.10: To what extent are beneficiaries aware of the dental care benefit?

Hypothesis 3: The Demonstration will improve health care access and engagement for the TAM population.

Primary research question 3.1: Did inpatient hospital utilization decrease, relative to baseline, for the TAM population?

Primary research question 3.2: Did ED visits decrease, relative to baseline, for the TAM population?

Subsidiary research question 3.2.a: Did ED visits for BH conditions decrease, relative to baseline, for the TAM population?

Primary research question 3.3: Did engagement in primary and ambulatory care increase, relative to baseline, for the TAM population?

Primary research question 3.4: Did engagement in behavioral health care increase, relative to baseline, for the TAM population?

Primary research question 3.5: Did dental service provision increase relative to baseline for the TAM population?

Primary research question 3.6: Did ED visits for non-traumatic dental conditions decrease relative to baseline for the TAM population?

Primary research question 3.7: Did follow-up after ED visits for non-traumatic dental conditions increase relative to baseline for the TAM population?

Hypothesis 4: The HRSN Services demonstration will effectively mitigate members' housing and transportation needs, lead to more appropriate service utilization and improved physical and mental health outcomes.

Primary research question 4.1: What is the prevalence and severity of beneficiaries' social needs?

Primary research question 4.2: Were HRSN services provided and utilized as planned?

Primary research question 4.3: Did the HRSN demonstration effectively mitigate beneficiaries' housing and transportation needs?

Primary research question 4.4: Did high-cost acute utilization decrease, relative to baseline, for HRSN recipients?

Primary research question 4.5: Did engagement in primary and ambulatory care increase, relative to baseline, for HRSN recipients?

Primary research question 4.6: Did engagement in behavioral health care increase, relative to baseline, for HRSN recipients?

Primary research question 4.7: From the beneficiaries' perspective, did the HRSN services meet their housing-related needs, support their engagement in behavioral health care, and overall positively impact their physical and mental health?

Primary research question 4.8: Did state and local investments in housing supports change over time during the HRSN demonstration?

Primary research question 4.9: Were there any improvements in the quality and effectiveness of downstream housing-related services and supports?

Hypothesis 5: The SMI and SUD Demonstrations increased access to appropriate treatment.

Primary research question 5.1: Did the number of individuals receiving services for SMI and/or SUD increase, relative to baseline?

Primary research question 5.2: Did ED visits for BH conditions decrease among individuals with SMI and/or SUD diagnoses, relative to baseline?

Primary research question 5.3: Did inpatient days (outside of IMDs) decrease, relative to baseline, for individuals with SMI and/or SUD?

Primary research question 5.4: Did engagement in SUD treatment increase among individuals with SUD diagnoses relative to baseline?

Primary research question 5.5: Did unplanned readmission following hospitalization for psychiatric treatment decrease among individuals with SMI relative to baseline?

Primary research question 5.6: Did utilization of any mental health service increase among low-income residents, relative to comparison states?

Primary research question 5.7: Did the number of individuals needing but not receiving SUD treatment decrease among low-income residents, relative to comparison states?

Primary research question 5.8: Did the rate of overdose deaths decrease, relative to baseline?

Primary research question 5.9: Did the number of individuals receiving crisis stabilization services increase (with an emphasis on non-hospital, non-residential services³⁸?

Hypothesis 6: The SMI and SUD Demonstrations stabilized or reduced cost of care for these populations.

Primary research question 6.1: Did the total cost of care for individuals with SMI diagnoses change, relative to baseline?

Subsidiary research question 6.1.a: Did costs related to the diagnosis and treatment of SMI change, relative to baseline? (SMI-IMD costs + other SMI costs + non-SMI costs)?

Subsidiary research question 6.1.b: What types of care (inpatient + non-ED outpatient, + ED outpatient + pharmacy, + long-term care) are the primary drivers of the cost of care for the SMI population?

Primary research question 6.2: Did the total cost of care for individuals with SUD diagnoses change, relative to baseline?

Subsidiary research question 6.2.a: Did costs related to the diagnosis and treatment of SUD change, relative to baseline? (SUD-IMD costs + other SUD costs + non-SUD costs)?

Subsidiary research question 6.2.b: What types of care (inpatient + non-ED outpatient, + ED outpatient + pharmacy, + long-term care) are the primary drivers of the cost of care for the SUD population?

Hypothesis 7: The Demonstration delivered coverage/ services appropriately to individuals in the smaller Demonstration populations and programs.

UPP/ESI

Primary research question 7.1: Did the number of individuals receiving coverage increase relative to baseline?

Primary research question 7.2: What was the average total Medicaid cost of care for enrollees?

Primary research question 7.3: Did the pmpm cost for enrollees change over time?

ISS

Primary research question 7.4: Did the number of individuals receiving ISS increase relative to baseline?

Former Foster Care Youth from Another State (FFCYAS)

Primary research question 7.5: How many FFCYAS received coverage?

³⁸ This includes services made available through crisis call centers, mobile crisis units, and coordinated community response services as defined in STC 12.4 SMI/SED Financing Plan.

Fertility and Genetic Testing Services

Primary research question 7.6: Did the number of individuals receiving fertility preservation services increase relative to baseline?

Primary research question 7.7: Did the number of individuals receiving genetic testing services increase relative to baseline?

Hypothesis 8: The Justice-Involved Reentry Benefit will enhance cross-system communication and coordination between correctional and community services.

Primary research question 8.1: Did the Demonstration's services facilitate beneficiaries' post-release transitions to care?

Primary research question 8.2: Was communication and coordination between the correctional system and community-based health services enhanced?

Hypothesis 9: The Justice-Involved Reentry Benefit will improve pre-release service provision during the covered period and continuity of coverage for the justice-involved population.

Primary research question 9.1: What Demonstration services did justice-involved individuals receive in the pre-release period?

Primary research question 9.2: What was beneficiaries' experience of pre-release service provision?

Primary research question 9.3: Were beneficiaries potentially in need of behavioral health services identified in the pre-release period?

Primary research question 9.4: What fraction of justice-involved individuals received navigation support for accessing Medicaid coverage pre-release?

Primary research question: 9.5: Did reentry continuity of coverage improve for incarcerated individuals compared to the pre-demonstration comparison population?

Hypothesis 10: The Justice-Involved Reentry Benefit's 90-day pre-release coverage period ("the coverage timeline") will support effective program implementation.

Primary research question 10.1: Did the coverage timeline facilitate providing more coordinated, efficient, and effective reentry planning?

Subsidiary research question 10.1.a: Were assessments and care plans completed in a timely manner?

Subsidiary research question 10.1.b: Did beneficiaries receive a 30-day supply of all prescribed medications immediately upon release from the carceral setting?

Primary research question 10.2: Did the coverage timeline enable pre-release management and stabilization of clinical, physical, and behavioral health conditions?

Primary research question 10.3: Did the coverage timeline help mitigate potential operational challenges the state might have encountered in a more compressed timeline?

Hypothesis 11: The Justice-Involved Reentry Benefit will improve engagement in health care services and social, reduce acute care utilization, and improve health outcomes for the justice-involved population post-release.

Primary research question 11.1: Did engagement in appropriate health care services post-release increase relative to a pre-demonstration comparison population?

Primary research question 11.2: Did inpatient hospital utilization post-release decrease relative to the pre-demonstration comparison population?

Primary research question 11.3: Did ED visits post-release decrease, relative to the pre-demonstration comparison population?

Primary research question 11.4: Did the rate of deaths post-release decrease relative to the pre-demonstration comparison population?

Primary research question 11.5: Was the timing or provision of specific pre-release services associated with better post-release outcomes?

3. Independent Assessments

In addition to evaluating the hypotheses and research questions outlined in the previous section, several independent assessments will be conducted. The purpose and methods for each of these assessments are described here.

Wind-down of Current Eligibles

An assessment of the wind-down of the Current Eligibles (CE) demonstration population will be conducted. The original PCN Demonstration provided a limited package of preventive and primary care benefits (the PCN benefit) to adults ages 19-64 with household incomes up to 150 percent of the Federal Poverty Level (FPL) and a slightly reduced benefit package to Parent/Caretaker Relatives (PCR) who comprised the Current Eligibles population. With Medicaid expansion in April 2019, PCN program participants became eligible for full state plan benefits, and the PCN benefit was phased out. The Current Eligible population was phased out entirely on December 31, 2023, eliminating disparities in benefit packages by parental status.

The research question is: Was the wind-down process implemented efficiently and effectively? The assessment data sources are:

Key Informant Interviews (KIIs) with 2-3 State agency staff

MRT Demonstration Quarterly Monitoring Reports

High-level topics for the KIIs include operational challenges and successes, strategies implemented to overcome barriers, and overall lessons learned throughout the wind-down process.

Cost Assessments

A Demonstration cost assessment will be conducted. The IE will use the cost analyses in concert with findings from hypothesis tests to assess the demonstration's effects on the fiscal sustainability of the State's Medicaid program.

The IE will conduct a comprehensive cost analysis to support developing estimates of implementing the Reentry Demonstration Initiative, including covering associated services.

For the HRSN Demonstration, the IE will conduct a cost analysis to support developing comprehensive and accurate cost estimates of providing such services.

Table 3: Description of Cost Assessments

Cost Assessment	Description
Medicaid Reform Demonstration	Administrative costs, health service expenditures, uncompensated care Exclude JIR costs, exclude HRSN costs
Justice-Involved Reentry	Administrative costs, health service expenditures Estimates of cost saved through reduced ED visits & hospital admissions
Health-Related Social Needs	Costs associated with potentially preventable high-acuity health care Administrative costs, health service expenditures Infrastructure investments

The cost assessments will rely on administrative data, the specific measures and data sources are provided in Table 4.

Table 4: Cost Assessment Measures & Data Sources

Measure	Data Source
Administrative Costs of the Demonstration Report for JIR, HRSN, all other Total and per beneficiary per month PMPM growth rate	Form CMS-64
Medicaid Health Service Expenditures Report for JIR, HRSN, all other Total and per beneficiary per month PMPM growth rate Report by type of service, identify cost drivers, where possible	Form CMS-64, Medicaid claims data
Demonstration Costs: sum of administrative & services Report for JIR, HRSN, all other	Form CMS-64, Medicaid claims data

Total and per beneficiary per month

PMPM growth rate

HRSN Infrastructure Costs

Form CMS-64, Annual Monitoring Reports

Provider Uncompensated Care Costs

CMS-HCRIS, NASHP HCT

C. Methodology

1. Evaluation Approach

The Independent Evaluator (IE) will use a mixed-methods evaluation approach that will combine administrative and survey data as well as qualitative data to address the goals and hypotheses presented in the Demonstration application and answer all research questions listed above.

The evaluation will employ multiple comparison strategies, both in-state and out-of-state. Interrupted Time Series (ITS) is the preferred approach to analyze the impact of the Demonstration by comparing trends during the pre-demonstration period to the Demonstration period. ITS will be the approach in all instances for which there is sufficient pre-demonstration data available. When pre-demonstration data is not available the evaluation will rely on descriptive statistics and trends over time. To assess the impact of UMIC plans, regression analysis will compare members in three plan types – fee for service, physical health-only ACO, and UMIC.

Results will be stratified by demographic characteristics SMI/SUD status, and plan type, when sufficient numbers are available to permit comparisons. A summary of the characteristics of the Demonstration populations as of the end of the previous waiver period (June 30, 2022) is provided in Table 13 in the Subgroup Analyses section.

Comparisons to Medicaid beneficiaries in other states also provide valuable context. A difference-in-difference (DiD) comparison, and a synthetic control method (SCM), will be used to compare the impact of the Demonstration as a whole on the aggregate Medicaid population to Medicaid beneficiaries in other states. Out-of-state comparisons will address the research question “Did the Demonstration as a whole improve health care access and quality for the Medicaid beneficiary population?”

Member perspectives will be collected through a customized member survey, and through interviews of members receiving HRSS and pre-release and reentry services. Where a survey provides a broader and more representative sample, individual interviews allow for in-depth understanding of member experiences. Additional qualitative data will be collected through key informant interviews with stakeholders. Together, these complementary methods will enable a comprehensive evaluation of the Demonstration.

2. Target and Comparison Populations

As summarized in [Table 1](#), the Demonstration provides coverage and services for multiple populations. Out-of-state comparison using national survey data and other publicly available data sources will be used for investigating the impact of the Demonstration as a whole on the full Medicaid eligible population. For specific populations, the comparison will be to pre-Demonstration trends. For UMIC plans, the comparison will be to other plan types without integrated BH services. The Demonstration populations (the target groups) and the approach to comparisons are shown below in [Table 5](#).

Table 5: Demonstration Populations, Benefits, and Comparisons

Demonstration (target) Population	Program Implementation Start	Baseline Years	Comparison ¹	Analytic Approach
Substance Use Disorder (SUD) IMD	November 9, 2017	November 1, 2017 - June 30, 2022	Pre-SUD demonstration baseline	Trend over time, Interrupted Time Series
Targeted Adult Medicaid (TAM)	November 1, 2017	November 1, 2017 - June 30, 2022	Pre-demonstration baseline	Trend over time, Interrupted Time Series
Adult Expansion Population	April 1, 2019 (partial expansion, up to 100% of the FPL) January 1, 2020 full expansion	July 1, 2018- June 30, 2022	Pre-demonstration baseline	Trend over time, Interrupted Time Series
Utah Medicaid Integrated Care (UMIC- subset of the Adult Expansion Population)	January 1, 2020	N/A	Three plan types: FFS, ACO, UMIC	Multiple Linear Regression
Serious Mental Illness (SMI) IMD	December 1, 2020	December 1, 2020 - June 30, 2022	Pre-demonstration baseline	Trend over time, Interrupted Time Series
Expanded Dental Benefit	January 13, 2025	January 1 2020 – December 31, 2024	Pre-Dental demonstration baseline	Interrupted Time Series
Health-related Social Needs Services	July 1, 2025	July 1, 2020— June 30, 2025	Pre-HRSN demonstration baseline	Longitudinal cohort design with pre-HRSN demonstration baseline, if available
Justice-Involved Adults	February 1, 2026	February 1, 2022-January 31, 2026	Pre-demonstration comparison baseline	Trend over time, Interrupted Time Series

¹ The term “pre-demonstration baseline” refers to the time period before the start of the current Demonstration period; before July 1, 2022. The term “pre-demonstration comparison baseline” refers to individuals who were incarcerated in Utah county jails or state prisons whose Medicaid status was paused due to incarceration.

Justice-Involved Reentry Comparison Group

To analyze outcomes for the Justice-Involved Adults, the IE plans to construct a historical, pre-demonstration comparison group comprised of individuals who were incarcerated in Utah county jails or state prisons before the implementation of the Justice-Involved Reentry benefit. Utah DHHS will provide Medicaid claims data for the pre-demonstration comparison group through the standardized claims-data transfer process. Utah DHHS can identify individuals for this population who have a suspension status due to incarceration for their Medicaid eligibility, and were assigned the “incarcerated benefit” during their incarceration, but are unable to identify specific carceral facilities. The accurate identification of this group relies on the historical assignment of the “incarcerated benefit”. All adults released from incarceration in Utah during the pre-demonstration baseline period, identified by a lift of Medicaid suspension status due to incarceration, will be included in the comparison group. There are no other criteria for inclusion in the comparison group. The IE has established a data use agreement between the IE, Utah DHHS, and the Utah Office of Vital Records and Statistics (OVRS) to provide vital statistics data. Appropriate identifiers will be used, including name, date of birth, social security number, and a unique client identifier to link vital statistics data with Medicaid data for the pre-demonstration comparison group.

Several demonstration populations are too small to feasibly conduct a comparison to a baseline period. The analytic approaches for these demonstration populations are primarily trend over time and descriptive statistics.


Table 6: Small Demonstration Populations

Demonstration (target) Population	Program Implementation Start	Analytic Approach
Utah Premium Partnership Program (UPP)	November 1, 2006	Trend over time, descriptive statistics
TAM Dental	March 1, 2019	Trend over time, descriptive statistics
Former Foster Care Youth from Another State (FFCYAS)	March 1, 2019	Counts (small population size)
Intensive Stabilization Services (ISS)	July 1, 2020	Counts (small population size)
TAM members receiving Housing Related Services and Supports (HRSS)	December 1, 2022	Trend over time, descriptive statistics, qualitative interviews and analysis
Fertility and Genetic Testing Services	May 1, 2024	Counts (small population size)
Justice-Involved Youth	January 1, 2025	Counts (small population size)

3. Evaluation Period

This evaluation will cover the five-year Demonstration period from July 1, 2022, through June 30, 2027. The pre-Demonstration baseline will be the previous waiver period from July 1, 2017- June 30, 2022. The IE acknowledges that many policies authorized under this waiver are continuations of policies implemented in previous waiver periods. The goal of this evaluation is to quantify any gains realized in the current waiver period. As a result, the baseline period for each analysis will be specific to program start dates listed in Table 5. Please see Figure 2 below for more information. Sensitivity analysis will be conducted to determine whether excluding part of 2020 due to the Covid-19 PHE is appropriate.

FIGURE 2: ELIGIBILITY GROUPS AND SERVICES TIMELINE



*The planned implementation start date for the Justice-Involved Reentry benefit for adults has been extended from July 1, 2025 to February 1, 2026. This image will be updated when the JIR benefit for adults has launched.

4. Evaluation Measures

Evaluation hypotheses and corresponding measures are listed in Section F.4., Evaluation Tables.

5. Data Sources

The evaluation will use the following quantitative and qualitative data sources:

National Surveys and Other Publicly Available Data Sources:

Behavioral Risk Factor Surveillance System (BRFSS)

National Survey of Drug Use and Health (NSDUH)

National Academy for State Health Policy's (NASHP) Hospital Cost Tool (HCT)

Utah Specific Data Sources:

Medicaid Administrative Data

Eligibility & enrollment

Claims

Cost (Form CMS-64)

Carceral Facility Administrative Data

Justice-Involved Correctional Facility Readiness Assessment

Vital Statistics

Consumer Assessment of Healthcare Providers and Systems (CAHPS) survey

Custom member survey

Participant interviews with TAM members receiving HRSS, JIR beneficiaries, and HRSN service recipients

Key Informant Interviews (KIIs)

National Surveys and Other Publicly Available Data Sources

Measures employing national survey data and other publicly available data sources for an out-of-state comparison will use a three-year pre-Demonstration baseline.

BRFSS

The BRFSS is a large, high-quality federal survey that may be used to measure outcomes of interest for out-of-state comparison groups. Importantly, the BRFSS contains respondents' state identifiers and demographic variables needed for comparison purposes. The IE will use the BRFSS data to address research questions related to coverage and access to care among low-income residents (Table 8).

The BRFSS insurance coverage question outcome does not allow determination of the source of coverage (e.g., Medicaid, Medicare, or private insurance) for years prior to 2022. In order to approximate which respondents are Medicaid eligible and who fall below 138 percent of the FPL, a continuous value for household income will be imputed using the midpoint of BRFSS income category. Using imputed

income with household size allows the ability to link to annual thresholds for 138 percent FPL in each state. This method will be employed for the years prior to 2022 only.

The IE has also conducted power analysis for using the BRFSS. Our analyses will have high statistical power due to the large sample sizes involved. We estimated the minimum detectable effect sizes for each of our outcomes using Hu & Hoover's (2018) power equation for non-randomized longitudinal difference-in-difference studies:

$$MDES = \frac{T(1 - \rho)\sigma}{bkn} \times \left(z_{1-\frac{\alpha}{2}} + z_{1-\beta} \right)^2$$

Where:

MDES = the minimum detectable effect size, defined as a percentage point change in outcome

T = the total number of time periods

b = the number of pre-intervention periods

k = the number of post-intervention periods

n = sample size

σ = standard deviation

ρ = serial correlation

$z_{1-\frac{\alpha}{2}}$ = The critical z-value for statistical significance

$z_{1-\beta}$ = desired statistical power

The final analysis will include 5 pre-intervention years and three post-intervention years. We used BRFSS data to identify serial correlations, standard deviations, and sample sizes for each study outcome. Serial correlation is the relationship between state-level means in consecutive years. We then calculated minimum detectable effect sizes (MDES) at 80% power and $\alpha=0.05$. The MDES ranges from 0.41% to 0.58% for our access outcomes. For preventive service outcomes, the MDES ranges from 0.54% (receipt of annual checkup) to 2.29% (receipt of HPV test in the past 12 months). The sexual and reproductive health questions are only asked of female respondents in even years, which limits our ability to detect smaller effects.

Table 7: Minimum Detectable Effect Sizes

Outcome	Serial correlation	Standard deviation	Sample size	MDES
Insurance Coverage	0.891	0.478	116,482	0.41
Having a personal doctor	0.840	0.488	116,893	0.48
Avoided care due to cost	0.796	0.460	117,000	0.58
Receipt of annual checkup	0.809	0.482	115,376	0.54
Receipt of mammogram in past 12 months	0.758	0.430	26,814	1.41

Notes: SD = Standard deviation. MDES = Minimum detectable effect size (percentage point change) at 80% for a difference-in-differences analysis with $\alpha=0.05$.

NSDUH

To investigate the SUD and SMI waiver impact, the IE will use the NSDUH public use dataset. NSDUH collects data annually on incidence and treatment of mental health and substance use conditions. Key NSDUH questions address whether individuals have experienced BH conditions, and whether they have

received treatment. The NSDUH public use dataset does not contain enough information to conduct a power analysis.

NASHP HCT

To investigate the Demonstration's impact on uncompensated care costs, the IIE will use the NASHP HCT. The HCT provides a range of measures for hospital revenue, costs, profitability, and break-even points across over 4,600 hospitals nationwide. The underlying dataset includes variables extracted and calculated from the national Healthcare Cost Report Information System (HCRIS).

Table 8: National Surveys and Other Publicly Available Data

Survey	Topic	Survey Questions
BRFSS	Health Risk Factors	Insurance Coverage Having a personal doctor Avoided care due to cost Receipt of annual checkup Receipt of mammogram in past 12 months
NSDUH	BH Needs and Services	Received treatment for SUD in the last 12 months Received treatment for mental health condition in the last 12 months Needed, but did not receive, treatment for BH condition
NASHP Hospital Cost Tool	Uncompensated Care Cost	Uncompensated care/bad debt as a percentage of net patient revenue, and as a percentage of operating expenditures

Medicaid Administrative Data

The IE anticipates receiving claims and other Medicaid administrative data, such as eligibility files, from the state on an annual basis. Administrative data is expected to be of high quality, in terms of completeness and accuracy.

The IE anticipates having access to aggregate CAHPS data collected by the health plans and reported to DHHS. Health plans are able to distinguish between ACO and UMIC plan enrollment in CAHPS data and report this information to the state. This data will allow for comparisons of plan types.

CAHPS data will also be used to analyze differences in access to care coordination and patient satisfaction between subgroups. Because CAHPS data will be available only in aggregate, subgroup analysis will be limited to the available demographic stratifications: age, race (White and Other), ethnicity (Hispanic/ Not Hispanic), and gender.

Correctional Facility Readiness Assessment and Carceral Facility Administrative Data

The state developed a Correctional Facility Readiness Assessment tool that is administered to each participating carceral facility prior to their implementation of the JIR benefit. The Readiness Assessment is a 37 item REDCap survey completed by an appropriate representative of each carceral facility. It captures information about facilities' existing operations and procedures (including screening for Medicaid enrollment, use of data sharing agreements, use of case management services, and provision of specific health services covered under the JIR benefit) and their plans for standing up the needed systems to support the JIR benefit.

The IE anticipates utilizing the results of the Correctional Facility Readiness Assessment to assess the pre-release services and operational capabilities of participating facilities prior to implementation of the Demonstration. This is important context for understanding the successes and challenges of Demonstration implementation.

Carceral facility administrative data refers to data elements that are pertinent to the evaluation of the Demonstration that are not captured in Medicaid administrative data. These data elements will be collected by the carceral facilities, and will be included in a Data Use Agreement developed between the carceral facilities, DHHS, and the IE. These data elements include information on date of incarceration, Medicaid eligibility screening and application support, care planning, 30 day supply of Rx Medication upon release, and provision of health or social service referrals pre-release.

The JIR evaluation design is being prepared in parallel with the JIR implementation planning process, which includes establishing an electronic interface between carceral facilities and Medicaid systems to enable more “real-time” eligibility and enrollment data to be exchanged. In addition, Medicaid is working closely with the participating carceral facilities to establish data collection tools, processes, and workflows. The data needs for the evaluation were shared with the implementation team.

Custom member survey

The member survey will be administered once during the Demonstration period to a sample of approximately 6,000 adult Medicaid members who received a mental health diagnosis or service in the past 6 months. The mental health selection criteria is needed because a section of the survey is about access to mental health care. Examples of survey topics are summarized below in Table 9.

Table 9: Member Survey Topics

Focus Area	Example topics
Access to Care	Able to obtain care in a timely manner Ease of obtaining BH services Barriers to accessing care
Patient-centered care	Satisfaction with amount of time doctor spent Doctor explains in a way you can understand
Coordination of care	Primary care doctor has information needed about specialty care received

Survey Design

The IE will design the survey to assess the impact of the Demonstration on members’ access to and engagement in health care. The survey will cover key topic areas related to members’ recent history of health care coverage, access to health care (whether they have a primary care provider, if they have seen a specialist when needed, the regularity with which they obtain preventive care, etc.), and experience with care coordination. Being mindful of respondent burden, the IE aims for the survey length to not exceed 12 minutes when administered by phone.

Sample Frame Development and Sampling

The IE will work with DHHS to obtain the necessary member data, from which the IE will select a sample of members to survey. The sample will be comprised of 4,000 members. Assuming an approximately 35% response rate, we expect n=1,400 completed surveys (expected confidence interval of +/-2.54 at the 95% confidence level). To ensure that the sample accurately reflects the member population, the IE will conduct implicit random sampling using the appropriate variables available in the Pathways member database, such as gender, age, race/ethnicity, income, and length of enrollment in the program.

Assuming equal propensity for non-response between subgroups, we expect that this sample size will allow for reliable estimates for some subgroups of interest within a margin of error of +/- 5 percentage points, including by age group (individuals aged 19-26 years, aged 27-44 years, and aged 45-64 years), sex, and some racial and ethnic groups (Asian, White, Hispanic, Black, American Indian/Alaska Native and individuals of multiple races).

The ability to detect a significant difference between two groups is in part dependent on the measured prevalence of an outcome, and it will vary for each variable captured in the survey. Generally, if the prevalence of an outcome is around 50% in one group, this study is powered to detect a difference of 6.7 to 15.7 percentage points between respondents of different age groups, genders and racial and ethnic groups, with probability (power) of 80% at the 95% confidence level. If the prevalence of an outcome is very rare or very common (e.g., prevalence of 5% or 95%), this study is powered to detect smaller differences of 2.5 to 9.4 percentage points.

Survey Preparation

To maximize response rates, the IE will prepare the survey for three modes of data collection – mail, online (via smartphone/tablet device/PC), and phone. Each version will be thoroughly tested for quality control. The survey will also be translated into Spanish for interviewing respondents whose preferred language may be Spanish. Additional languages may be added if a need is identified.

Survey Administration

The IE will send the survey by mail to all members in the selected sample together with a cover letter (which will include an online link to the survey), and postage paid business reply envelope. For beneficiaries for whom email addresses are available, we will also send an email invitation with a link to the survey, followed by weekly reminder emails. After 21 days from the mailing, the IE will begin phone follow-up to non-respondents to administer the survey over the phone. To maximize response rates, the IE will make up to five phone attempts to each non-respondent at different times of day and during different days of the week including weekdays and weekends.

Data Analysis and Reporting

The IE will apply weights to the survey data to ensure that the weighted distribution of survey respondents accurately reflects the distribution of the member population on key population metrics, including gender, age, race/ethnicity, income, and length of enrollment in the program. Analysis of the survey data will focus on understanding members' access to health care, availability of employer-sponsored health insurance, and plans to transition to commercial health insurance. The IE will include analysis by key subgroups of interest, such as gender, age, and race/ethnicity.

Participant interviews with members receiving HRSS and/or pre-release and reentry services

Participant interviews will provide a necessary understanding of the experience of members receiving HRSS as well as pre-release and reentry services, including facilitators and barriers impacting the key outcome measures. The IE anticipates that the HRSS and JI populations will overlap, and interviews will be tailored to the experience and services received by members. The IE will conduct phone interviews to directly capture the input of participants, with privacy protections in accordance with CMS guidelines. Two waves of interviews will be conducted, with approximately 75-80 individuals in each wave (based on projected enrollment of approximately 56000 individuals) or until thematic saturation is reached for each subgroup. For this component of the evaluation, the IE is partnering with Dr. Palmira Santos, a doctoral-level social worker and researcher with expertise in interviewing individuals experiencing housing insecurity, BH conditions, and justice-involvement. Dr. Santos will lead the development of the interview guides, conduct interviews, and analyze results.

Potential interviewees will be invited to participate by their case managers, who will explain that the purpose of the evaluation is to improve the program and ask for permission to release their phone number. If an individual chooses to participate, the interviewer will receive only a first name (or chosen alias) and phone number for each participant. When a participant is reached by phone the interviewer will explain the evaluation and seek informed consent before beginning the interview.

Interviewees will be given a gift card as a thank-you, in a small amount for a store that does not sell alcohol or cigarettes.

Table 10: Participant Interview Topics

Interview Question	Example topics
How do participants' interaction with care managers happen? In what ways is it helpful, or not helpful?	Outreach approach, engagement, and follow through. Understanding of participant needs and perspective – whether care manager took steps to assist or explained limitations of service
What role did the HRSS case manager have in participants' housing situation?	Addressing specific patient needs, timeliness, role of other housing liaisons
What factors enhance or inhibit participants' engagement in behavioral health care?	Factors (barriers/facilitators) to access, coordination, continuity, and outcome
Are participants experiencing unmet needs for health care, including SUD and SMI treatment?	Participation in behavioral and physical health services and support. Use of the ED and hospitalizations (avoidable and/or BH related) – perspective on alternatives. Participation in preventive, acute and chronic condition services
Do participants perceive their life circumstances have changed since receiving HRSS services?	Previous and current life (SDOH, family, work etc.) situation
Did participants receive services in the pre-release period that met their needs? Was there enough time to get the screening and services you needed prior to release? And did such services result in stable physical and behavioral health upon release?	Access to and quality of pre-release services (case management, behavioral health care, diagnostic services, family planning services). Perceptions of stigma associated with care.
Were participants' post-release transitions to care needs adequately met by the pre-release services?	Access to care and medications, continuity of coverage, care, medication, and providers.

NOTE: Participants interviewed include TAM members receiving HRSS, JIR beneficiaries, and HRSN service recipients

Key Informant Interviews

Qualitative data on program implementation will be gathered through key informant interviews (KIIs) with providers and state administrators. A total of 30-35 -30 KIIs are planned; three at each of the four health plans, five state employees participating in implementation, at least three community-based providers, case managers supporting HRSS and JIR, and carceral-setting administrators.

In addition to the administrative contacts from the ACOs and MCOs, the IE will interview at least three community-based providers, such as primary care providers and behavioral health clinicians, who directly serve Medicaid patients at sites such as community health centers, in order to capture the perspective of

front-line clinicians working through the UMIC Demonstration. These providers will be asked about topics including integration of behavioral health care, barriers to access, and their perceptions of patients' engagement in care.

Because HRSS and JIR are new components of the Demonstration, interviews with case managers will provide essential insights into the challenges and successes during implementation. Case managers will be asked about topics including their observations regarding communication with members and providers, ways in which HRSS and JIR services are effective or not, and promising practices in care coordination for a population with housing instability and/or justice-involvement.

Semi-structured key informant interviews lasting 30-45 minutes per contact will be conducted by phone or videoconference, with privacy protections in accordance with CMS guidelines. Interviews will be recorded and transcribed. The IE will develop Interview guides in collaboration with DHHS for providers, health plans, and for state administrators involved in implementation of the Demonstration. The interview guide and questions will be tailored to the interviewee role. For example, state administrators will be invited to discuss the program rollout and feedback received from plans, health plan representatives will be asked about the plan's approach to integrating BH services, and questions regarding telehealth experiences will be directed towards clinicians.

As appropriate, interviews will explore successes and challenges with regard to program implementation, and other topics drawn from the logic model; examples are shown in Table 7.³⁹ Interview guides will include questions that address disparities and health equity as appropriate for the interviewee's role. This may include population health analysis strategies, language services, and targeted outreach programs.

Table 11: Topics for Key Informant Interviews

Interview Question	Example topics
Was the Demonstration implemented effectively? Could the pre-release services provided under the JIR benefit have been effectively implemented in a shorter time period? Why or why not?	Perceived successes and challenges in implementation Care integration with behavioral health Perceived steps towards integrating behavioral health with physical health services, e.g., screening and referrals Perceptions about the role of telehealth in achieving Demonstration goals
Was cross-system coordination effective?	Experiences with communication and data sharing between the carceral settings, Medicaid, and community-based services/health care
To what extent are BH services integrated with physical health services?	Screening and referrals Care coordination for members with BH conditions Sharing of patient data across practices Access to MAT pre-release and post-release
Did enrollment or outcomes differ by demographic factors?	Perceptions of barriers to access and participation in care

³⁹ KIIs will cover topics relevant to the evaluation of the Adult Expansion and ESI components of the Demonstration as well; these are covered in separate evaluation designs.

	Steps health plans/providers are taking to identify, understand, and address disparities in access and engagement
Was continuity of coverage and care improved by the Demonstration?	Medicaid enrollment or redetermination navigation support for justice-involved population Access to care pre-release in the carceral setting

6. Analytic Methods

Quantitative Analyses

The evaluation design includes multiple analytic strategies to answer the research questions and provide robust conclusions. The proposed approach is to use quasi-experimental analyses, employing descriptive statistics, trends over time, interrupted time-series analysis (ITS), regression, difference-in-differences (DiD), and synthetic control methods (SCM) Quasi-experimental analyses will be conducted where data is available. Multivariate regression will be used to model outcomes over time, following individuals longitudinally. This approach allows for the trend over time to be adjusted for changes in the Demonstration populations as members enter and leave the Populations. For example, for Hypotheses 4, 5, and 6, interrupted time series will be used where data is available over the time period of interest.

For smaller Demonstration populations and small subgroups where regression analysis is not feasible, the evaluation will focus on trends over time. For example, Hypothesis 6 focuses on the smaller demonstration populations; most research questions for this hypothesis will be addressed with descriptive statistics, such as service counts and cost over time.

The specific analytic method for each research question is provided in section F.4 Evaluation Tables.

Table 12: Summary of Analytic Tactics to be Used for Evaluation

Method	Comparison	Data sources
Subgroup comparison	Demonstration participants stratified by demographic and health factors	Encounter data, Administrative data
Event study/ time series	Trend during Demonstration vs baseline	Encounter data, Administrative data
Difference in difference; Synthetic Control Methods	Pre/Post change in Utah vs Pre/Post change in other states; predicted outcomes for 'synthetic UT'	National surveys and other public data sources

Descriptive statistics

The evaluation will provide summary tables of population size and characteristics, and outcomes for the three groups of Demonstration participants. Data will be analyzed using standard tests as rates, proportions, frequencies, and measures of central tendency (e.g., mean, median, mode). These tables will be used to develop a quantitative picture of the population, to describe raw trends, and to identify characteristics that will be included as covariates in regression modeling.

Prior to performing regression analysis of the plan types within AE, the composition of the beneficiary population in the three groups (FFS, ACO, and UMIC) will be compared to identify differences in demographic or clinical characteristics. ANOVA/MANOVA tests will be used as a first pass comparison of mean outcomes for the three groups. For metrics derived from BRFSS survey data, results for Utah will be compared to national averages for each year.

Trend over time and linear regression modeling

Outcomes of interest will be plotted over time for the duration of the Demonstration. The trend for each evaluation group will be modeled using multivariate linear regression and compared. The null hypothesis will be that the groups have identical trends. In order to account for demographic characteristics such as age and gender that may differ among groups, the IE will use inverse probability of treatment weighting. Individuals in intervention groups will be assigned weights based on the composition of the reference group, producing groups that are equivalent for measurable characteristics and allowing any difference in outcomes to be attributed to the intervention.⁴⁰

For the measures with binary outcomes the models will be logistic; Poisson models will be used for count-based outcomes. The mixed effects logistic regression model accommodates for both fixed and random effects. In this case, it allows for the fact that members can appear multiple times in the datasets and that they can appear different numbers of times resulting in unbalanced data. The models will include the 'client id' variable as a random effect. The outcome variable will be the binary or count outcome. To assess changes over time for each population, a fixed effect for measurement year and population will be included in addition to an interaction term between them. Measurement year will be included as a continuous variable after plotting raw trends to assess linearity. Adjusted models will include the covariates gender, race/ethnicity, age as a continuous variable, region, and SMI/SUD diagnosis group, as appropriate. Additional covariates will be considered for analyses specific to the JIR benefit, such as facility type. The post-release address of the JIR beneficiary may impact access to care outcomes and will be considered as a covariate. When adjustment variables besides age, gender and race are not statistically significantly associated ($p < 0.05$) the IE will proceed with a stepwise selection to reduce the number of covariates in the model. The IE will also run stratified mixed models by gender, age group and race/ethnicity with the same adjustment procedures, if subgroup size is adequate. Models are described in the following formulas.

Mixed logistic regression model

$$\text{logit}(Y = 1_{ij}) = \beta_0 + \beta_1 \text{Pop}_i + \beta_2 \text{MY}_{ij} + \beta_3 \text{MY}_{ij} * \text{Pop}_i + \beta_x X_i + \gamma_{0i}$$

Mixed Poisson regression model

$$\log \log (Y)_{ij} = \beta_0 + \beta_1 \text{Pop}_i + \beta_2 \text{MY}_{ij} + \beta_3 \text{MY}_{ij} * \text{Pop}_i + \beta_x X_i + \gamma_{0i} + \ln(\text{offset})$$

Where Y corresponds to outcome of interest with a different expression depending on its distribution, β_0 to the overall intercept of the model, $\beta_1 \text{Pop}_i$ to the effect of belonging to a certain population group compared to a reference group, $\beta_2 \text{MY}_{ij}$ to the effect of measurement year as a continuous variable, $\beta_3 \text{MY}_{ij} * \text{Pop}_i$ is the interaction effect between population and measurement year which allows us to estimate change over time between populations, $\beta_x X_i$ corresponds to individual level adjustment covariates, and γ_{0i} corresponds to the random intercept of each client to account for the clustering effect of appearing in more than one measurement year. In the case of Poisson models, the model includes an offset, for EDU corresponding the total number of clients and for IPU to the total member-months.

⁴⁰ Austin PC, Stuart EA. Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies. *Stat Med.* 2015; 34(28):3661–79. Epub 2015/08/05. <https://doi.org/10.1002/sim.6607> PMID: 26238958; PubMed Central PMCID: PMC4626409.

Difference-in-difference

To examine the impact of the demonstration on its overarching aim of improved access, PCG will conduct a difference-in-difference (DiD) analysis to model the effect of the demonstration in Utah relative to comparison states. The comparison states are those states not exposed to the treatment of interest – in this case, all other states that either (1) have not expanded Medicaid, or (2) expanded Medicaid before the pre-intervention period (July 1st 2017 – June 30th 2022) The parallel trends assumption will be tested over the five years before the demonstration period. Sensitivity analysis will be conducted to determine whether the PHE influences the baseline or the parallel trends assumption.

The DiD model equation is:

$$Y_{its} = \alpha_s + \beta_t + \beta_2 \text{Expansion}_s + \beta_3 \text{Post}_t + \beta_4 \text{Intervention}_s \times \text{Post}_t + \delta X_{it} + \varepsilon_{ist}$$

Where:

Y_{its} = Our outcome(s) of interest

α_s = A vector of state fixed effects

β_t = A vector month and year fixed effects

Intervention_s = A binary indicator for residence in our treated state (Utah)

Post_t = A binary indicator for whether the outcome occurred during the demonstration period

δX_{it} = A vector of observed individual-level characteristics

Covariates will include respondent age, education, employment status, household size, veteran status, sex, household income, homeownership status, presence of children in the household, survey month, and whether the survey was conducted via landline or cell phone. The regression coefficient β_4 thus represents our regression-adjusted estimates of changes in outcomes associated with Utah's Medicaid expansion, after controlling for state, month, year, and observed covariates.

Synthetic control method

In addition to the DiD approach, the IE will use synthetic control methods (SCM) to estimate the association between implementation of the Demonstration and study outcomes. SCM have been employed to evaluate state-level policy impacts because they are particularly useful when estimating the impact of a policy change that affects a small number of treatment groups (i.e., a state).^{41,42,43,44} These methods are a quasi-experimental approach similar to traditional difference-in-difference (DID) estimation but require fewer assumptions to obtain estimates of association. DID assumes that any differential changes in outcomes between treated and control groups are attributable to the policy change. Yet treated and control groups are often nonequivalent in terms of pre-treatment outcome levels, trends in outcomes, and other important covariates. To mitigate this limitation, researchers typically attempt to control for observed variables that may be associated with both treatment likelihood and the outcome of interest. However, treatment and control groups may still differ in terms of outcome pre-trends and levels due to unobserved factors. This introduces potential selection issues, which may bias any estimates of association.

⁴¹ Abadie, A., 2012. *Synthetic control methods for comparative case studies: estimating the effect of California's tobacco control program*. *J Am Stat Assoc* 105(490):493-505. <https://www.tandfonline.com/doi/abs/10.1198/jasa.2009.ap08746>

⁴² Rudolph, K.E., et al., 2015. *Association between Connecticut's Permit-to-Purchase handgun law and homicides*. *Am J Public Health* 105(8):e49-e54. <https://ajph.aphapublications.org/doi/pdf/10.2105/AJPH.2015.302703>

⁴³ Santella-Tenorio, J. et al., 2020. *Association of recreational cannabis laws in Colorado and Washington state with changes in traffic fatalities*. *JAMA* 180 (8):1061-1068. <https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2767647>

⁴⁴ Bhatt, A. et al. 2020. *Association of changes in Missouri firearm laws with adolescent and young adult suicides by firearms*. *JAMA Netw Open* 3(11). <https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2772526>

In contrast, SCM constructs a synthetic control. The synthetic control is constructed using a weighted average of the states included, with weights determined through a fully empirical process; weights for individual control units may range from 0 to 1 and are assigned so the synthetic control is as similar as possible to the treated group in terms of outcome pre-trends. Unlike traditional regression, inclusion of covariates is not required to achieve equivalence between treated and control groups.

Public Health Emergency; Sensitivity Analysis

The pre-Demonstration baseline period to be used for all quasi-experimental methods includes the period where the Covid-19 pandemic had a profound impact on health care utilization. First, trends for UT and controls will be modeled with and without the most affected months in 2020 and 2021. This sensitivity analysis will help to identify whether the groups have been impacted differentially. If the pattern changes observed in the first quarter of the Public Health Emergency are similar for all evaluation groups, then confounding of the results by pandemic impacts is less likely. The most affected quarters may be omitted from the baseline depending on the results.

Subgroup Analyses

The evaluation will seek to understand how different subgroups of participants are impacted by the Demonstration. Analyses will partition participants by gender, race/ethnicity, age, and SMI/ SUD diagnosis status. Where possible, race will include White, Black, Asian, Latinx, and Native American populations and Ethnicity will be characterized as Hispanic/Not Hispanic. Due to the low prevalence of some subgroups, it may be necessary to combine racial and ethnic groups for purposes of stratification. As seen in Table 13 below, 45% of race/ethnicity data gathered during the previous waiver period was missing. It is unlikely the evaluation will be able to identify racial/ethnic disparities in outcomes due to the high amount of missing data unless there is substantial improvement in the availability of this data. While data on region is available (urban, rural, frontier), the state does not plan to conduct subgroup analyses by geographic location because the geography variable is confounded with Plan Type. Specifically, Adult Expansion members in 5 counties *must* enroll in the UMIC plans with integrated physical and behavioral health benefits. In 8 other counties, Adult Expansion *must* enroll in an ACO and a Prepaid Mental Health Plan. In the remaining counties of the state, members may enroll in an ACO or stay with FFS.

Analyses of the JIR benefit will be stratified by adult versus juvenile facility and by facility type (prison vs jail), as feasible. In Utah, there are 26 jails, two prisons, and nine juvenile detention centers. The IE's ability to stratify analyses by facility type will depend on facility-level participation in implementing the JIR benefit during the course of the demonstration period. Analyses will also be stratified by beneficiary demographic characteristics such as gender, age, SMI/SUD diagnosis, and length of incarceration as feasible.

Table 13: Previous Waiver Demonstration Period; Population Characteristics

Demographic / Health Characteristic		Adult Expansion (N= 92,026)	Targeted Adult Medicaid (N=9,582)
Gender	Male	44,703 (48.6%)	7,223 (75.4%)
	Female	47,323 (51.4%)	2,359 (24.6%)
Age	19-44	62,781 (68.2%)	6,948 (72.5%)
	45-54	15,821 (17.2%)	1,791 (18.7%)
	55-64	13,424 (14.6%)	843 (8.8%)
Race/ethnicity	Other/Missing	41,772 (45.4%)	3,840 (40.1%)

	White (non-Hispanic)	14,963 (16.3%)	1,634 (17.1%)
	Hispanic, Black, AIAN, Pacific Islander	35,291 (38.3%)	4,108 (42.9%)
SMI/SUD Diagnosis	None	66,539 (72.3%)	1,781 (18.6%)
	SMI Only	3,155 (3.4%)	171 (1.8%)
	SUD Only	16,658 (18.1%)	5,652 (59.0%)
	Both SMI/SUD	5,674 (6.2%)	1,978 (20.6%)

NOTE: The characteristics shown above represent every person ever enrolled during the previous waiver demonstration period (7/1/2017--6/30/2022), as of their last appearance in the claims data.

Cost Analyses for SUD and SMI Demonstrations

The analytic methods for the SUD Demonstration cost analysis are detailed below. *The same approach will be taken for the SMI Demonstration.* The only difference is the target group and the dates of the pre-demonstration baseline periods (outlined in Table 5).

SUD demonstration target group beneficiaries will be identified based on claims and encounters with an SUD diagnosis and/or procedure code. Pharmacy claims and encounters with a dispensed drug for Medication Assisted Treatment (MAT) will also be used to identify the population of interest. Once a beneficiary has been identified, they will remain in the population of interest until 11 months pass without another qualifying SUD claim or encounter.

There will be three levels of cost analyses:

Total Cost of Care = Total Medicaid Costs (claims and managed care capitation payments) + federal costs (Total Medicaid Costs * the Utah specific Federal Financial Participation rate)

Costs related to the diagnosis and treatment of SUD = SUD-IMD costs + other SUD costs + non-SUD costs

Source of care cost drivers = inpatient + non-ED outpatient, + ED outpatient + pharmacy, + long-term care

The Total Cost of Care will not include administrative costs, as the State does not currently track administrative costs specific to these demonstrations. Given the large number of waivers and amendments in Utah, it is not possible to estimate administrative costs separately.

Within each of the three levels, the results will be stratified by: SUD diagnosis only; SMI/SUD dual diagnosis. Given the lack of a comparison group, an interrupted time series model will be used to estimate the linear effects of the SUD demonstration. The IE will conduct both a logit model for estimating zero-cost months and a generalized linear model [GLM] for estimating non-zero cost months. The GLM model will use log costs to account for costs that are not normally distributed.

Qualitative analysis

Qualitative analysis will be used for participant and key informant interview transcripts. The research questions to be addressed, with corresponding example topics, are listed in Tables 18, 22, 23, 24, and 25 (Attachment 4). Interviews will address these questions by probing for perspectives from providers and from administrators involved in implementing the Demonstration. Thematic analysis using a coding tree derived from the Demonstration logic model will be used to excerpt transcripts. Additional themes that arise during coding will be added to the analysis. Results of provider interviews will be used to add context to the quantitative findings regarding experience of care, beneficiary engagement, and barriers to engagement. Results of provider and administrator interviews will address implementation and will inform the Evaluation Report chapter on Lessons Learned and Recommendations.

D. Methodological Limitations

Lack of a true comparison group. The Demonstration is implemented statewide, making a perfect comparison group impossible. To mitigate this limitation, the IE plans to use both in-state comparison among benefit groups, and out-of-state comparisons using national survey data sources. The JIR amendment to the Demonstration specifically also lacks a true comparison group as the state is unable to collect data from carceral settings who have not yet implemented the pre-release and reentry services. While the IE considered the use of leveraging the phased implementation of the JIR benefit by facility to create a comparison group and allow for a more rigorous analysis, data collection from non-participating facilities is not feasible due to limitations in data collection and data sharing infrastructure and processes at this time. To address this limitation, the IE plans to use a historical pre-demonstration comparison group, comprised of individuals who were incarcerated and released from state carceral facilities during the two years prior to the demonstration.

Lack of pre-demonstration data on health care service provision in carceral settings. Interrupted time-series is the preferred statistical method for analyzing the impact of the JIR demonstration by comparing pre-demonstration trends to post-intervention trends. The lack of pre-demonstration data on health care service provision in carceral settings prohibits using ITS to determine the impact of JIR on access to health care services pre-release.

Sample size. Population sample sizes may not support quasi-experimental analyses or stratification. Full UMIC participation is projected to be around 60,000 individuals. The data set for specific outcomes may not have sufficient size statistical analysis on all subgroups of interest. The IE will explore disparities in outcomes by race/ethnicity within the groups where numbers are sufficient. To further investigate health equity, KII interview guides will include questions about health plan efforts to identify and remediate disparities in access, such as population health analyses and targeted outreach. TAM and other populations are smaller. For the smallest populations, regression analysis is unlikely to be feasible, so descriptive and trend over time analyses will be used and stratification will be limited. For the ISS FFCYAS, and youth JI populations, the number of individuals may be too small to support significance testing, in which case descriptive results will be provided.

Health Plan Reporting. The independent evaluator will receive aggregate CAHPS data reported in aggregate by the health plans, stratified by gender, age, and race/ethnicity. Patient-level data is not available for privacy reasons. Data aggregation will limit the available subgroup analyses that can be performed. The current age and race/ethnicity reporting buckets for CAHPS data are limited and are not standardized across health plans. In order to aggregate data across the population, the IE will combine categories as needed, creating wider age bands, and characterizing race as White/Other.

Lack of data on source of insurance coverage in national survey data. The use of national survey data allows for out of state comparison groups but limits the ability to specifically identify individuals enrolled in the Demonstration. As noted in Section C.5, prior to 2022 the BRFSS insurance coverage outcome did not allow determination of the source of coverage (e.g., Medicaid, Medicare, or private insurance) As a result, it was not possible to identify individuals enrolled in Medicaid and thus not possible to determine if respondents fell into the Demonstration group or were enrolled in Medicaid in comparison states. While an approximation will be achieved by using income and household size to define a sample representing Demonstration participants as closely as possible, the inclusion of respondents who may not be part of the Demonstration group or be Medicaid enrolled in comparison states is expected to attenuate the effect estimates during the pre-demonstration period. While differences in BRFSS responses between Utah and the comparison states are of interest, the evaluation's results should be interpreted as associations and may not necessarily be directly attributed to the Demonstration.

Historic effects. The impacts of the Covid-19 pandemic/PHE were profound in 2020 and 2021 and are likely to continue to influence health care delivery well into the current Demonstration period. Analytic techniques described above will be used to minimize confounding by PHE effects during the baseline period. The PHE unwinding will take place during the Demonstration period, with eligibility

redeterminations beginning in April 2023, and may lead to unusual levels of disenrollment and enrollment category changes. Ongoing direct and indirect impacts of the PHE such as staffing shortages will be considered in interpreting findings.

Data availability for national surveys, publicly available data sources, and carceral setting data. The evaluation design includes national surveys and other publicly available data sources for some research questions that involve comparisons between states and over time. The design plan is contingent on the continued administration of these surveys, data release schedules, the elements included in public use files, the timing and process for accessing restricted data, and the comparability of the surveys to previous years. The NASHP HCT utilizes cost reports submitted by hospitals; as such, hospital reporting errors may be introduced. Should barriers be encountered, the IE will explore other options. Additionally, the JIR amendment introduces data from the carceral setting (prisons, jails, and youth correctional facilities). The IE anticipates that there may be early availability or quality challenges with this new data source, as carceral facilities become familiarized with Medicaid billing and claims systems.

Implementation dates and data sources for amendments newly approved during the Demonstration period. The evaluation design includes evaluation plans for amendments newly approved during the Demonstration period (JIR and HRSN) that have not been implemented at the time of writing this evaluation design document. The evaluation of these amendments relies on administrative data sources that are currently being designed or built. The IE works closely with the state to align on data sources and availability. In addition, the JIR and HRSN implementations may take place too late in the Demonstration to generate sufficient claims data for claims-based measures, or for year-over-year comparisons to be feasible.

F. Attachments

1. Independent Evaluator

As required by the Centers for Medicare & Medicaid Services (CMS) and the Section 1115 Demonstration's Special Terms and Conditions (STCs), DHHS conducted an open solicitation process to secure a third-party evaluator to conduct an evaluation of the State of Utah's Section 1115 Demonstration.

The State issued one contract for all evaluation activities and the production of required CMS reports.⁴⁵ As the successful bidder, Public Consulting Group (PCG) demonstrated the following qualifications:

Experience conducting program evaluations for programs administered by the federal department of Health and Human Services.

Ability to provide at least two examples of program evaluations conducted meeting the above criterion.

Experience with Medicaid claims data.

Experience complying with human subjects' protection and data confidentiality laws (state and federal)

Experience with quantitative and qualitative evaluation design, implementation, analysis, and reporting, and impact evaluations in public health and social services settings.

Consistent with the requirements of the State of Utah Division of Purchasing, DHHS selected and retained PCG as an independent evaluator to complete the independent evaluation of the Demonstration. DHHS contracted with the evaluator, PCG, to promote an independent evaluation, following the general requirements for each state contractor as well as project-specific standards.

The third-party evaluator, PCG, will conduct an evaluation following guidelines set forth by DHHS and CMS. The Department retains responsibility for monitoring the Demonstration activities and providing oversight of the evaluation design and overall approach for the contractor. To ensure a fair and impartial evaluation and mitigate any potential conflict of interest, the independent evaluator, PCG, will:

Conduct an evaluation of the 1115 Demonstration hypotheses for the Adult Expansion, Current Eligible, Targeted Adult Medicaid (TAM), Targeted Adult Dental (TAM-Dental), Blind and Disabled Dental (BDD), Aged Dental, Employer-Sponsored Insurance (ESI), Utah Premium Partnership (UPP), Intensive Stabilization Services (ISS), and Former Foster Care Youth from Another State (FFCYAS) populations of the 1115 waiver, as well as for the Serious Mental Illness (SMI) and Substance Use Disorder (SUD) components⁴⁶, IVF and Genetic Testing, Fertility Treatment for Individuals Diagnosed with Cancer, Housing Related Services and Supports and Justice-Involved Reentry Services to determine if the goals and objectives of the Demonstration have been achieved.

Meet the evaluation requirements of the 1115 Demonstration STCs.

Follow the CMS approved evaluation design.

Provide DHHS with the required annual interim evaluation report and summative evaluation report at the end of the 1115 Demonstration approval period, by the due dates outlined in the contract.

Provide future evaluations as required by the contract, at the option of DHHS, and develop the evaluation design and implement the design upon CMS approval.

⁴⁵ This procurement sought an Independent Evaluator for all the components of the current waiver period which runs from July 1, 2022, through June 30, 2027. PCG was awarded a five-year contract covering these components.

⁴⁶ The Utah Department of Health requested that PCG develop a single comprehensive Evaluation Design for the Utah Medicaid Reform 1115 Demonstration encompassing all evaluation populations and waiver components.

Complete any required IRB applications, data sharing agreements, or other documents needed to protect human subjects and data confidentiality.

Appropriately safeguard evaluation data in compliance with HIPAA requirements, protection of human subjects, data sharing agreements, state or federal laws, and other applicable regulations.

The 1115 Demonstration evaluation conducted by PCG will determine if the goals and objectives of the 1115 Demonstration have been achieved. The evaluation will meet the requirement of the 1115 Demonstration STCs, follow the CMS approved evaluation design, and provide required deliverables.

DHHS staff worked with the evaluator to identify and address concerns that might arise during the administration of the contract. By requiring initial satisfaction of these standards by the contracting party in order to be awarded the contract, as well as ongoing maintenance of the requirements during the term of service, DHHS is in a position to receive an objective evaluation report that is the product of a fair, impartial, and conflict-free evaluation.

2. Evaluation Budget

Table 14: Estimated Evaluation Budget


Evaluation Activity	Current Demonstration Period					Post Yr1	Post Yr2	TOTAL
	DY1	DY2	DY3	DY4	DY5			
	7/1/2022 – 6/30/2023	7/1/2023 – 6/30/2024	7/1/2024 – 6/30/2025	7/1/2025 – 6/30/2026	7/1/2026 – 6/30/2027	7/1/2027 – 6/30/2028	7/1/2028 – 6/30/2029	
Project Management	\$49,500	\$49,500	\$153,082	\$204,110	\$102,055	\$82,920	\$76,541	\$717,708
Evaluation Design		\$16,875	\$255,137	\$68,037				\$340,049
Quantitative Data	\$289,980	\$48,973	\$102,055	\$204,110	\$204,110	\$160,311	\$163,288	\$1,172,827
Summative Report Prior Demo Period	\$143,820	\$157,790						\$301,610
Key Informant Interviews			\$81,644	\$136,073	\$68,037	\$27,640	\$25,514	\$338,908
Participant Interviews Wave 1		\$50,000	\$91,849	\$149,680				\$291,529
Custom Member Survey		\$180,000	\$10,205	\$244,932	\$68,037			\$503,174
Participant Interviews Wave 2					\$163,288	\$22,112	\$15,308	\$200,708
Midpoint Assessment: SUD/SMI		\$71,100	\$204,110					\$275,210

Interim Report			\$122,466	\$353,790	\$40,822			\$517,078
Midpoint Assessment: JIR						\$116,087		\$116,087
Summative Report					\$34,018	\$143,727	\$229,623	\$407,368
TOTAL	\$483,300	\$574,238	\$1,020,548	\$1,360,731	\$680,366	\$552,797	\$510,274	\$5,182,256

Note: Line items for new primary data collection activities (interviews and surveys) include costs for developing the tools, gathering the data, and performing data analytics.

3. Timeline and Major Milestones

FIGURE 3: EVALUATION TIMELINE



2. EVALUATION DESIGN TABLES

Table 15: Evaluation Summary, Hypothesis 1, Low-income UT residents

Hypothesis 1: The 1115 Demonstration overall will improve access to coverage and engagement in health care for low-income UT residents.				
Comparison Strategy	Measure Name	Measure Description	Data source	Analytic Approach
Primary research question 1.1: Did the fraction of low-income residents with no coverage decrease, relative to comparison states?				
Comparison states	Any coverage	Fraction with any health insurance coverage	BRFSS	Difference-in-difference Synthetic control model
Primary research question 1.2: Did the fraction of low-income residents who avoided care due to cost decrease, relative to comparison states?				
Comparison states	Avoided care due to cost	Fraction who delayed or avoided needed care because of cost	BRFSS	Difference-in-difference Synthetic control model
Primary research question 1.3: Did the fraction of low-income residents who have a personal doctor or usual source of care increase, relative to comparison states?				
Comparison states	Has a personal doctor	Fraction who says they have one person they think of as their person doctor or provider	BRFSS	Difference-in-difference Synthetic control model
Primary research question 1.4: Did the fraction of low-income residents who had a primary or specialty care appointment in the last year increase, relative to comparison states?				
Comparison states	Had a primary or specialty appointment	Had a checkup or visit with a specialist in the last 12 months	BRFSS	Difference-in-difference Synthetic control model
Primary research question 1.5: Did the fraction of low-income residents who had a preventive screening in the last year increase, relative to comparison states?				
Comparison states	Had a preventative screening	Fraction who reported having a mammogram in the last 12 months	BRFSS	Difference-in-difference Synthetic control model
Primary research question 1.6: What is the member experience of care in terms of access, timeliness, and patient-centeredness?				
Pre-Demonstration baseline	Member satisfaction	Getting needed care Getting needed care quickly How well doctors communicate	CAHPS	Descriptive statistics; Trend over time
Single point in time survey	Member satisfaction	Access to care Access to BH care Barriers to accessing physical care Barriers to accessing behavioral health care	Custom Member/Beneficiary Survey	Descriptive statistics

Hypothesis 1: The 1115 Demonstration overall will improve access to coverage and engagement in health care for low-income UT residents.				
Comparison Strategy	Measure Name	Measure Description	Data source	Analytic Approach
		Patient centered care Coordination of care		
Primary research question 1.7: Did Low Value Care decrease among Demonstration participants, relative to baseline?				
Pre-Demonstration baseline	Low Value Care	List of low value care scenarios appropriate for the Demonstration will be developed	Claims	Trend over time Interrupted Time Series

Table 16: Evaluation Summary, Hypothesis 2, Adult Expansion / UMIC

Hypothesis 2: The Demonstration will improve health care access and engagement for the Adult Expansion population.				
Comparison Strategy	Measure Name	Measure Description	Data source	Analytic Approach
Primary research question 2.1: Did inpatient hospital utilization decrease, relative to baseline, for the Adult Expansion population?				
Pre-Demonstration baseline	Inpatient Utilization (IPU)	Inpatient admissions per member per year	Claims	Trend over time Interrupted Time Series
Primary research question 2.2: Did ED visits decrease, relative to baseline, for the Adult Expansion population?				
Pre-Demonstration baseline	ED visits (EDU)	ED visits per member per year	Claims	Trend over time Interrupted Time Series
<i>Subsidiary research question 2.2.a: Did ED visits for BH conditions decrease, relative to baseline, for the Adult Expansion population?</i>				
Pre-Demonstration baseline	ED-BH visits (EDU-BH)	ED visits for BH condition per member per year	Claims	Trend over time Interrupted Time Series
<i>Subsidiary research question 2.2.b: Did UMIC plans reduce ED visits for BH conditions for Adult Expansion population, relative to FFS or physical health-only ACO plans?</i>				
Plan Type Comparison: UMIC, FFS/PMHP, ACO/PMHP	ED-BH visits (EDU-BH)	ED visits for BH condition per member per year	Claims	Multiple linear regression; ANOVA
Primary research question 2.3: Did engagement in primary and ambulatory care increase, relative to baseline, for the Adult Expansion population?				

Hypothesis 2: The Demonstration will improve health care access and engagement for the Adult Expansion population.				
Comparison Strategy	Measure Name	Measure Description	Data source	Analytic Approach
Pre-Demonstration baseline	Adults' Access to Preventative/Ambulatory Health Services (AAP)	Fraction of beneficiaries who had an ambulatory or preventive care visit during the measurement year	Claims	Interrupted Time Series
Primary research question 2.4: Did engagement in behavioral health care increase, relative to baseline, for the Adult Expansion population?				
Pre-Demonstration baseline	Antidepressant Medication Management (AMM)	Adults with a diagnosis of major depression who were newly treated with antidepressant medication and remained on their antidepressant medications.	Claims	Interrupted Time Series
Pre-Demonstration baseline	Initiation and Engagement of Alcohol and Other Drug Abuse or Dependence Treatment (IET)	Fraction with a new episode of alcohol or other drug dependence who: 1) initiated treatment within 14 days of diagnosis. 2) engaged in continued treatment within 34 days of the initiation visit.	Claims	Interrupted Time Series
Pre-Demonstration baseline	Follow-Up After Hospitalization for Mental Illness (FUH)	Following discharge for mental illness or intentional self-harm, fraction with outpatient follow-up in 7 days, and within 30 days.	Claims	Interrupted Time Series
Pre-Demonstration baseline	30-Day All-Cause Unplanned Readmission Following Psychiatric Hospitalization in an Inpatient Psychiatric Facility (REA)	The rate of unplanned, 30-day, readmission for Demonstration beneficiaries with a primary discharge diagnosis of a psychiatric disorder or dementia/Alzheimer's disease.	Claims	Interrupted Time Series
<i>Subsidiary research question 2.4.a: Did UMIC plans improve engagement in behavioral health care for Adult Expansion population, relative to FFS or physical health-only ACO plans?</i>				
Plan Type Comparison: UMIC, FFS/PMHP, ACO/PMHP	Antidepressant Medication Management (AMM)	Adults with a diagnosis of major depression who were newly treated with antidepressant medication and remained on their antidepressant medications.	Claims	Multiple linear regression; ANOVA

Hypothesis 2: The Demonstration will improve health care access and engagement for the Adult Expansion population.				
Comparison Strategy	Measure Name	Measure Description	Data source	Analytic Approach
Plan Type Comparison: UMIC, FFS/PMHP, ACO/PMHP	Initiation and Engagement of Alcohol and Other Drug Abuse or Dependence Treatment (IET)	Fraction with a new episode of alcohol or other drug dependence who: 1) initiated treatment within 14 days of diagnosis. 2) engaged in continued treatment within 34 days of the initiation visit.	Claims	Multiple linear regression; ANOVA
Plan Type Comparison: UMIC, FFS/PMHP, ACO/PMHP	Follow-Up After Hospitalization for Mental Illness (FUH)	Following discharge for mental illness or intentional self-harm, fraction with outpatient follow-up in 7 days, and within 30 days.	Claims	Multiple linear regression; ANOVA
Plan Type Comparison: UMIC, FFS/PMHP, ACO/PMHP	30-Day All-Cause Unplanned Readmission Following Psychiatric Hospitalization in an Inpatient Psychiatric Facility (REA)	The rate of unplanned, 30-day, readmission for Demonstration beneficiaries with a primary discharge diagnosis of a psychiatric disorder or dementia/Alzheimer's disease.	Claims	Multiple linear regression; ANOVA
Primary research question 2.5: Did engagement in treatment for chronic conditions increase, relative to baseline, for the Adult Expansion population?				
Pre-Demonstration baseline	Monitoring for persistent medications (MPM)	Assesses adults who received at least 180 treatment days of ambulatory medication therapy for a select therapeutic agent (for hypertension or heart disease) during the measurement year and received at least one therapeutic monitoring event for the therapeutic agent during the measurement year:	Claims	Interrupted Time Series
Pre-Demonstration baseline	Engagement in Diabetes Care (EDC)	Adults with type 1 or type 2 diabetes who had at least two A1C tests in the year	Claims	Interrupted Time Series
Primary research question 2.6: Did preventive cancer screening increase, relative to baseline, for the Adult Expansion population?				
Pre-Demonstration baseline	Breast Cancer Screening (BCS)	Women 50 years and over who had at least one mammogram to screen	Claims	Interrupted Time Series

Hypothesis 2: The Demonstration will improve health care access and engagement for the Adult Expansion population.				
Comparison Strategy	Measure Name	Measure Description	Data source	Analytic Approach
		for breast cancer in the past two years		
Primary research question 2.7: Did dental service provision increase relative to baseline for the Adult Expansion population?				
N/A	Dental Service Recipients	Number of unique individuals who received dental services	Claims	Descriptive statistics
N/A	Dental Services	Number of dental services provided	Claims	Descriptive statistics
Primary research question 2.8: Did ED visits for non-traumatic dental conditions decrease relative to baseline for the Adult Expansion population?				
Pre-Dental Expansion baseline	Ambulatory Care Sensitive ED Visits for Non-Traumatic Dental Conditions in Adults (Dental Quality Alliance measure EDV-A-A)	Number of emergency department (ED) visits for ambulatory care sensitive non-traumatic dental conditions per 100,000 member months for adults	Pre-Dental Expansion baseline	Interrupted Time Series
Primary research question 2.9: Did follow-up after ED visits for non-traumatic dental conditions increase relative to baseline for the Adult Expansion population?				
Pre-Dental Expansion baseline	Follow-Up after Emergency Department Visits for Non-Traumatic Dental Conditions in Adults (Dental Quality Alliance EDF-A-A)	The percentage of ambulatory care sensitive non-traumatic dental condition emergency department visits among adults aged 18 years and older in the reporting period for which the member visited a dentist within (a) 7 days and (b) 30 days of the ED visit	Claims	Interrupted Time Series
Primary research question 2.10: To what extent are beneficiaries aware of the dental care benefit?				
N/A	Dental Benefit Awareness	Percentage of survey respondents who answer "yes" to: Does your health insurance cover any dental services, such as routine cleanings?	Custom Member Survey	Descriptive statistics

Table 17: Evaluation Summary, Hypothesis 3, TAM

Hypothesis 3: The Demonstration will improve health care access and engagement for the TAM population.				
Comparison Strategy	Measure Name	Measure Description	Data source	Analytic Approach
Primary research question 3.1: Did inpatient hospital utilization decrease, relative to baseline, for the TAM population?				
Pre-Demonstration baseline	Inpatient Utilization (IPU)	Inpatient admissions per member per year	Claims	Interrupted Time Series
Primary research question 3.2: Did ED visits decrease, relative to baseline, for the TAM population?				
Pre-Demonstration baseline	ED visits (EDU)	ED visits per member per year	Claims	Interrupted Time Series
<i>Subsidiary research question 3.2.a: Did ED visits for BH conditions decrease, relative to baseline, for the TAM population?</i>				
Pre-Demonstration baseline	ED-BH visits	ED visits for BH condition per member per year	Claims	Interrupted Time Series
Primary research question 3.3: Did engagement in primary and ambulatory care increase, relative to baseline, for the TAM population?				
Pre-Demonstration baseline	Adults' Access to Preventative/Ambulatory Health Services (AAP)	Fraction of beneficiaries who had an ambulatory or preventive care visit during the measurement year	Claims	Interrupted Time Series
Baseline	Monitoring for persistent medications (MPM)	Assesses adults who received at least 180 treatment days of ambulatory medication therapy for a select therapeutic agent (for hypertension or heart disease) during the measurement year and received at least one therapeutic monitoring event for the therapeutic agent during the measurement year:	Claims	Interrupted Time Series
Primary research question 3.4: Did engagement in behavioral health care increase, relative to baseline, for the TAM population?				

Hypothesis 3: The Demonstration will improve health care access and engagement for the TAM population.				
Comparison Strategy	Measure Name	Measure Description	Data source	Analytic Approach
Pre-Demonstration baseline	Follow-Up After Hospitalization for Mental Illness (FUH)	Following discharge for mental illness or intentional self-harm, fraction with outpatient follow-up in 7 days, and within 30 days.	Claims	Interrupted Time Series
Pre-Demonstration baseline	30-Day All-Cause Unplanned Readmission Following Psychiatric Hospitalization in an Inpatient Psychiatric Facility (REA)	The rate of unplanned, 30-day, readmission for Demonstration beneficiaries with a primary discharge diagnosis of a psychiatric disorder or dementia/Alzheimer's disease.	Claims	Interrupted Time Series
Pre-Demonstration baseline	Initiation and Engagement of Alcohol and Other Drug Abuse or Dependence Treatment (IET)	Fraction with a new episode of alcohol or other drug dependence who: 1) initiated treatment within 14 days of diagnosis. 2) engaged in continued treatment within 34 days of the initiation visit.	Claims	Interrupted Time Series
Primary research question 3.5: Did dental service provision increase relative to baseline for the TAM population?				
N/A	Dental Service Recipients	Number of unique individuals who received dental services	Claims	Descriptive statistics
N/A	Dental Services	Number of dental services provided	Claims	Descriptive statistics
Primary research question 3.6: Did ED visits for non-traumatic dental conditions decrease relative to baseline for the TAM population?				
Pre-TAM Dental Benefit baseline	Ambulatory Care Sensitive ED Visits for Non-Traumatic Dental	Number of emergency department (ED) visits for ambulatory care sensitive	Claims	Interrupted Time Series

Hypothesis 3: The Demonstration will improve health care access and engagement for the TAM population.				
Comparison Strategy	Measure Name	Measure Description	Data source	Analytic Approach
	Conditions in Adults (Dental Quality Alliance measure EDV-A-A)	non-traumatic dental conditions per 100,000 member months for adults		
Primary research question 3.7: Did follow-up after ED visits for non-traumatic dental conditions increase relative to baseline for the TAM population?				
Pre-TAM Dental Benefit baseline	Follow-Up after Emergency Department Visits for Non-Traumatic Dental Conditions in Adults (Dental Quality Alliance EDF-A-A)	The percentage of ambulatory care sensitive non-traumatic dental condition emergency department visits among adults aged 18 years and older in the reporting period for which the member visited a dentist within (a) 7 days and (b) 30 days of the ED visit	Claims	Interrupted Time Series

Table 18: Evaluation Summary, Hypothesis 4, HRSN Demonstration

Hypothesis 4: The HRSN Services demonstration will effectively mitigate members' housing and transportation needs, lead to more appropriate service utilization and improved physical and mental health outcomes.				
Comparison Strategy	Measure Name	Measure Description	Data source	Analytic Approach
Primary research question 4.1: What is the prevalence and severity of beneficiaries' social needs?				
N/A	Prevalence of housing-related needs; individual level	Number and percent of beneficiaries eligible for HRSS	Administrative Data	Descriptive statistics
N/A	Extent of housing-related needs; Community level	Housing affordability (<=30% of income) at the county level	American Community Survey, Area	Trend over time

Hypothesis 4: The HRSN Services demonstration will effectively mitigate members' housing and transportation needs, lead to more appropriate service utilization and improved physical and mental health outcomes.				
Comparison Strategy	Measure Name	Measure Description	Data source	Analytic Approach
			Health Resources File	
Primary research question 4.2: Were HRSN services provided and utilized as planned?				
N/A	HRSN Provider Availability	Number of HRSN providers and description of service offerings	Administrative	Descriptive statistics
N/A	HRSN Service Utilization	HRSN service counts by type of service	Claims	Descriptive statistics Trend over time
N/A	NMT Utilization	NMT service counts	Administrative	Descriptive statistics Trend over time
Primary research question 4.3: Did the HRSN demonstration effectively mitigate beneficiaries' housing and transportation needs?				
N/A	Found housing	Fraction of previously unhoused HRSS participants who moved into housing while receiving HRSS.	Administrative	Descriptive statistics
N/A	Housing stability	Fraction of HRSS participants who maintained stable housing for a defined time period.	Case records	Descriptive statistics
Primary research question 4.4: Did high-cost acute utilization decrease, relative to baseline, for HRSN recipients?				
Longitudinal cohort design with pre-HRSN demonstration baseline, if available	ED visits	ED visits condition per member per year	Claims	Trend over time or Interrupted time series
Longitudinal cohort design with pre-HRSN demonstration baseline, if available	ED-BH visits	ED visits for BH condition per member per year	Claims	Trend over time or Interrupted time series
Longitudinal cohort design with pre-HRSN demonstration baseline, if available	Potentially preventable ED visits	ED visits for ambulatory sensitive conditions, such as asthma, urinary tract infections, and complications from diabetes (AHRQ measure)	Claims	Trend over time or Interrupted time series
Longitudinal cohort design with pre-HRSN demonstration baseline, if available	Inpatient utilization	Inpatient stays per member year	Claims	Trend over time or Interrupted time series

Hypothesis 4: The HRSN Services demonstration will effectively mitigate members' housing and transportation needs, lead to more appropriate service utilization and improved physical and mental health outcomes.				
Comparison Strategy	Measure Name	Measure Description	Data source	Analytic Approach
Longitudinal cohort design with pre-HRSN demonstration baseline, if available	Potentially preventable inpatient utilization	Inpatient stays for ambulatory sensitive conditions, such as asthma, urinary tract infections, and complications from diabetes (AHRQ measure)	Claims	Trend over time or Interrupted time series
Primary research question 4.5 Did engagement in primary and ambulatory care increase, relative to baseline, for HRSN recipients?				
Longitudinal cohort design with pre-HRSN demonstration baseline, if available	Adults' Access to Preventative/Ambulatory Health Services (AAP)	Fraction of beneficiaries who had an ambulatory or preventive care visit during the measurement year	Claims	Trend over time or Interrupted time series
Longitudinal cohort design with pre-HRSN demonstration baseline, if available	Monitoring for persistent medications	Assesses adults who received at least 180 treatment days of ambulatory medication therapy for a select therapeutic agent (for hypertension or heart disease) during the measurement year and received at least one therapeutic monitoring event for the therapeutic agent during the measurement year:	Claims	Trend over time or Interrupted time series
Primary research question 4.6: Did engagement in behavioral health care increase, relative to baseline, for HRSN recipients?				
Longitudinal cohort design with pre-HRSN demonstration baseline, if available	30-Day All-Cause Unplanned Readmission Following Psychiatric Hospitalization in an Inpatient Psychiatric Facility (REA)	The rate of unplanned, 30-day, readmission for Demonstration beneficiaries with a primary discharge diagnosis of a psychiatric disorder or dementia/Alzheimer's disease.	Claims	Trend over time or Interrupted time series
Longitudinal cohort design with pre-HRSN demonstration baseline, if available	Follow-Up After Hospitalization for Mental Illness (FUH)	Following discharge for mental illness or intentional self-harm, fraction with outpatient follow-up in 7 days, and within 30 days.	Claims	Trend over time or Interrupted time series
Primary research question 4.7: From the beneficiaries' perspective, did the HRSN services meet their housing-related needs, support their engagement in behavioral health care, and overall positively impact their physical and mental health?				

Hypothesis 4: The HRSN Services demonstration will effectively mitigate members' housing and transportation needs, lead to more appropriate service utilization and improved physical and mental health outcomes.				
Comparison Strategy	Measure Name	Measure Description	Data source	Analytic Approach
N/A	Quality of HRSS, participant perspective	How satisfied are participants with the HRSS they received? What was helpful, not helpful? How easy or difficult is it to find appropriate housing without, and with, HRSS assistance? Are participants satisfied with their housing arrangements?	Participant Interviews	Qualitative analysis
N/A	Engagement in care, participant perspective	What factors enhance or inhibit participants' engagement in physical health care? in behavioral health care?	Participant Interviews	Qualitative analysis
N/A	Overall physical and mental health, participant perspective	How do participants think their physical and mental health has changed since receiving HRSS services?	Participant Interviews	Qualitative analysis
Primary research question 4.8: Did state and local investments in housing supports change over time during the HRSN demonstration?				
Baseline year	Local availability of HRSS	Percent change in number of HRSS type programs for the duration of the amendment	Administrative: Maintenance of Effort section of Annual Monitoring Reports	Percent change in each year compared to the baseline year
Primary research question 4.9: Were there any improvements in the quality and effectiveness of downstream housing-related services and supports?				
N/A	HRSN Provider Self-Assessment	Provider perceptions of the impact of infrastructure investments and related supports on the quality and effectiveness of their housing-related services and supports.	Key Informant Interviews	Qualitative

Table 19: Evaluation Summary, Hypothesis 5, SMI/SUD

Hypothesis 5: The SMI and SUD Demonstrations increased access to appropriate treatment.				
Comparison Strategy	Measure Name	Measure Description	Data source	Analytic Approach
Primary research question 5.1: Did the number of individuals receiving services for SMI and/or SUD increase, relative to baseline?				
Baseline year (DY1)	Service Counts: SUD	Number of members receiving SUD treatment	Claims	Descriptive statistics; Trend over time
Baseline year (DY1)	Service Counts: SMI	Number of members receiving SUD treatment	Claims	Descriptive statistics; Trend over time
Primary research question 5.2: Did ED visits for BH conditions decrease among individuals with SMI and/or SUD diagnoses, relative to baseline?				
Pre-Demonstration baseline Stratify by: SMI only, SUD only, SMI/SUD dually diagnosed	ED-BH visits	ED visits for BH condition per member per year	Claims	Interrupted Time Series
Primary research question 5.3: Did inpatient days (outside of IMDs) decrease, relative to baseline, for individuals with SMI and/or SUD?				
Pre-Demonstration baseline Stratify by: SMI only, SUD only, SMI/SUD dually diagnosed	Inpatient days	Inpatient days PMPY, exclusive of IMD stays	Claims	Interrupted Time Series
Primary research question 5.4: Did engagement in SUD treatment increase among individuals with SUD diagnoses relative to baseline?				
Pre-Demonstration baseline	Initiation and Engagement of Alcohol and Other Drug Abuse or Dependence Treatment (IET)	Fraction with a new episode of alcohol or other drug dependence who: 1) initiated treatment within 14 days of diagnosis. 2) engaged in continued treatment within 34 days of the initiation visit.	Claims	Interrupted Time Series
Primary research question 5.5: Did unplanned readmission following hospitalization for psychiatric treatment decrease among individuals with SMI relative to baseline?				
Pre-Demonstration baseline	30-Day All-Cause Unplanned Readmission Following Psychiatric Hospitalization in an Inpatient Psychiatric Facility (REA)	The rate of unplanned, 30-day, readmission for Demonstration beneficiaries with a primary discharge diagnosis of a psychiatric disorder or dementia/Alzheimer's disease.	Claims	Interrupted Time Series

Hypothesis 5: The SMI and SUD Demonstrations increased access to appropriate treatment.				
Comparison Strategy	Measure Name	Measure Description	Data source	Analytic Approach
Primary research question 5.6: Did utilization of any mental health service increase among low-income residents, relative to comparison states?				
Comparison states	Mental health treatment	Percentage who reported receiving mental health (non-SUD) treatment in the last 12 months	NSDUH	Difference-in-difference; Synthetic control model
Primary research question 5.7: Did the number of individuals needing but not receiving SUD service decrease among low-income residents, relative to comparison states?				
Comparison states	SUD treatment	Percentage who reported receiving SUD treatment in the last 12 months	NSDUH	Difference-in-difference; Synthetic control model
Primary research question 5.8: Did the rate of overdose deaths decrease, relative to baseline?				
Pre-Demonstration baseline	Overdose deaths	State rate of overdose deaths	Administrative	Interrupted Time Series
Primary research question 5.9: Did the number of individuals receiving crisis stabilization services increase (with an emphasis on non-hospital, non-residential services)?				
Pre-Demonstration baseline	Crisis stabilization services	Crisis Stabilization service count	Claims	Interrupted Time Series

Table 20: Evaluation Summary, Hypothesis 6, SMI/SUD Cost of Care

Hypothesis 6: The SMI and SUD Demonstrations stabilized or reduced cost of care for these populations.				
Comparison Strategy	Measure Name	Measure Description	Data source	Analytic Approach
Primary research question 6.1: Did the total cost of care for individuals with SMI diagnoses change, relative to baseline?				
Pre-Demonstration baseline	Total Cost of Care	Total costs per beneficiary per month is the sum of the state's Medicaid costs (inpatient, outpatient, pharmacy, long-term care, IMD, and MCO capitated payments) and the federal cost (total Medicaid * FMAP for Utah).	Claims	Interrupted time series

Hypothesis 6: The SMI and SUD Demonstrations stabilized or reduced cost of care for these populations.				
Comparison Strategy	Measure Name	Measure Description	Data source	Analytic Approach
<i>Subsidiary research question 6.1.a: Did costs related to the diagnosis and treatment of SMI change, relative to baseline? (SMI-IMD costs + other SMI costs + non-SMI costs)?</i>				
Pre-Demonstration baseline	Costs related to the diagnosis and treatment of SMI	These costs include <i>SMI-IMD costs + other SMI costs + non-SMI costs</i>	Claims	Interrupted time series
<i>Subsidiary research question 6.1.b: What types of care (inpatient + non-ED outpatient, + ED outpatient + pharmacy, + long-term care) are the primary drivers of the cost of care for the SMI population?</i>				
Pre-Demonstration baseline	Source of treatment cost drivers	These costs include inpatient + non-ED outpatient, + ED outpatient + pharmacy, + long-term care	Claims	Interrupted time series
Primary research question 6.2: Did the total cost of care for individuals with SUD diagnoses change, relative to baseline?				
Pre-Demonstration baseline	Total Cost of Care	Total costs per beneficiary per month is the sum of the state's Medicaid costs (inpatient, outpatient, pharmacy, long-term care, IMD, and MCO capitated payments) and the federal cost (total Medicaid * FMAP for Utah).	Claims	Interrupted time series
<i>Subsidiary research question 6.2.a: Did costs related to the diagnosis and treatment of SUD change, relative to baseline? (SUD-IMD costs + other SUD costs + non-SUD costs)?</i>				
Pre-Demonstration baseline	Costs related to the diagnosis and treatment of SMI	These costs include <i>SMI-IMD costs + other SMI costs + non-SMI costs</i>	Claims	Interrupted time series
<i>Subsidiary research question 6.2.b: What types of care (inpatient + non-ED outpatient, + ED outpatient + pharmacy, + long-term care) are the primary drivers of the cost of care for the SUD population?</i>				
Pre-Demonstration baseline	Source of treatment cost drivers	These costs include <i>inpatient + non-ED outpatient, + ED outpatient + pharmacy, + long-term care</i>	Claims	Interrupted time series

Table 21: Evaluation Summary, Hypothesis 7, Small Demonstration Populations: UPP/ESI, ISS, FFCYAS, Fertility and Genetic Testing Services

Hypothesis 7: The Demonstration delivered coverage/ services appropriately to individuals in the smaller Demonstration populations.				
Comparison Strategy	Measure Name	Measure Description	Data source	Analytic Approach
UPP/ESI				
Primary research question 7.1: Did the number of individuals receiving coverage increase relative to baseline?				
Baseline year (DY1)	Enrollment	Number of unique individuals enrolled in each plan (UPP/ESI)	Claims	Descriptive statistics Trend over time
Primary research question 7.2: What was the average total Medicaid cost of care for enrollees?				
Baseline year (DY1)	Total cost of care	Total cost of care (paid claims plus premium payments) for each plan (UPP/ESI)	Claims	Descriptive statistics Trend over time
Primary research question 7.3: Did the pmpm cost for enrollees change over time?				
Baseline year (DY1)	Average pmpm expenditure	Total per member per month cost of care (paid claims plus premium payments) for each plan (UPP/ESI)	Claims	Descriptive statistics Trend over time
ISS				
Primary research question 7.4 Did the number of individuals receiving ISS increase relative to baseline?				
Baseline year (DY1)	ISS Service Recipients	Number of unique individuals who received ISS	Claims	Counts
FFCYAS				
Primary research question 7.5: How many FFCYAS received coverage?				
Baseline year (DY1)	Number of FFCYAS	Number of unique individuals in FFCYAS coverage group	Required Monitoring Reports	Counts
Fertility and Genetic Testing Services				
Primary research question 7.6: Did the number of individuals receiving fertility preservation services increase relative to baseline?				
Baseline year (DY1)	Fertility services	Number of unique individuals receiving fertility preservation services	Claims	Counts
Primary research question 7.7: Did the number of individuals receiving genetic testing services increase relative to baseline?				

Hypothesis 7: The Demonstration delivered coverage/ services appropriately to individuals in the smaller Demonstration populations.				
Comparison Strategy	Measure Name	Measure Description	Data source	Analytic Approach
Baseline year (DY1)	Genetic testing services	Number of unique individuals receiving genetic testing services	Claims	Counts

Table 22: Evaluation Summary, Hypothesis 8, Justice-Involved Populations

Hypothesis 8: The Justice-Involved Reentry Benefit will enhance cross-system communication and coordination between correctional and community services.				
Comparison Strategy	Measure Name	Measure Description	Data source	Analytic Approach
Primary research question 8.1: Did the Demonstration's services facilitate beneficiaries' post-release transitions to care?				
N/A	Were beneficiaries able to access and engage in continuous care post-release that met their needs?	Beneficiaries' Perceptions	Beneficiary Interviews	Qualitative Analysis
N/A	Were beneficiaries able to access and engage in continuous care post-release that met their needs?	Case Managers' Perceptions	Case Manager Interviews	Qualitative Analysis
Primary research question 8.2: Was communication and coordination between the correctional system and community-based health services enhanced?				
N/A	What changes were made to communication systems between institutions?	Correctional system staff Perceptions	Correctional system staff interviews	Qualitative Analysis
N/A	What changes were made to communication systems between institutions?	Community-based providers' Perceptions	Community-based providers interviews	Qualitative Analysis

Table 23: Evaluation Summary, Hypothesis 9, Justice-Involved Populations

Hypothesis 9: The Justice-Involved Reentry Benefit will improve pre-release service provision during the covered period and continuity of coverage for the justice-involved population.						
Comparison Strategy	Measure Name	Measure Description	Numerator	Denominator	Data source	Analytic Approach
Primary research question 9.1: What Demonstration services did justice-involved individuals receive in the pre-release period?						
N/A	Pre-release service distribution	Distribution of services rendered by service type and date. Service types include: clinical consultation (non-BH), diagnostic (radiology and lab), treatment (non-MAT), family planning and supplies, CHW, hepatitis C, medical equipment and supplies, hepatitis C screening, hepatitis C treatment if indicated, SUD services, MAT, MAT counseling, peer support	N/A	N/A	Claims/administrative	Descriptive statistics
N/A	Pre-demonstration carceral setting service offerings	Description of services offered by participating carceral settings in their institution's pre-demonstration	N/A	N/A	Carceral Facility Readiness Assessment and Key Informant Interviews	Document Review Descriptive statistics Qualitative Analysis
N/A	What services (case management or care provision) did beneficiaries receive in the 90 days before release? What services	Beneficiaries' Perceptions	N/A	N/A	Beneficiary Interviews	Qualitative Analysis

	that beneficiaries needed did they not receive in the 90 days before your release?					
Primary research question 9.2: What was beneficiaries' experience of pre-release service provision?						
N/A	Beneficiary experience of pre-release services	Beneficiary self-reported experience of quality of care	N/A	N/A	Beneficiary interviews	Qualitative Analysis
N/A	Provider availability	Ratio of facility Medicaid-enrolled providers to JIR beneficiaries	Medicaid-enrolled providers	JIR beneficiaries	TBD ⁴⁷	Descriptive statistics stratified by provider type
N/A	Pre-release service wait time	Time from JIR benefit start date to first Medicaid reimbursed service	N/A	N/A	Claims	Descriptive statistics stratified by service type (where feasible)

Primary research question 9.3: Were beneficiaries potentially in need of behavioral health services identified during the pre-release period?						
N/A	Diagnosed Mental Health Disorders (DMH)	The percentage of JIR beneficiaries who were diagnosed with a mental health disorder	Of the denominator, number diagnosed with a mental health disorder	JIR beneficiaries	Claims	Descriptive statistics
N/A	Diagnosed Substance Use Disorders (DSU)	The percentage of JIR beneficiaries who were diagnosed with a substance use disorder <ul style="list-style-type: none"> Alcohol disorder 	Of the denominator, number diagnosed with	JIR beneficiaries	Claims	Descriptive statistics

⁴⁷ The data source for facility Medicaid-enrolled providers has not yet been fully determined. It will likely be a combination of Medicaid provider enrollment data and carceral facility administrative data, such lists of providers that have entered into contracts or agreements with the facility.

		<ul style="list-style-type: none"> • Opioid disorder • Other or unspecified drugs • Any SUD 	a substance use disorder			
Primary research question 9.4: What fraction of justice-involved individuals received navigation support for accessing Medicaid coverage pre-release?						
N/A	Intake coverage screening	Percentage of individuals newly incarcerated in participating institutions who were screened for coverage status ⁴⁸	Newly incarcerated individuals screened for Medicaid coverage	All newly incarcerated individuals in participating facilities	Carceral Facility Administrative Data	Descriptive statistics (stratified by time from intake to screening)
N/A	Medicaid renewal applications for justice-involved population	Percentage of incarcerated individuals who responded completely to Medicaid redetermination request	Incarcerated individuals who responded completely to Medicaid redetermination requests	Incarcerated individuals who received Medicaid redetermination requests	Medicaid Administrative Data: Eligibility and Enrollment	Descriptive statistics
N/A	New Medicaid applications for justice-involved population	Number of incarcerated individuals who submitted applications for Medicaid coverage	N/A/	N/A	Medicaid Administrative Data: Eligibility and Enrollment	Descriptive statistics
Primary research question 9.5: Did JIR beneficiaries experience gaps in coverage at the time of release?						
N/A ⁴⁹	Reentry continuity of coverage	Average number of days from release to Medicaid coverage reinstatement for incarcerated individuals with suspended status	N/A	N/A	Medicaid Administrative Data: Eligibility and Enrollment	Descriptive statistics

⁴⁸ In addition to coverage screening of newly incarcerated individuals, the carceral facilities will also screen individuals who were incarcerated prior to the demonstration. The process and timeline for such screenings is not yet in place. The IE may add a measure for screening of previously incarcerated individuals to the design once the planning process is complete.

⁴⁹ The preferred design is to compare JIR beneficiaries to a pre-demonstration group, or a non-participating comparison group, on continuity of coverage. The design will include the comparison approach if release dates are available for a potential comparison group.

TABLE 24: EVALUATION SUMMARY, HYPOTHESIS 10, JUSTICE-INVOLVED POPULATIONS

Hypothesis 10: The Justice-Involved Reentry Benefit’s 90-day pre- release coverage period (“the coverage timeline”) will support effective program implementation.						
Comparison Strategy	Measure Name	Measure Description	Numerator	Denominator	Data source	Analytic Approach
Primary research question 10.1: Did the coverage timeline facilitate providing coordinated, efficient, and effective reentry planning?						
Subsidiary research question 10.1.a: Were assessments and care plans completed in a timely manner?						
N/A	Timely case management assessment	Time from JIR benefit start to first case management meeting/assessment	N/A	N/A	Carceral Facility Administrative Data	Descriptive statistics
N/A	Timely care planning	Time from JIR benefit start date to development of a care plan	N/A	N/A	Carceral Facility Administrative Data	Descriptive statistics
Subsidiary research question 10.1.b: Did beneficiaries receive a 30-day supply of all prescribed medications immediately upon release from the carceral setting?						
N/A	Prescription Medication Supply	Percentage of JIR beneficiaries who received a 30-day supply of all prescription medications that have been prescribed for the individual at the time of release immediately upon release from the correctional facility	JIR beneficiaries who received a 30-day supply of all prescription medications at release	JIR beneficiaries with prescription medication needs	Carceral Facility Administrative Data	Descriptive statistics
Primary research question 10.2: Did the coverage timeline enable pre-release management and stabilization of clinical, physical, and behavioral health conditions?						
N/A	Did the coverage timeline enable pre-release management and stabilization of	Beneficiary Perceptions	N/A	N/A	Beneficiary Interviews	Qualitative Analysis

Hypothesis 10: The Justice-Involved Reentry Benefit’s 90-day pre- release coverage period (“the coverage timeline”) will support effective program implementation.						
Comparison Strategy	Measure Name	Measure Description	Numerator	Denominator	Data source	Analytic Approach
	clinical, physical, and behavioral health conditions?					
Primary research question 10.3: Did the coverage timeline help mitigate potential operational challenges the state might have encountered in a more compressed timeline?						
N/A	Did the coverage timeline help mitigate operational challenges?	State and Correctional System Perceptions	N/A	N/A	State and Correctional system staff interviews	Qualitative Analysis

Table 25: Evaluation Summary, Hypothesis 11, Justice-Involved Populations

Hypothesis 11: The Justice-Involved Reentry Benefit will improve engagement in health care and social services, reduce acute care utilization, and improve health outcomes for the justice-involved population post-release.						
Comparison Strategy	Measure Name	Measure Description	Numerator	Denominator	Data source	Analytic Approach
Primary research question 11.1: Did engagement in appropriate health care services post-release increase relative to a pre-demonstration comparison population?						
Pre-demonstration comparison population	Controlling High Blood Pressure (CBP)	The percentage of JIR beneficiaries who had a diagnosis of hypertension (HTN) and whose blood pressure was adequately controlled	JIR beneficiaries with a diagnosis of hypertension with blood pressure adequately controlled	JIR beneficiaries with a diagnosis of hypertension	Claims	Trend over time Interrupted Time Series
Pre-demonstration comparison population	Monitoring for Persistent Medications (MPM)	JIR beneficiaries who received at least 180 treatment days of ambulatory medication therapy for a select therapeutic agent (for hypertension or heart	JIR beneficiaries who received at least 180 treatment days of ambulatory medication for a	JIR beneficiaries prescribed an ambulatory medication therapy	Claims	Trend over time Interrupted Time Series

Hypothesis 11: The Justice-Involved Reentry Benefit will improve engagement in health care and social services, reduce acute care utilization, and improve health outcomes for the justice-involved population post-release.

Comparison Strategy	Measure Name	Measure Description	Numerator	Denominator	Data source	Analytic Approach
		disease) during the measurement year and received at least one therapeutic monitoring event for the therapeutic agent during the measurement year	select therapeutic agent and received at least one therapeutic monitoring event for the therapeutic agent			
Pre-demonstration comparison population	Adults' Access to Preventative/Ambulatory Health Services (AAP)	Fraction of JIR beneficiaries who had an ambulatory or preventive care visit during the measurement year	Number of JIR beneficiaries who had an ambulatory or preventive care visit	JIR beneficiaries	Claims	Trend over time Interrupted Time Series
Pre-demonstration comparison population	Pharmacotherapy for Opioid Use Disorder (POD)	The percentage of OUD pharmacotherapy events that lasted at least 180 days among JIR beneficiaries with a diagnosis of OUD and a new OUD pharmacotherapy event	OUD pharmacotherapy events that lasted at least 180 days	JIR beneficiaries with a diagnosis of OUD and a new OUD pharmacotherapy event	Claims	Trend over time Interrupted Time Series
N/A	Access to social services post-release	Beneficiary and case manager perceptions of beneficiary engagement in social services in the post-release period	N/A	N/A	Beneficiary and case manager interviews	Qualitative Analysis
Primary research question 11.2: Did inpatient hospital utilization post-release decrease relative to the pre-demonstration comparison population?						
Pre-demonstration comparison population	Inpatient Utilization (IPU)	Inpatient admissions per JIR beneficiary per year	Total inpatient admissions	Total JIR beneficiaries	Claims	Trend over time Interrupted Time Series

Hypothesis 11: The Justice-Involved Reentry Benefit will improve engagement in health care and social services, reduce acute care utilization, and improve health outcomes for the justice-involved population post-release.

Comparison Strategy	Measure Name	Measure Description	Numerator	Denominator	Data source	Analytic Approach
Primary research question 11.3: Did ED visits post-release decrease, relative to the pre-demonstration comparison population?						
Pre-demonstration comparison population	ED visits (EDU)	ED visits per JIR beneficiary per year	Total ED visits	Total JIR beneficiaries	Claims	Trend over time Interrupted Time Series
Pre-demonstration comparison population	ED-BH visits (EDU-BH)	ED visits for BH condition per JIR beneficiary per year	Total ED visits for BH conditions	Total JIR beneficiaries	Claims	Trend over time Interrupted Time Series
Pre-demonstration comparison population	Potentially Preventable ED visits	Non-Emergent ED visits per JIR beneficiary per year	Total non-emergent ED visits	Total JIR beneficiaries	Claims	Trend over time Interrupted Time Series
Primary research question 11.4: Did the rate of deaths post-release decrease relative to the pre-demonstration comparison population?						
Pre-demonstration comparison population	All-cause deaths	All-cause deaths among JIR beneficiaries	All cause deaths among JIR beneficiaries	JIR beneficiaries	Vital statistics	Trend over time Interrupted Time Series
Pre-demonstration comparison population	Suicide deaths	Suicide deaths among JIR beneficiaries	Suicide deaths among JIR beneficiaries	JIR beneficiaries	Vital statistics	Trend over time Interrupted Time Series
Pre-demonstration comparison population	Overdose deaths	Overdose deaths among JIR beneficiaries	Overdose deaths among JIR beneficiaries	JIR beneficiaries	Vital statistics	Trend over time Interrupted Time Series
Primary research question 11.5: Was the timing or provision of specific pre-release services associated with better post-release outcomes?						
Associations between the pre-release service distribution data and post-release outcomes (utilization, engagement, deaths) will be explored. There are no new measures needed for this analysis.						Exploratory Regression

3. HRSS PARTICIPANT INTERVIEW METHODOLOGY

Interim Evaluation: Participant Experience, Housing-Related Services and Supports

Overview

In January 2025, Utah received approval from the federal government to update its Housing-Related Services and Supports (HRSS) program and extend it to more people enrolled in Medicaid. These expanded services are being rolled out over time. Currently, HRSS covers costs associated with moving for eligible individuals, such as paying a security deposit, buying essential household items, paying application fees, or hiring movers. Once fully implemented, HRSS will also include services to help people stay in their homes, avoid eviction, make medically necessary home modifications (such as removing mold or installing air filters), and make accessibility modifications (such as installing ramps or grab bars). The State hypothesizes that HRSS will make housing needs less common and less severe, increase continuity of behavioral health treatment, and improve health outcomes for the eligible population. To examine the HRSS program's impact, the independent evaluation examines and analyzes the utilization of services included in the 1115 waiver, as well as associated outcomes. It also examines and analyzes the perspectives, experiences, and insights of HRSS participants. This midpoint evaluation covers the methodology being used, the specific individuals included in this portion of the midpoint evaluation, and the status of data gathering.

Eligibility

There are three Medicaid populations, outlined in Table 1, that currently are or eventually will be eligible for HRSS. This midpoint independent evaluation report focuses on the first eligible group, Targeted Adult Medicaid (TAM) individuals. The final report will include all groups presented in Table 1.

Table 1. Medicaid Covered Populations Eligible for HRSS

Covered Groups	Membership Criteria
Targeted Adult Medicaid Population <i>Current version: 1/2025</i>	<ul style="list-style-type: none"> ● Age 19-64 ● No dependent children ● Income below 5% of the federal poverty line ● At least one of the following: <ul style="list-style-type: none"> ○ Chronically homeless ○ Involved in the justice system and need substance use or mental health treatment ○ Need substance use or mental health treatment
Adult Expansion Population <i>Began: 1/2025</i>	<ul style="list-style-type: none"> ● Age 19-64 ● US citizen or qualified non-citizen ● Utah resident ● Household income at or below 133% of the federal poverty line
Recently Incarcerated Individuals <i>Future date</i>	<ul style="list-style-type: none"> ● Age 18 or older ● Released from incarceration within the last 12 months ● Received the Medicaid Justice Benefit Plan while incarcerated

Evaluation Methodology

To gather HRSS participant perspectives, experiences, and insights, the independent evaluator collaborates with providers to identify HRSS-eligible individuals who would be interested in sharing their experience. Once identified by the provider, these volunteers are contacted by the evaluator, who is an established expert in reaching out to and interviewing individuals with substance use disorders (SUDs), behavioral health concerns, chronic homelessness, and recent incarceration.

Volunteers are contacted to arrange the best time for them to participate in an interview. They are informed that the interview is confidential and given information about its purpose and how the information will be used. Volunteers can decline to move forward with the interview or end an interview at any time. Their decisions about interview participation do not affect their services. Interviews use a semi-structured format, are conducted via telephone, and last between 40-60 minutes. Participants receive a grocery store gift card to thank them for their time. With the interview participant's permission, the evaluator will contact them in three to four months to gather their experience and perspective after utilization of the HRSS benefit. The interview question areas and related topics covered in the interviews are listed in Table 2.

Table 2. Interview Questions and Potential Related Topics

Interview Questions	Potential Related Topics
How do participants' interactions with care managers happen? In what ways are these interactions helpful or not helpful?	<ul style="list-style-type: none"> • Outreach approach, engagement, and follow-through • Understanding of participant needs and perspective – whether care manager took steps to assist or explained limitations of service
What role did the HRSS case manager have in participants' housing situation?	<ul style="list-style-type: none"> • Addressing specific patient needs, timeliness, role of other housing liaisons
What factors enhance or inhibit participants' engagement in behavioral health care?	<ul style="list-style-type: none"> • Factors (barriers/facilitators) to access, coordination, continuity, and outcome
Are participants experiencing unmet needs for health care, including SUD and serious mental illness treatment?	<ul style="list-style-type: none"> • Participation in behavioral and physical health services and support • Use of the emergency department and hospitalizations (avoidable and/or behavioral health related) – perspective on alternatives • Participation in preventive, acute, and chronic condition services
Do participants perceive their life circumstances have changed since receiving HRSS services?	<ul style="list-style-type: none"> • Previous and current life (social determinants of health, family, work, etc.) situation
Did participants receive services in the pre-release period that met their needs? Was there enough time to get the screening and services needed prior to release? Did such services result in stable physical and behavioral health upon release?	<ul style="list-style-type: none"> • Access to and quality of pre-release services (case management, behavioral health care, diagnostic services, family planning services) • Perceptions of stigma associated with care
Were participants' post-release transitions to care needs adequately met by the pre-release services?	<ul style="list-style-type: none"> • Access to care and medications, continuity of coverage, care, medication, and providers

For the HRRS population, the evaluator expects to conduct approximately 75-80 interviews, or until thematic saturation is reached. Thematic saturation occurs when new interviews do not add additional insight – themes have consistently been shared. Saturation will be assessed separately for three HRSS-eligible categories: individuals planning to utilize HRSS, those who have used HRSS, and those who were unable to access HRSS. Ensuring input from individuals with this range of HRSS experience will provide depth to this portion of the evaluation.

Data Collection and Analysis

A matrix template is used to code interview data and enable the identification of themes. Data is analyzed in the aggregate to ensure participant confidentiality. Interview data analysis will occur once interviews are completed and will utilize an inductive and deductive framework. The deductive approach will provide structure and organization to the non-open-ended questions, while the inductive approach enables the identification and explanation of findings. The analysis occurs through an iterative

process, with steps including sorting data into organizational categories; organizing data into categories aligned with the research questions; developing codes, themes, and findings using the conceptual framework; identifying representative data to support findings; and explaining findings, including connecting and comparing them with existing literature.

Addressing Limitations. There are limitations in every evaluation. The HRSS participant evaluation uses mitigation strategies throughout the process to achieve the highest level of validity. This includes incorporating peer review and inter-rater reliability prior to the inductive stage of the analysis, creating tested interview guides, conducting triangulation (comparing findings from three sources) and member checking (participant review of their data and findings), and assessing saturation separately for different groups. These strategies help to mitigate any bias or subjectivity.

Interim Evaluation Status

On December 2, 2024, the evaluator provided an orientation to 13 qualified organizations. Another orientation was conducted in January 2025 with case managers from 6 of these organizations. In addition, the evaluator met individually with case managers to discuss specific processes that would work for their organization and safeguards required for confidentiality. Several providers have just begun adding case managers to their organizations, delaying their inclusion in the evaluation. Currently, 7 of the 13 initial HRSS qualified providers are engaged in identifying HRSS-eligible individuals who wish to participate in evaluation interviews. Additional providers are aiming to begin identifying evaluation participants in the next few months.

Across the currently engaged providers, 64 individuals have been referred for interviews and 48 were able to participate. Once all providers are ready to identify evaluation participants, the data collection will be representative of individuals eligible for HRSS. In addition, a portion of the interview participants will be contacted again several months after utilizing HRSS to gain a deeper insight into its impact. Once data collection is completed, the analysis will be conducted.

4. MEMBER SATISFACTION SURVEY REPORT

Utah Medicaid Reform 1115 Demonstration

Report of Member Survey Results

Prepared for:



Table of Contents

• Survey Objectives & Methodology	2
• Survey Findings	7
▪ Member Profile	9
▪ Health Care Access	13
▪ Primary Care	18
▪ Mental Health Care	24
▪ Substance Use Treatment	30
▪ Medication Management	32
▪ Dental Services	34
• Conclusions	36
• Appendix	41
▪ Subgroup Differences	42
▪ Disposition Report	52

© 2025. The consulting and operations division of UMass Chan Medical School. Confidential



forHealth[®]
CONSULTING
at UMass Chan
Medical School

Survey Objectives & Methodology

© 2025. The consulting and operations division of UMass Chan Medical School. Confidential

2

Background and Objectives

To assess the impact of the Utah Medicaid Reform 1115 Demonstration on members' access to and engagement in health care, Public Consulting Group (PCG) commissioned ForHealth Consulting at UMass Chan Medical School to conduct a survey of Utah Medicaid members.

Specific objectives of the survey were to understand the following:

- Members' access to health care, including urgent care, routine care, mental health care, and substance use treatment.
- Members' perceived barriers to primary care and mental health care.
- Member perceptions of care coordination and shared decision making with providers.
- Members' self-reported health status, including physical and mental health.

© 2025. The consulting and operations division of UMass Chan Medical School. Confidential

Methodological Overview

Who?

6,000 Utah Adult Expansion Medicaid members who met the following criteria:

- Continuously enrolled in Medicaid (any Accountable Care Organization (ACO), Fee for Service (FFS), or Utah Medicaid Integrated Care (UMIC) program) for a period of six months prior to the start of the survey period.
- Had at least one primary care or preventive service over a period of six months prior to the start of the survey period.

When?

The survey was administered from July 2, 2025 to September 17, 2025.

How?

ForHealth Consulting's Office of Survey Research (OSR) conducted the survey in English and Spanish using three modes of data collection:

- **Mail:** All members in the survey sample were mailed a survey packet, containing a cover letter, questionnaire, and a postage-paid reply envelope. The cover letter included OSR's toll-free number that members could call if they preferred to complete the survey over the phone as well as a QR code/online link to the survey along with a username and password.
- **Online:** OSR sent survey invitations to members for whom an email address was available, with a unique web link for each member, followed by reminder emails to non-respondents.
- **Phone:** OSR made five attempts to reach non-respondents and conduct the survey over the phone.

© 2025. The consulting and operations division of UMass Chan Medical School. Confidential

4

Survey Response Rate

From the 23,011 Utah Adult Expansion Medicaid members included in the sampling frame, a total of 6,000 members were selected for the survey, of which 1,865 responded for a response rate of 32%.

- OSR applied implicit random sampling to ensure that the survey sample was representative of the population by using the following variables: age, gender, race and ethnicity, and member type.
- To produce representative estimates of population parameters, survey respondents were subsequently weighted using the sampling variables.

	Sampling Frame	Sample Size	Completed Surveys	Response Rate*
Total	23,011	6,000	1,865	32%

*See the Appendix for the full disposition report.

Survey Content

OSR designed the survey in consultation with PCG to understand member access to health care, experiences with health care, and health status.

- Select questions from the Consumer Assessment of Healthcare Providers and Systems (CAHPS) surveys were included in addition to custom questions.




Survey Findings

© 2025. The consulting and operations division of UMass Chan Medical School. Confidential

7

How to Read the Data in This Report

The illustrated example below serves as a guide on how to read the survey data.



© 2025. The consulting and operations division of UMass Chan Medical School. Confidential

8

Member Profile

© 2025. The consulting and operations division of UMass Chan Medical School. Confidential

9

Member Demographics

Adult Medicaid Expansion members are an average age of 41 years, skew female, are primarily white (non-Hispanic), and the majority have English as their primary language.

		%
Age	19 to 25	14
	26 to 35	25
	36 to 45	24
	46 to 55	19
	56 to 64	19
	Mean Age	41
Gender	Male	40
	Female	60

		%
Race/ Ethnicity	White (non-Hispanic)	39
	Hispanic or Latino	9
	Black (non-Hispanic)	1
	Asian (non-Hispanic)*	1
	Another race or multi-race	4
	Missing	46
	Primary Language	English
Spanish		4
Another language		3

*In the Utah Medicaid member database, Asian includes "Asian or Pacific Islander"

Age, Gender, Race/Ethnicity, and Primary Language from Utah Medicaid member data (n=1,865)
© 2025. The consulting and operations division of UMass Chan Medical School. Confidential

10

Member Type and Length of Enrollment

Members have been enrolled in their Medicaid plan for 14 months on average, with Utah Medicaid Integrated Care (UMIC) having the most enrollment.



Member Type and Length of Enrollment in Medicaid from Utah Medicaid member data (n=1,885)
© 2025. The consulting and operations division of UMass Chan Medical School. Confidential

11

Member Health

Members' ratings of their overall health or specifically, mental health, range mostly from good to poor.

- Less than a third of members rate their overall health or mental health as very good or excellent.



Q33 In general, how would you rate your overall health? (n=1,845)
Q34 In general, how would you rate your overall mental or emotional health? (n=1,851)
© 2025. The consulting and operations division of UMass Chan Medical School. Confidential

12

Health Care Access

© 2025. The consulting and operations division of UMass Chan Medical School. Confidential


13

Access to Urgent Care


About half of members report having an illness, injury, or condition that needed care right away, and of them, 85% report always or usually getting care as soon as needed.

- 56% of those who needed urgent care report always being able to get care as soon as needed.

Needed Urgent Care in Last 6 Months



Access to Urgent Care: Got Care as Soon as Needed
— Among those who needed urgent care —



Q1 In the last 6 months, did you have an illness, injury, or condition that needed care right away? (n=1,849)
Q2 In the last 6 months, when you needed care right away, how often did you get care as soon as you needed? (n=913)
© 2025. The consulting and operations division of UMass Chan Medical School. Confidential


14

Lack of Access to Urgent Care

Reasons for lack of access center largely around long wait times for an appointment and, to a lesser extent, inability to get an appointment at a convenient time.

- Additional reasons include lack of transportation, inability to find a doctor in the network, and high cost of care.

Reasons Could Not Get Care as Soon as Needed
– Among those who sometimes/never got care as soon as needed –




Q3 Why were you not able to get care as soon as you needed? Please select all that apply. (n=134)
© 2025. The consulting and operations division of UMass Chan Medical School. Confidential

Access to Non-Urgent Care


Roughly three-quarters of members report making an appointment for routine care in the past six months, and of them, 82% report always or usually getting the appointment as soon as needed.

- 48% of those who needed an appointment for routine care report always being able to get the appointment as soon as needed.

Made Appointment for Routine Care in Last 6 Months



Got Appointment for Routine Care as Soon as Needed
– Among those who made an appointment –




Q4 In the last 6 months, did you make any in-person, phone, or video appointments for a check-up or routine care? (n=1,851)
Q5 In the last 6 months, how often did you get an appointment for a check-up or routine care as soon as you needed? (n=1,396)
© 2025. The consulting and operations division of UMass Chan Medical School. Confidential

Ease of Accessing Care, Tests, or Treatment

Most members (85%) report it was always or usually easy to get the care, tests, or treatment they needed in the past six months.

- Just over half the members select the highest rating of “always” on this access measure.

Easily Got Needed Care, Tests, or Treatment in Last 6 Months



Q6 In the last 6 months, how often was it easy to get the care, tests, or treatment you needed? (n=1,831)
© 2025. The consulting and operations division of UMass Chan Medical School. Confidential

17


Primary Care

© 2025. The consulting and operations division of UMass Chan Medical School. Confidential

18

Access to Primary Care

86% of members report having a personal doctor (i.e., primary care provider), and of them, 83% report having had a visit with their PCP in the last six months.




Q7 A personal doctor is the one you would talk to if you need a check-up, want advice about a health problem, or get sick or hurt. Do you have a personal doctor? (n=1,850)
Q8 In the last 6 months, did you have an in-person, phone, or video visit with your personal doctor about your health? (n=1,588)

© 2025. The consulting and operations division of UMass Chan Medical School. Confidential

How Well Providers Communicate

Member perceptions of how well their PCP communicates with them are relatively positive, particularly on treating them with respect, explaining things in a way that is easy to understand, and listening carefully.

- Member perceptions of their PCP spending enough time with them show a somewhat wider gap for improvement.



Q12 In the last 6 months, how often did your personal doctor show respect for what you had to say? (n=1,306)
Q9 In the last 6 months, how often did your personal doctor explain things in a way that was easy to understand? (n=1,311)
Q10 In the last 6 months, how often did your personal doctor listen carefully to you? (n=1,306)
Q13 In the last 6 months, how often did your personal doctor spend enough time with you? (n=1,308)

© 2025. The consulting and operations division of UMass Chan Medical School. Confidential

Providers' Use of Information to Coordinate Patient Care

Member perceptions of their PCP's use of information to coordinate their care show several gaps, particularly on knowing important information about their medical history and being informed about specialist care, tests, and results.

- There is also a perceived gap on discussing all prescription medications that the patient is taking.

Personal Doctors' Use of Information to Coordinate Care
– Among those who had a visit with personal doctor in last 6 months –




Q11 In the last 6 months, how often did your personal doctor seem to know the important information about your medical history? (n=1,307)
 Q16 In the last 6 months, did you take any prescription medicine? (n=1,310)
 Q17 In the last 6 months, how often did you and your personal doctor talk about all the prescription medicines you were taking? (n=1,256)
 Q20 Specialists are doctors like surgeons, heart doctors, allergy doctors, skin doctors, and other doctors who specialize in one area of health care. In the last 6 months, did you have an in-person, phone, or video visit with a specialist? (n=1,301)
 Q21 In the last 6 months, how often did your personal doctor seem informed and up-to-date about the care you got from specialists? (n=811)
 Q22 In the last 6 months, how often did your personal doctor know about any tests or results you got from specialists? (n=737)
 © 2025. The consulting and operations division of UMass Chan Medical School. Confidential

Shared Decision Making

Nearly 90% of members who had a PCP visit in the last six months needed medical treatment, and of them, nearly three-quarters report that their PCP always involved them when developing their treatment plan.


Needed Medical Treatment in Last 6 Months

– Among those who had a visit with personal doctor in last 6 months –



Personal Doctor Involved Patient in Treatment Plan

– Among those who needed medical treatment in last 6 months –




Q14 In the last 6 months, did you need any medical treatment, such as medicine or a procedure? (n=1,303)
 Q15 In the last 6 months, how often did your personal doctor work with you to make a treatment plan that works best for you? (n=1,155)
 © 2025. The consulting and operations division of UMass Chan Medical School. Confidential

Social Determinants of Health

Less than half of members report that someone from their PCP's office asked them if there were things that make it difficult for them to take care of their health or if they are facing any difficulties related to social determinants of health.

Social Determinants of Health
– Among those who had a visit with personal doctor in last 6 months –

Someone from provider's office asked member if there are:




Q18 In the last 6 months, did someone from your personal doctor's office ask you if there are things that make it hard for you to take care of your health? (n=1,280)
Q19 In the last 6 months, did someone from your personal doctor's office ask if you are facing any difficulties in other areas of your life, such as food, housing, transportation, or childcare? (n=1,290)
© 2025. The consulting and operations division of UMass Chan Medical School. Confidential

Mental Health Care

Access to Mental Health Care

42% of members report needing mental health counseling in the last six months, and of them, nearly 80% were able to get mental health counseling.

- Nearly half of those who got mental health counseling report experiencing no difficulty in finding a counselor, while 27% report that it was somewhat or very difficult to find a counselor.




Q23 By mental health we mean your sense of wellbeing and emotional health. In the last 6 months, did you need any mental health counseling for any reason? (n=1,847)
 Q24 In the last 6 months, did you get any mental health counseling for any reason? (n=766)
 Q25 In this survey, your main mental health counselor is the mental health counselor you talked with most often in the last 6 months. How difficult was it to find this mental health counselor? (n=580)
 © 2025. The consulting and operations division of UMass Chan Medical School. Confidential

Lack of Access to Mental Health Counseling

Reasons for lack of access center largely around not being able to find a counselor in the network, someone they felt comfortable with, or who was accepting new patients.

- Long wait times to get an appointment also comprise a relatively common reason for lack of access.




Q26 Why was it difficult to find your main mental health counselor? Please select all that apply. (n=150)
 © 2025. The consulting and operations division of UMass Chan Medical School. Confidential

Accessing a Mental Health Counselor

The majority of those who got mental health counseling (85%) do not report experiencing much difficulty in making appointments with their counselor.

- 15% report that it was either somewhat or very difficult to get an appointment with their counselor.

Difficulty Making Appointments with Mental Health Counselor
– Among those who got counseling in last 6 months –



Q27 In the last 6 months, how difficult was it to make appointments with your main mental health counselor? (n=589)
© 2025. The consulting and operations division of UMass Chan Medical School. Confidential


27

How Well Mental Health Counselors Communicate

Member perceptions of how well their mental health counselor communicates with them are relatively positive, particularly on treating them with respect and listening to them carefully.

- Member perceptions of their counselor spending enough time with them show a slightly wider gap for improvement.

Perceptions of Communication with Mental Health Counselor
– Among those who got counseling in last 6 months –




Q28 In the last 6 months, how often did your main mental health counselor listen carefully to you? (n=589)
Q29 In the last 6 months, how often did your main mental health counselor show respect for what you had to say? (n=589)
Q30 In the last 6 months, how often did your main mental health counselor spend enough time with you? (n=590)
© 2025. The consulting and operations division of UMass Chan Medical School. Confidential

28


Shared Decision Making

Nearly 90% of members who got mental health counseling in the last six months needed treatment, and of them, 88% report that their counselor always or usually involved them when developing their treatment plan.

Needed Mental Health Treatment in Last 6 Months
– Among those who got counseling –



Counselor Involved Patient in Treatment Plan
– Among those who needed treatment in last 6 months –




Q31 In the last 6 months, did you need any mental health treatment, such as medicine or a therapy? (n=590)
Q32 In the last 6 months, how often did your main mental health counselor work with you to make a treatment plan that works best for you? (n=519)
© 2025. The consulting and operations division of UMass Chan Medical School. Confidential

Substance Use Treatment

Access to Substance Use Treatment

Six percent of members report needing any health care services in the last six months to help them with alcohol or drug use, and of them, 82% report getting treatment or services.




Q39 In the last 6 months, did you need any health care services to help you with alcohol use or drug use? (n=1,847)
Q40 In the last 6 months, did you get any health care services to help you with alcohol use or drug use? (n=114)
© 2025. The consulting and operations division of UMass Chan Medical School. Confidential

Medication Management

Rx Needs and Provider Communication

83% of members report currently taking prescription medication, mostly for a condition that has lasted for at least three months; however, only 36% report that their provider's office contacted them to ensure they were taking the medication as directed.




Q35 Do you now need or take medicine prescribed by a doctor? Do not include birth control. (n=1,859)
Q36 Is this medicine to treat a condition that has lasted for at least 3 months? Do not include pregnancy or menopause. (n=1,541)
Q37 In the last 6 months, did anyone from a doctor's office contact you to make sure you were taking medicine as directed? (n=1,532)
© 2025. The consulting and operations division of UMass Chan Medical School. Confidential

Dental Services

Awareness of Dental Benefit

Over a third of members (36%) are not aware that their Medicaid plan covers dental services.

Awareness that Health Insurance Covers Dental Services



Q38 Does your health insurance cover any dental services, such as routine cleanings? (n=1,511)
© 2025. The consulting and operations division of UMass Chan Medical School. Confidential

35

Conclusions

© 2025. The consulting and operations division of UMass Chan Medical School. Confidential

36

Health Care Access

- **There are some gaps in member access to urgent care.**
 - 56% of members who needed urgent care report always being able to get the care as soon as they needed, indicating a gap of 44%.
 - Among members who report sometimes or never getting urgent care as soon as needed, reasons for lack of access center primarily around long wait times for an appointment and, to a lesser extent, inability to get an appointment at a convenient time.
- **There are also some gaps in member access to routine care.**
 - Among members who made an appointment for a check-up or routine care, just over half (52%) report not always being able to get an appointment as soon as they needed.
- **Similarly, there is a gap in members' ease of accessing medical care, tests, or treatment.**
 - Overall, 53% of members report always finding it easy to get the care, tests, or treatment they needed, indicating a gap of 47%.

© 2025. The consulting and operations division of UMass Chan Medical School. Confidential

37

Access to and Perceptions of Primary Care

- **There appears to be some gap in access to primary care.**
 - 14% of members report not having a personal doctor (i.e., a primary care provider).
- **Perceptions of how well primary care providers communicate are relatively positive.**
 - Member perceptions of how well their PCP communicates with them are relatively positive, particularly on treating them with respect, explaining things in a way that is easy to understand, and listening carefully.
 - Member perceptions of their PCP spending enough time with them show some room for improvement.
- **There is some room for improvement on care coordination.**
 - Member perceptions of their PCP's use of information to coordinate their care show several gaps, particularly on knowing important information about their medical history and being informed about specialist care, tests, and results.
 - There is also a perceived gap on discussing all prescription medications that the patient is taking.
- **Perceptions of shared decision-making are relatively positive.**
 - Nearly three-quarters (73%) of members who had a PCP visit and needed medical treatment in the last six months report that their PCP always involved them when developing their treatment plan.
- **Providers' focus on members' social determinants of health appears to be limited.**
 - Less than half of members report that someone from their PCP's office asked them if there were things that make it difficult for them to take care of their health or if they are facing any difficulties related to social determinants of health.

© 2025. The consulting and operations division of UMass Chan Medical School. Confidential

38

Access to and Perceptions of Mental Health Care

- **Some members experience difficulty in accessing mental health care.**
 - 42% of members report needing mental health counseling in the last six months, and of them, nearly 80% report getting mental health counseling.
 - Nearly half of those who got mental health counseling report experiencing no difficulty in finding a counselor, while 27% report that it was somewhat or very difficult to find a counselor.
 - Reasons for lack of access center largely around not being able to find a counselor in the network, someone the member felt comfortable with, or who was accepting new patients.
 - 63% of those who got mental health counseling do not report experiencing any difficulty in making appointments with their counselor; however, 15% report that it was somewhat or very difficult to make an appointment.
- **Perceptions of how well mental health counselors communicate are largely positive.**
 - Member perceptions of how well their mental health counselor communicates with them are relatively positive, particularly on treating them with respect and listening to them carefully.
 - Member perceptions of their counselor spending enough time with them show a slightly wider gap for improvement.
- **Perceptions of shared decision-making are positive.**
 - Nearly three-quarters (72%) of members who got mental health counseling and needed treatment in the last six months report that their counselor always involved them when developing their treatment plan.
- **A majority of members who need substance use treatment report being able to access it.**
 - Among the six percent of members who report needing health care services related to substance use in the last six months, 82% report getting treatment or services.
 - There is a gap in access for the 18% of members who were unable to get substance use treatment or services.

© 2025. The consulting and operations division of UMass Chan Medical School. Confidential

39

Medication Management and Awareness of Dental Benefit

- **Provider follow up for medication management appears limited.**
 - Among members currently taking prescription medication for a condition that has lasted for at least three months, only 36% report being contacted by their provider's office to ensure they were taking the medication as directed.
- **There is a need for greater communication of the available dental benefit to members.**
 - Over a third of members (36%) are not aware that their Medicaid plan covers dental services.

© 2025. The consulting and operations division of UMass Chan Medical School. Confidential

40

Appendix

© 2025. The consulting and operations division of UMass Chan Medical School. Confidential

41



Subgroup Differences

© 2025. The consulting and operations division of UMass Chan Medical School. Confidential

42

Subgroup Analysis

This section compares survey results by Member Type and Race & Ethnicity subgroups.



* Rebased by removing 46% of members for whom race/ethnicity data are not available in the Utah Medicaid Member database.

Note:

- Only those measures are included in this section on which the subgroups show statistically significant differences at the 95% confidence level.
- Survey measures on which there are no significant differences between subgroups are not displayed.
 - In such instances, it can be assumed that the results displayed for members overall are consistent across subgroups.
 - For certain measures where the base size is too low due to skip logic in questions (e.g., "reasons for lack of access to urgent care" has low base sizes among ACO and FFS members), the ability to detect significant differences at the 95% confidence level would be limited.
- For measures where the results are based on a low base size (n<75), a footnote is included to suggest caution in interpreting those findings.

© 2025. The consulting and operations division of UMass Chan Medical School. Confidential

43

Differences by Member Type: Primary Care

Access to primary care appears to be strongest among ACO members compared to UMIC members and member perceptions of their PCP are stronger among ACO and UMIC members compared to FFS members.

		UMIC (U)	ACO (A)	FFS (F)
Access to Primary Care	Have a personal doctor	84%	92% ^U	88%
How Well Providers Communicate*	Always/usually explained things in a way that was easy to understand	96% ^F	97%	92%
Care Coordination**	Personal doctor usually seemed informed and up-to-date about specialist care	27% ^F	32% ^F	18%
Social Determinants of Health*	Someone from provider's office asked about difficulties with food, housing, transportation, or childcare	44% ^F	48% ^F	36%

*Among those who had a visit with their personal doctor in the last 6 months
**Among those who had a visit with a specialist in the last 6 months

U/A/F: Significantly higher than specified group at 95% confidence level

Q7 A personal doctor is the one you would talk to if you need a check-up, want advice about a health problem, or get sick or hurt. Do you have a personal doctor? (UMIC n=1356; ACO n=236; FFS n=258)
Q9 In the last 6 months, how often did your personal doctor explain things in a way that was easy to understand? (UMIC n=957; ACO n=173; FFS n=181)
Q21 In the last 6 months, how often did your personal doctor seem informed and up-to-date about the care you got from specialists? (UMIC n=596; ACO n=97; FFS n=118)
Q19 In the last 6 months, did someone from your personal doctor's office ask if you are facing any difficulties in other areas of your life, such as food, housing, transportation, or childcare? (UMIC n=941; ACO n=169; FFS n=165)
© 2025. The consulting and operations division of UMass Chan Medical School. Confidential

44

Differences by Member Type: Mental Health

Ratings of overall mental health are stronger among FFS members compared to UMIC members, while ACO members are more likely than UMIC members to report no difficulty in finding a mental health counselor.

- FFS members are more likely than UMIC members to report having some difficulty in making appointments with their mental health counselor.

		UMIC (U)	ACO (A)	FFS (F)
Overall Mental or Emotional Health	Very good overall mental or emotional health	19%	21%	25% ^U
	Fair/poor overall mental or emotional health	38% ^F	33%	30%
Accessing a Mental Health Counselor*	Not difficult at all to find mental health counselor	47%	62% ^{U*}	53%
	Somewhat difficult to make appointments with mental health counselor	12%	11%	21% ^U

*Among those who got mental health counseling in last 6 months

U/A/F: Significantly higher than specified group at 95% confidence level

^{*}Low base size; interpret results with caution

Q25 In this survey, your main mental health counselor is the mental health counselor you talked with most often in the last 6 months. How difficult was it to find this mental health counselor? (UMIC n=439; ACO n=65; FFS n=76)

Q27 In the last 6 months, how difficult was it to make appointments with your main mental health counselor? (UMIC n=448; ACO n=87; FFS n=74)

Q34 In general, how would you rate your overall mental or emotional health? (UMIC n=1,356; ACO n=237; FFS n=258)

© 2025. The consulting and operations division of UMass Chan Medical School. Confidential

45

Differences by Member Type: Awareness of Dental Benefit

FFS members are more aware than UMIC members of their dental coverage.

		UMIC (U)	ACO (A)	FFS (F)
Awareness of Dental Benefit	Aware that health insurance covers dental services	63%	64%	71% ^U

U/A/F: Significantly higher than specified group at 95% confidence level

Q38 Does your health insurance cover any dental services, such as routine cleanings? (UMIC n=1110; ACO n=196; FFS n=205)

© 2025. The consulting and operations division of UMass Chan Medical School. Confidential

46

Differences by Race & Ethnicity: Member Health

The status of self-reported overall health and mental health is somewhat stronger among non-white than among white members.

		White (W)	Non-White (N)
Overall Health	Excellent/Very good	26%	25%
	Good	32%	40%^{WN}
	Fair/Poor	42%	35%
Overall Mental or Emotional Health	Excellent/Very good	28%	32%
	Good	32%	37%
	Fair/Poor	40%^W	31%

WN: Significantly higher than specified group at 95% confidence level

Q33. In general, how would you rate your overall health? (White n=675; Non-White n=240)
 Q34. In general, how would you rate your overall mental or emotional health? (White n=677; Non-White n=242)
 © 2025. The consulting and operations division of UMass Chan Medical School. Confidential

Differences by Race & Ethnicity: Health Care Access

White members are more likely than non-white members to report having made an appointment for non-urgent care in the last six months.

		White (W)	Non-White (N)
Access to Non-Urgent Care	Made an appointment for non-urgent care in last 6 months	79%^W	69%

WN: Significantly higher than specified group at 95% confidence level

Q4. In the last 6 months, did make any in-person, phone, or video appointments for a check-up or routine care? (White n=682; Non-White n=244)
 © 2025. The consulting and operations division of UMass Chan Medical School. Confidential

Differences by Race & Ethnicity: Primary Care

Access to primary care is somewhat stronger among white than non-white members and while white members have slightly more positive perceptions of provider communication, perceptions of care coordination are somewhat stronger among non-white members.

		White (W)	Non-White (N)
Access to Primary Care	Has a personal doctor	88% ^A	82%
	Has a specialist	76%	82%
How Well Providers Communicate*	Always listened carefully to patient	76%	82%
	Usually listened carefully to patient	19% ^A	10%
	Sometimes/Never listened carefully to patient	5%	8%
Care Coordination*	Always seemed to know important information about patient's medical history	62%	73% ^W
	Never knew about tests or results from specialists ^A	6% ^N	1%

*Among those who had a visit with their personal doctor in the last 6 months

W/N: Significantly higher than specified group at 95% confidence level

^AAmong those who had a visit with a specialist in the last 6 months

Q7. A personal doctor is the one you would talk to if you need a check-up, want advice about a health problem, or get sick or hurt. Do you have a personal doctor? (White n=680; Non-White n=243)

Q10. In the last 6 months, how often did your personal doctor listen carefully to you? (White n=494; Non-White n=165)

Q11. In the last 6 months, how often did your personal doctor seem to know the important information about your medical history? (White n=495; Non-White n=166)

Q22. In the last 6 months, how often did your personal doctor know about any tests or results you got from specialists? (White n=287; Non-White n=95)

© 2025. The consulting and operations division of UMass Chan Medical School. Confidential

49

Differences by Race & Ethnicity: Mental Health Care

Consistent with lower ratings on their self-reported mental health status, white members are more likely than non-white members to have experienced a need for mental health counseling and treatment in the past six months.

		White (W)	Non-White (N)
Need for Mental Health Care	Needed mental health counseling in the last 6 months	45% ^A	32%
	Needed mental health treatment in the last 6 months*	92% ^A	81% ^A

*Among those who got mental health counseling in the last 6 months

W/N: Significantly higher than specified group at 95% confidence level

^ALow base size; interpret results with caution

Q23. By mental health we mean your sense of wellbeing and emotional health. In the last 6 months, did you need any mental health counseling for any reason? (White n=682; Non-White n=239)

Q31. In the last 6 months, did you need any mental health treatment, such as medicine or a therapy? (White n=226; Non-White n=82)

© 2025. The consulting and operations division of UMass Chan Medical School. Confidential

50

Differences by Race & Ethnicity: Medication Management

White members are more likely than non-white members to report taking prescription medication; however, non-white members are more likely to report provider involvement in medication management.

		White (W)	Non-White (N)
Need Prescription Medicine for Condition	Currently need or take prescription medicine	84% ^W	75%
	Medicine is treating a condition that has lasted 3 months or more*	97% ^W	89%
Doctor's Office Communication about Medicine*	Contacted by doctor's office to make sure they were taking medicine as directed	35%	46% ^W

*Among those who currently need or take prescription medicine

W/N: Significantly higher than specified group at 95% confidence level

Q35 Do you now need or take medicine prescribed by a doctor? Do not include birth control. (White n=688; Non-White n=243)
 Q36 Is this medicine to treat a condition that has lasted for at least 3 months? Do not include pregnancy or menopause. (White n=578; Non-White n=186)
 Q37 In the last 6 months, did anyone from a doctor's office contact you to make sure you were taking medicine as directed? (White n=577; Non-White n=184)

© 2025. The consulting and operations division of UMass Chan Medical School. Confidential

Disposition Report

© 2025. The consulting and operations division of UMass Chan Medical School. Confidential

Final Disposition Report

	Counts	% of Total Sample
Total Sample	6,000	
Interviews:	1865	31%
Completes	1862	31%
Mail	332	6%
Phone	1193	20%
Web	337	6%
Partials (any mode)*	3	0.1%
Eligible, Non-Interviews:	38	0.6%
Break-offs*	38	0.6%
Unknown Eligibility, Non-Interviews:	4015	67%
Answering machine or voicemail	2449	41%
Refusal	455	8%
Non-working/disconnected/wrong number	464	8%
No reply	387	6%
Respondent not available	100	2%
Busy	160	3%
Ineligible:	82	1%
Language barrier	31	0.5%
Not a Utah Medicaid Member	28	0.5%
Mentally/physically unable to complete survey and no available proxy	14	0.2%
Invalid address and phone number	6	0.1%
Deceased	3	0.1%
Response Rate**	32%	

	Counts	% of Completed Interviews
Completed Interviews	1865	
By Language		
English	1802	96.6%
Spanish	63	3.4%

*Partials: those who answered at least through Q33 are included in analysis; Break-offs: those who broke off before Q33 are not included in analysis.

**AAPOR Response Rate 4, calculated as $\frac{(I+P)}{(I+P)+(EN)+(UE)} = \frac{1865}{(1865)+(38)+0.9597(4015)} = 32.4\%$, where e is the estimated proportion of eligible cases among cases of unknown eligibility.

© 2025. The consulting and operations division of UMass Chan Medical School. Confidential

53



© 2025. The consulting and operations division of UMass Chan Medical School. Confidential

54

Project Team

Office of Survey Research

- Bittie Behl-Chadha, PhD**
Executive Director
Bittie.BehlChadha@umassmed.edu
- Melissa Karapanos, RD, MPH**
Principal
Melissa.Karapanos@umassmed.edu
- Pei-Pei Lei, MA**
Senior Biostatistician
Pei-Pei.Lei@umassmed.edu
- Sierra Svendsen, MPH**
Biostatistician
Sierra.Svendsen@umassmed.edu
- Zachary Jonas, MPH**
Biostatistician
Zachary.Jonas@umassmed.edu

Public Consulting Group

- Jessica Lang, PhD, MPH**
Director of Evaluation / Associate Manager
JLang@pcgus.com
- Colleen Florio, PhD**
Senior Evaluation Manager
CFlorio@pcgus.com
- Courtney Wright, MPH**
Evaluation Supervisor, Health Policy & Program Evaluation
CWright@pcgus.com
- Hannah Lieberman, MPH**
Consultant
HLieberman@pcgus.com


© 2025. The consulting and operations division of UMass Chan Medical School. Confidential

55

5. ADULT EXPANSION: TREND OVER TIME RESULTS BY MEASURE


Acute Hospital Utilization (AHU)

Admissions Per 1,000 Members
Adult Expansion Population




Emergency Department Utilization (EDU)

ED Visits Per 1,000 Members
Adult Expansion Population




Emergency Department Utilization, Behavioral Health Condition (EDU-BH)


ED Visits For BH Conditions Per 1,000 Members
Adult Expansion Population




Adult Access to Ambulatory/Preventive Care (AAP)




Initiation and Engagement in SUD Treatment (IET), Initiation




Initiation and Engagement in SUD Treatment (IET), Engagement




Follow-Up After Hospitalization for Mental Illness (FUH), 7-Day



Follow-Up After Hospitalization for Mental Illness (FUH), 30-Day




30-Day All-Cause Unplanned Readmission Following Hospitalization in an Inpatient Psychiatric Facility (IPF)



6. TARGETED ADULT MEDICAID: TREND OVER TIME RESULTS BY MEASURE


Acute Hospital Utilization (AHU)

Admissions Per 1,000 Members
Targeted Adults Population




Emergency Department Utilization (EDU)

ED Visits Per 1,000 Members
Targeted Adults Population




Emergency Department Utilization, Behavioral Health Condition (EDU-BH)

ED Visits For BH Conditions Per 1,000 Members
Targeted Adults Population




Adult Access to Ambulatory/Preventive Care (AAP)


Percent of Members with Ambulatory Care Visit
Targeted Adults Population




Initiation and Engagement in SUD Treatment (IET), Initiation




Initiation and Engagement in SUD Treatment (IET), Engagement



Follow-Up After Hospitalization for Mental Illness (FUH), 7-Day




Follow-Up After Hospitalization for Mental Illness (FUH), 30-Day



30-Day All-Cause Unplanned Readmission Following Hospitalization in an Inpatient Psychiatric Facility (IPF)

Percent of Unplanned Readmissions Within 30 Days
Targeted Adults Population



7. ADULT EXPANSION: REGRESSION RESULTS BY MEASURE

Acute Hospital Utilization (AHU)

	Adjusted	SE	CI
Measure Year	0.028	0.023	[-0.018, 0.074]
Post-Demonstration*Measure Year	0.159***	0.033	[0.094, 0.224]
Age	0.042***	0.002	[0.038, 0.047]
Gender			
Male	Ref	-	-
Female	-0.381***	0.054	[-0.487, -0.275]
Ethnicity			
Non-Hispanic	Ref	-	-
Hispanic	-0.007	0.078	[-0.159, 0.145]
Race			
White	Ref	-	-
Non-White	-0.003	0.042	[-0.086, 0.080]
Other or Missing	-0.018	0.031	[-0.078, 0.043]
N	314,247		

95% confidence intervals in brackets

*p < 0.05, **p < 0.01, ***p < 0.001

Emergency Department Utilization (EDU)

	Adjusted	SE	CI
Measure Year	43.555***	3.104	[37.471, 49.639]
Post-Demonstration*Measure Year	-67.164***	7.094	[-81.071, -53.257]

Age	-0.469*	0.187	[-0.835, -0.103]
Gender			
Male	Ref	-	-
Female	-36.053***	4.967	[-45.791, -26.316]
Ethnicity			
Non-Hispanic	Ref	-	-
Hispanic	41.590***	5.160	[31.474, 51.705]
Race			
White	Ref	-	-
Non-White	13.527*	6.104	[1.561, 25.492]
Other or Missing	-17.988**	6.090	[-29.926, -6.050]
N	8,170		

95% confidence intervals in brackets

*p < 0.05, **p < 0.01, ***p < 0.001

Emergency Department Utilization, Behavioral Health Condition (EDU-BH)

	Adjusted	SE	CI
Measure Year	19.437***	4.890	[9.850, 29.025]
Post-Demonstration*Measure Year	2.603	13.132	[23.146, 28.352]
Age	-0.015	0.346	[-0.693, 0.663]
Gender			
Male	Ref	-	-
Female	-98.963***	9.416	[-117.326, -80.400]
Ethnicity			
Non-Hispanic	Ref	-	-
Hispanic	-14.120	9.555	[-32.855, 4.616]
Race			
White	Ref	-	-
Non-White	2.470	10.560	[-15.236, 26.177]
Other or Missing	-33.174*	13.953	[-60.532, -5.815]
N	2,983		

95% confidence intervals in brackets

*p < 0.05, **p < 0.01, ***p < 0.001

Adult Access to Ambulatory/Preventive Care (AAP)

	Adjusted	SE	CI
Measure Year	-0.843***	0.204	[-1.243, -0.444]
Post-Demonstration*Measure Year	2.790***	0.485	[1.840, 3.741]
Age	0.150***	0.013	[0.125, 0.175]
Gender			
Male	Ref	-	-
Female	2.258***	0.347	[1.578, 2.938]
Ethnicity			
Non-Hispanic	Ref	-	-
Hispanic	-1.510***	0.350	[-2.196, -0.824]

Race			
White	Ref	-	-
Non-White	-1.055**	0.390	[-1.820, -0.290]
Other or Missing	-0.366	0.511	[-1.369, 0.637]
N	2,875		

95% confidence intervals in brackets

*p < 0.05, **p < 0.01, ***p < 0.001

Initiation and Engagement in SUD Treatment (IET), Initiation

	Adjusted	SE	CI
Measure Year	0.982	0.026	[0.932, 1.035]
Post-Demonstration*Measure Year	1.387***	0.119	[1.171, 1.642]
Age	1.010**	0.003	[1.004, 1.016]
Gender			
Male	Ref	-	-
Female	1.163***	0.040	[1.088, 1.244]
Ethnicity			
Non-Hispanic	Ref	-	-
Hispanic	0.823***	0.033	[0.761, 0.891]
Race			
White	Ref	-	-
Non-White	0.778	0.102	[0.602, 1.007]
Other or Missing	1.085	0.064	[0.966, 1.218]
N	45,241		

95% confidence intervals in brackets

*p < 0.05, **p < 0.01, ***p < 0.001

Initiation and Engagement in SUD Treatment (IET), Engagement

	Adjusted	SE	CI
Measure Year	0.820	0.444	[-0.050, 1.690]
Post-Demonstration*Measure Year	3.546**	1.350	[0.900, 6.192]
Age	-0.012	0.036	[-0.082, 0.059]
Gender			
Male	Ref	-	-
Female	2.904**	0.968	[1.007, 4.802]
Ethnicity			
Non-Hispanic	Ref	-	-
Hispanic	-2.387*	1.022	[-4.392, -0.383]
Race			
White	Ref	-	-
Non-White	-2.817*	1.095	[-4.963, -0.671]
Other or Missing	1.009	1.467	[-1.867, 3.885]
N	2,785		

95% confidence intervals in brackets

*p < 0.05, **p < 0.01, ***p < 0.001

Follow-Up After Hospitalization for Mental Illness (FUH), 7-Day

	Adjusted	SE	CI
Measure Year	1.100***	0.029	[1.045, 1.158]
Post-Demonstration*Measure Year	1.021	0.041	[0.944, 1.105]
Age	0.996*	0.002	[0.992, 1.000]
Gender			
Male	1	-	[1, 1]
Female	1.343***	0.037	[1.271, 1.418]
Ethnicity			
Non-Hispanic	1	-	[1, 1]
Hispanic	0.713**	0.072	[0.586, 0.868]
Race			
White	1	-	[1, 1]
Non-White	0.891**	0.039	[0.819, 0.970]
Other or Missing	0.834*	0.065	[0.717, 0.971]
N	16,003		

95% confidence intervals in brackets

*p < 0.05, **p < 0.01, ***p < 0.001

Follow-Up After Hospitalization for Mental Illness (FUH), 30-Day

	Adjusted	SE	CI
Measure Year	1.099***	0.017	[1.066, 1.132]
Post-Demonstration*Measure Year	0.977	0.031	[0.918, 1.040]
Age	0.999	0.002	[0.995, 1.002]
Gender			
Male	1	-	[1, 1]
Female	1.383***	0.049	[1.290, 1.482]
Ethnicity			
Non-Hispanic	1	-	[1, 1]
Hispanic	0.624***	0.054	[0.527, 0.739]
Race			
White	1	-	[1, 1]
Non-White	0.883***	0.031	[0.824, 0.947]
Other or Missing	0.807***	0.044	[0.726, 0.897]
N	16,003		

95% confidence intervals in brackets

*p < 0.05, **p < 0.01, ***p < 0.001

30-Day All-Cause Unplanned Readmission Following Hospitalization in an Inpatient Psychiatric Facility (IPF)

	Adjusted	SE	CI
Measure Year	1.037	0.051	[0.942, 1.142]
Post-Demonstration*Measure Year	1.287***	0.068	[1.160, 1.427]

Age	1.039***	0.002	[1.036, 1.042]
Gender			
Male	Ref	-	-
Female	0.705***	0.031	[0.648, 0.768]
Ethnicity			
Non-Hispanic	Ref	-	-
Hispanic	1.057	0.084	[0.905, 1.236]
Race			
White	Ref	-	-
Non-White	1.066	0.071	[0.935, 1.215]
Other or Missing	1.071	0.099	[0.893, 1.284]
N	21,197		

95% confidence intervals in brackets

*p < 0.05, **p < 0.01, ***p < 0.001

8. TARGETED ADULT MEDICAID: REGRESSION RESULTS BY MEASURE

Acute Hospital Utilization (AHU)

	Adjusted	SE	CI
Measure Year	0.010	0.037	[-0.062, 0.082]
Post-Demonstration*Measure Year	-0.087	0.054	[-0.193, 0.019]
Age	0.029***	0.002	[0.025, 0.033]
Gender			
Male	Ref	-	-
Female	0.099	0.053	[-0.005, 0.203]
Ethnicity			
Non-Hispanic	Ref	-	-
Hispanic	-0.062	0.100	[-0.258, 0.133]
Race			
White	Ref	-	-
Non-White	-0.119*	0.047	[-0.211, -0.278]
Other or Missing	0.094	0.133	[-3.105, -2.582]
N	28,147		

95% confidence intervals in brackets

*p < 0.05, **p < 0.01, ***p < 0.001

Emergency Department Utilization (EDU)

	Adjusted	SE	CI
Measure Year	0.982	0.013	[0.957, 1.007]
Post-Demonstration*Measure Year	0.913***	0.023	[0.869, 0.960]
Age	1.004***	0.001	[1.003, 1.005]
Gender			
Male	1	-	[1, 1]
Female	1.102***	0.027	[1.050, 1.157]
Ethnicity			
Non-Hispanic	1	-	[1, 1]

Hispanic	1.011	0.042	[0.932, 1.098]
Race			
White	1	-	[1, 1]
Non-White	1.056*	0.027	[1.004, 1.111]
Other or Missing	0.864**	0.043	[0.783, 0.953]
N	36,719		

95% confidence intervals in brackets

*p < 0.05, **p < 0.01, ***p < 0.001

Emergency Department Utilization, Behavioral Health Condition (EDU-BH)

	Adjusted	SE	CI
Measure Year	46.577**	17.366	[15.521, 83.633]
Post-Demonstration*Measure Year	-45.816	38.642	[-121.594, 29.963]
Age	-2.379*	1.164	[-4.661, -0.096]
Gender			
Male	Ref	-	-
Female	-13.620	28.938	[-70.370, 43.130]
Ethnicity			
Non-Hispanic	Ref	-	-
Hispanic	-55.068	30.582	[-115.041, 4.906]
Race			
White	Ref	-	-
Non-White	919.188	32.760	[-83.433, 45.056]
Other or Missing	-160.314***	41.699	[-242.088, -78.540]
N	2,172		

95% confidence intervals in brackets

*p < 0.05, **p < 0.01, ***p < 0.001

Adult Access to Ambulatory/Preventive Care (AAP)

	Adjusted	SE	CI
Measure Year	1.041**	0.014	[1.013, 1.069]
Post-Demonstration*Measure Year	1.314***	0.026	[1.265, 1.366]
Age	1.004**	0.001	[1.001, 1.006]
Gender			
Male	1	-	[1, 1]
Female	1.627***	0.112	[1.422, 1.861]
Ethnicity			
Non-Hispanic	1	-	[1, 1]
Hispanic	0.838***	0.026	[0.789, 0.891]
Race			
White	1	-	[1, 1]
Non-White	0.876***	0.012	[0.853, 0.899]
Other or Missing	0.922***	0.011	[0.902, 0.943]
N	89,355		

95% confidence intervals in brackets

*p < 0.05, **p < 0.01, ***p < 0.001

Initiation and Engagement in SUD Treatment (IET), Initiation

	Adjusted	SE	CI
Measure Year	1.571**	0.526	[0.539, 2.603]
Post-Demonstration*Measure Year	3.611*	1.434	[0.799, 6.422]
Age	0.044	0.045	[-0.045, 0.132]
Gender			
Male	Ref	-	-
Female	-1.002	1.095	[-3.150, 1.146]
Ethnicity			
Non-Hispanic	Ref	-	-
Hispanic	1.159	1.208	[-1.209, 3.527]
Race			
White	Ref	-	-
Non-White	-3.287**	1.235	[-5.709, -0.865]
Other or Missing	-0.443	1.618	[-3.616, 2.730]
N	1,993		

95% confidence intervals in brackets

*p < 0.05, **p < 0.01, ***p < 0.001

Initiation and Engagement in SUD Treatment (IET), Engagement

	Adjusted	SE	CI
Measure Year	0.993	0.019	[0.956, 1.031]
Post-Demonstration*Measure Year	1.483***	0.032	[1.421, 1.548]
Age	1.003*	0.002	[1.000, 1.006]
Gender			
Male	Ref	-	-
Female	0.943	0.040	[0.966, 1.025]
Ethnicity			
Non-Hispanic	Ref	-	-
Hispanic	1.038	0.040	[0.962, 1.120]
Race			
White	Ref	-	-
Non-White	0.896***	0.014	[0.868, 0.924]
Other or Missing	1.002	0.030	[0.945, 1.063]
N	14,378		

95% confidence intervals in brackets

*p < 0.05, **p < 0.01, ***p < 0.001

Follow-Up After Hospitalization for Mental Illness (FUH), 7-Day

	Adjusted	SE	CI
Measure Year	1.030	0.019	[0.993, 1.069]
Post-Demonstration*Measure Year	1.141*	0.064	[1.022, 1.273]

Age	1.003	0.005	[0.993, 1.013]
Gender			
Male	1	-	[1, 1]
Female	1.203	0.117	[0.994, 1.456]
Ethnicity			
Non-Hispanic	1	-	[1, 1]
Hispanic	0.954	0.135	[0.722, 1.260]
Race			
White	1	-	[1, 1]
Non-White	0.951	0.093	[0.785, 1.151]
Other or Missing	1.029	0.109	[0.836, 1.267]
N	2,879		

95% confidence intervals in brackets

*p < 0.05, **p < 0.01, ***p < 0.001

Follow-Up After Hospitalization for Mental Illness (FUH), 30-Day

	Adjusted	SE	CI
Measure Year	1.026	0.023	[0.981, 1.073]
Post-Demonstration*Measure Year	1.044	0.062	[0.929, 1.173]
Age	1.005	0.003	[0.999, 1.011]
Gender			
Male	1	-	[1, 1]
Female	1.279**	0.108	[1.084, 1.510]
Ethnicity			
Non-Hispanic	1	-	[1, 1]
Hispanic	1.091	0.170	[0.803, 1.482]
Race			
White	1	-	[1, 1]
Non-White	1.085	0.076	[0.972, 1.211]
Other or Missing	1.007	0.076	[0.869, 1.166]
N	2,879		

95% confidence intervals in brackets

*p < 0.05, **p < 0.01, ***p < 0.001

30-Day All-Cause Unplanned Readmission Following Hospitalization in an Inpatient Psychiatric Facility (IPF)

	Adjusted	SE	CI
Measure Year	0.995	0.080	[0.849, 1.165]
Post-Demonstration*Measure Year	0.978	0.065	[0.859, 1.113]
Age	1.026***	0.003	[1.020, 1.032]
Gender			
Male	Ref	-	-
Female	0.658***	0.043	[0.579, 0.747]
Ethnicity			

Non-Hispanic	Ref	-	-
Hispanic	1.263	0.232	[0.881, 1.809]
Race			
White	Ref	-	-
Non-White	1.049	0.048	[0.959, 1.147]
Other or Missing	0.910	0.114	[0.712, 1.163]
N	4,383		

95% confidence intervals in brackets

*p < 0.05, **p < 0.01, ***p < 0.001

9. SMI/SUD DEMONSTRATIONS: REGRESSION RESULTS BY MEASURE

Initiation and Engagement in SUD Treatment (IET), Initiation, SUD

	Adjusted	SE	CI
Measure Year	0.990	0.019	[0.954, 1.028]
Post-Demonstration*Measure Year	1.406***	0.060	[1.294, 1.528]
Age	1.014***	0.001	[1.011, 1.017]
Gender			
Male	Ref	-	-
Female	1.083*	0.039	[1.010, 1.162]
Ethnicity			
Non-Hispanic	Ref	-	-
Hispanic	0.870***	0.022	[0.828, 0.915]
Race			
White	Ref	-	-
Non-White	0.769**	0.067	[0.648, 0.912]
Other or Missing	1.028	0.043	[0.947, 1.116]
N	75,605		

95% confidence intervals in brackets

*p < 0.05, **p < 0.01, ***p < 0.001

Initiation and Engagement in SUD Treatment (IET), Engagement, SUD

	Adjusted	SE	CI
Measure Year	0.987	0.012	[0.964, 1.010]
Post-Demonstration*Measure Year	1.270***	0.040	[1.193, 1.351]
Age	0.993***	0.001	[0.992, 0.995]
Gender			
Male	Ref	-	-
Female	0.987	0.023	[0.943, 1.033]
Ethnicity			
Non-Hispanic	Ref	-	-
Hispanic	0.877***	0.027	[0.826, 0.931]
Race			
White	Ref	-	-
Non-White	0.857***	0.038	[0.786, 0.934]

Other or Missing	1.004	0.016	[0.973, 1.035]
N	75,605		

95% confidence intervals in brackets

*p < 0.05, **p < 0.01, ***p < 0.001

30-Day All-Cause Unplanned Readmission Following Hospitalization in an Inpatient Psychiatric Facility (IPF), SMI

	Adjusted	SE	CI
Measure Year	3.020***	0.383	[2.269, 3.771]
Post-Demonstration*Measure Year	4.815***	1.177	[2.507, 7.122]
Age	1.150***	0.21	[1.108, 1.192]
Gender			
Male	Ref	-	-
Female	-1.714*	0.871	[3.422, -0.006]
Ethnicity			
Non-Hispanic	Ref	-	-
Hispanic	-15.794***	0.968	[-17.693, -13.896]
Race			
White	Ref	-	-
Non-White	-4.304***	0.993	[-6.250, -2.358]
Other or Missing	-0.629	1.303	[-3.183, 1.925]
N	3,687		

95% confidence intervals in brackets

*p < 0.05, **p < 0.01, ***p < 0.001